Wissenschaftliche Publikationstätigkeit

2026

Kunadt D, Zukunft S, Röllig C, Metzelder S, Burchert A, Wagner-Drouet E, Kriege O, Schliemann C, Stelljes M, Ronnacker J, Bethge W, Weller JF, Steffen B, Bug G, Kouidri K, Baldus C, Fransecky L, Sala E, Platzbecker U, Metzeler K, Kayser S, Hilgendorf I, Hochhaus A, Brümmendorf TH, Jost E, Doleschall AD, Schroeder T, Kaivers J, Kordelas L, Holtick U, Unglaub JM, Sauer T, Jäger PS, Kobbe G, Stauffer E, Tischer J, Herold T, Steiner N, Nachbaur D, Kröger N, Frietsch JJ, Kraus S, Einsele H, Hänel M, Schaffrath J, Krüger W, Brandenburg A, Holderried TAW, Reinhardt L, Maulhardt M, Thiede C, Bornhäuser M, Schetelig J, Middeke JM, Stölzel F; German Cooperative Transplant Study Group and Study Alliance Leukemia (SAL). Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study. Br J Haematol. 2026 Aug 18. doi: 10.1111/bjh.70735. Epub ahead of print. PMID: 42610785

Rocke P, Tandetzky L, Wolff D, Egger-Heidrich K, Heidenreich D, Schaefer-Eckart K, Wagner-Drouet E, Frietsch JJ, Hochhaus A, Hilgendorf I. Comorbid conditions after allogeneic haematopoietic stem cell transplantation in young adults in Germany-A prospective, multicentre trial. Br J Haematol. 2026 Aug 10. doi: 10.1111/bjh.70738. Epub ahead of print. PMID: 42575722.

Gimbel M, Stoll C, Fuxius S, Prott FJ, Münstedt K, Zomorodbakhsch B, Wittmann S, Kastrati K, Hübner J. Efficacy of a Decision-Making Aid About Homeopathy in Patients With Cancer: A Single-Arm, Pre-Post Observational Study. Health Sci Rep. 2026 Jul 30;9(8):e72943. doi: 10.1002/hsr2.72943. PMID: 42534408; PMCID: PMC13420187

Ciarlo, G., Oehlrich, M. & Huebner, J. Online cancer forums and complementary and alternative medicine in cancer care: effects of ehealth literacy and psychological distress on use and attitudes. Support Care Cancer 34, 827 (2026). https://doi.org/10.1007/s00520-026-11049-3

Ciarlo G, Josfeld L, Hübner J. The Needs of Patients with Cancer Interested in Complementary and Alternative Medicine with Respect to the Physician's Attitude and Behaviour. Cancer Invest. 2026 Aug;44(7):755-768. doi: 10.1080/07357907.2026.2675656. Epub 2026 May 26. PMID: 42186825

Ussmann J, Jentzsch M, Schwind S, Herling M, Vučinić V, Merz M, Hilgendorf I, Hochhaus A, Platzbecker U, Metzeler KH, Franke GN. Relapse risk after FLAMSA RIC based allogeneic hematopoietic stem cell transplantation in heavily pretreated AML patients. Bone Marrow Transplant. 2026 Jul 15. doi: 10.1038/s41409-026-02960-8. Epub ahead of print. PMID: 42457984

Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, Hochhaus A, Lang F, Heinrich MC, Breccia M, Deininger M, Goh YT, Janssen JJWM, Talpaz M, de Soria VGG, le Coutre P, DeAngelo DJ, Damon A, Cacciatore S, Polydoros F, Agrawal N, Rea D. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia. 2024 Jul;38(7):1522-1533. doi: 10.1038/s41375-024-02278-8. Epub 2024 May 16. PMID: 38755421; PMCID: PMC11217003

Ruhe J, Hochhaus A, Wolf G, Hammersen J: Hämatologische Erkrankungen und Niere. Nephrologie aktuell 2026; 30: 264–274

Issa GC, Larson RA, Hughes TP, Hochhaus A, Takahashi N, Bombaci F, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, Le Coutre P, Kim I, Etienne G, Andorsky D, Gu E, Zhang Y, McCulloch T, Agrawal N, Jinwal R, Damon A, Sadek I, Cortes JE. Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia. Haematologica. 2026 Jul 2. doi: 10.3324/haematol.2025.300145. Epub ahead of print. PMID: 42389818

Ghazvini Zadegan F, Stanko C, Fiedler F, Ölsner L, Özcan SG, Schütt J, Schnöder TM, Sbirkov Y, Szymanski L, Stengel S, Dittrich P, Müller JP, Heidel FH, Hochhaus A, Scholl S, Schnetzke U, Brioli A, Schenk T. Am80 (tamibarotene) and ATRA induce highly similar molecular responses and myeloid differentiation in non-APL AML, enhanced by LSD1/GCN5 inhibition and increased RARA expression. BMC Cancer. 2026 Jun 27;26(1):777. doi: 10.1186/s12885-026-16388-2. PMID: 42365243; PMCID: PMC13309949

Vogel A, Ben Khaled N, Ramirez JR, Marhenke S, Siegler G, Siebler J, Lindig U, Schwartz G, Schultheiss M, Mueller T, Simon H, De Toni EN, Karl D, Al-Batran SE, Saborowski A. Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 study. Eur J Cancer. 2026 Jun 3;243:116847. doi: 10.1016/j.ejca.2026.116847. Epub ahead of print. PMID: 42284972

Bagdonas S, Schäfer L, Wolf C, Hübner J: The financial burden resulting from complementary and alternative medicine in oncology care. BMC Complement Med Ther 26, 205 (2026). https://doi.org/10.1186/s12906-026-05417-z

Arends J, Rubin D, Mathies V, Mensger C, Hübner J: Aktualisierte S3-Leitlinie „Klinische Ernährung in der Onkologie“. Forum 41, 216–220 (2026). https://doi.org/10.1007/s12312-026-01557-y

Brock H, Mehnert-Theuerkauf A, Kreilinger D, Strauß B, Schunke R, Grüner P, Hochhaus A, Stolzenburg J, Lordick F, Springer F: Wirksamkeit eines digitalen Unterstützungsangebots in der onkologischen Routineversorgung. Forum 41, 231–233 (2026). https://doi.org/10.1007/s12312-026-01560-3

Eigendorff F, Görke F, Zeremski V, Wollnitza S, Shumilov E, Lenz G, et al. Response-adapted consolidation and salvage strategies in secondary central nervous system lymphoma: Insights from a multicentre cohort. Br J Haematol. 2026;00:1–10. https://doi.org/10.1111/bjh.70633

Ossami Saidy A, Boumendil A, Dreger P, Stella F, Ram R, Kröger N, Castagna L, Pabst T, Wulf GG, Martin Garcia-Sancho A, Solano C, Stelljes M, Reinhardt HC, Forcade E, von Bonin M, Hilgendorf I, Martínez López J, Bethge W, Bazarbachi A, Sureda A, Schmitz N, Glass B; GOCART initiative; Lymphoma Working Party (LWP) of the EBMT. The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL). Bone Marrow Transplant. 2026 Jun 19. doi: 10.1038/s41409-026-02913-1. Epub ahead of print. PMID: 42321403

Arends J, Rubin D, Mathies V, Mensger C, Hübner J: Aktualisierte S3-Leitlinie „Klinische Ernährung in der Onkologie“. Forum 41, 216–220 (2026). https://doi.org/10.1007/s12312-026-01557-y

Bagdonas S, Schäfer L, Wolf C, Hübner J. The financial burden resulting from complementary and alternative medicine in oncology care. BMC Complement Med Ther. 2026 Jun 6;26(1):205. doi: 10.1186/s12906-026-05417-z. PMID: 42249373; PMCID: PMC13242131

Grüll S, Huebner J, Ciarlo G. Acculturation, resilience, and healthcare trust in migrant populations: an equity perspective. Arch Public Health. 2026 Jun 4;84(1):126. doi: 10.1186/s13690-026-01946-8. PMID: 42243944

Arndt Vogel, Najib Ben Khaled, Javier Ruiz Ramirez, Silke Marhenke, Gabriele Siegler, Jürgen Siebler, Udo Lindig, Gregory Schwartz, Michael Schultheiss, Tobias Mueller, Henry Simon, Enrico N. De Toni, Daniel Karl, Salah-E. Al-Batran, Anna Saborowski,Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: the IKF-t006/IMMUNIB translational phase-2 study, European Journal of Cancer, 2026, 116847, ISSN 0959-8049, https://doi.org/10.1016/j.ejca.2026.116847

Wickel J, Ceanga M, Vlad B, von Stackelberg N, Tochoedo NR, Schulz D, Yomade O, Dudziak D, Geis C. Therapeutic effect of T-cell engager in two patients with autoimmune neuropathy. Nat Commun. 2026 May 30;17(1):4816. doi: 10.1038/s41467-026-73819-1. PMID: 42218153; PMCID: PMC13222356

Ernst P, Rachow T, Henn S, Hammersen JF, Dittrich S, Heßmer A, Hillig A, Heßmer A, Hochhaus A. Residential radon exposure and lung cancer histology and stage: a population-based ecological study in Central Germany. J Cancer Res Clin Oncol. 2026 May 31. doi: 10.1007/s00432-026-06524-7. Epub ahead of print. PMID: 42218725

Falkenried J, Ahmadi E, Davitian K, Hübner J. The relationship between patient activation measure and use of complementary and alternative medicine in oncology patients. Patient Educ Couns. 2026 Apr 18;149:109650. doi: 10.1016/j.pec.2026.109650. Epub ahead of print. PMID: 42019172

Manz K, Kobrosly M, Crodel CC, Al-Ali H, Isfort S, Kleppe D, Neubert M, Schnöder TM, Rogalski I, Jilg S, Stauch T, Hoffmann W, Krüger WH, Krönke J, Hochhaus A, Homann C, Heidel FH. Value of functional iron parameters in diagnostic re-assessment of MPN: refinement of iron-deficiency markers by zinc protoporphyrin (ZPP). Ann Hematol. 2026 May 23;105(6):294. doi: 10.1007/s00277-026-07077-y. PMID: 42176009; PMCID: PMC13198467

Gale RP, Hochhaus A.: 2001–2026: LEUKEMIA celebrates 25 years of tyrosine kinase inhibitors. Leukemia (2026). https://doi.org/10.1038/s41375-026-02981-8

Hochhaus A, Talpaz M, Saglio G, Cortes JE, Hughes T, Apperley J, Hantschel O, Rea D, Schuld P, Kantarjian H: . From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia. Leukemia (2026). https://doi.org/10.1038/s41375-026-02984-5

Hübner, J: Gibt es Parallelen zwischen Alternativer Medizin und Postmoderne? Und was lernen wir daraus für eine gute Patientenversorgung? Jahrbuch Wissenschaftsfreiheit, Vol. 2026(2026), Iss. 3 : pp. 297–311 | First published online: May 12, 2026

Ernst P, Theis B, Franiel T: Hypoglycemia due to a hormone-secreting tumor. Dtsch Arztebl Int 2026; 123

Maschmeyer G, Fehm T, Loibl S, Dittrich R, Hilgendorf I. Onkopedia: What's New? Systemic Tumor Treatment in Pregnancy. Oncol Res Treat. 2026;49(3):134-149. doi: 10.1159/000547137. Epub 2025 Jul 2. PMID: 40602390

Kanellopoulos A, Koster L, de Lavallade H, Ortí G, Francis S, Passweg J, Apperley J, Bethge W, Rabitsch W, Clay J, Forcade E, Hurst E, Besley C, Kinsella F, Aljurf M, Huang H, Ho A, Hilgendorf I, Choi G, Ayuk F, Grzegorz H, Stelljes M, Richardson D, Morozova E, Prejzner W, Zeiser R, Armstrong C, Raj K, Drozd-Sokolowska J, Chalandon Y, McLornan DP. Management of tyrosine kinase inhibitors and donor lymphocyte infusions post transplantation for chronic myeloid leukemia: a survey of contemporary practice on behalf of the chronic malignancies working party of the EBMT. Bone Marrow Transplant. 2026 Jun;61(6):711-717. doi: 10.1038/s41409-026-02862-9. Epub 2026 Apr 10. PMID: 41963641

Massoud R, Flossdorf S, Hanke F, Schroeder T, Bethge W, Zeiser R, Pabst C, Wulf G, Sala E, Hilgendorf I, Scheid C, Edinger M, Stölzel F, Blau IW, Stelljes M, Kobbe G, Platzbecker U, Bittenbring JT, Eder M, Fleischhauer K, Burchert A, Schmid C, Kröger N. Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib. Haematologica. 2026 Mar 5. doi: 10.3324/haematol.2025.300176. Epub ahead of print. PMID: 41784041

Grundherr JV, Elmers S, Samland L, Mühlberg R, Dwinger S, Baumann J, Koch B, Wolters F, Hail LA, Escherich G, Bergelt C, Jensen W, Vettorazzi E, Pinnschmidt H, Valentini L, Baumann FT, Singer S, Reer R, Metz C, Calaminus G, Faber J, Schmidt D, Langer T, Hilgendorf I, Koehler M, Puzik A, Aschhoff M, Sander A, Schiffmann L, Sokalska-Duhme M, Schuster S, Kock-Schoppenhauer AK, Smollich M, Rostock M, Bokemeyer C, Stein A, Sinn M. Dietary intervention among young cancer survivors within the CARE for CAYA program. J Cancer Surviv. 2026 Mar 26. doi: 10.1007/s11764-026-01997-4. Epub ahead of print. PMID: 41886140

Walter A, Katenkamp K, Gaßler N, Lehmann T, Weschenfelder W, Spiegel C, Hofmann GO, Malouhi A, Hochhaus A, Rinke J, Clement JH, Schrenk KG. MiRNA-based expression signatures in differential diagnosis of enchondroma and chondrosarcoma. J Bone Oncol. 2026 Apr 8;58:100761. doi: 10.1016/j.jbo.2026.100761. PMID: 42095206; PMCID: PMC13141744

Altmann E, Hübner J, Bauer-Büntzel C, Büntzel J. Implementing Instagram as educational tool for teaching hematology and medical oncology - a cross-sectional study. BMC Med Educ. 2026 May 5. doi: 10.1186/s12909-026-09350-0. Epub ahead of print. PMID: 42087121

Hauff J, Josfeld L, Hübner J. Online information for patients on cancer diets - a comparison of German- and English-language websites. BMC Med Inform Decis Mak. 2026 Apr 30;26(1):149. doi: 10.1186/s12911-026-03529-7. PMID: 42063128; PMCID: PMC13134107

Annabell Walter, Kathrin Katenkamp, Nikolaus Gaßler, Thomas Lehmann, Wolfram Weschenfelder, Christian Spiegel, Gunther O. Hofmann, Amer Malouhi, Andreas Hochhaus, Jenny Rinke, Joachim H. Clement, Karin G. Schrenk: MiRNA-based expression signatures in differential diagnosis of enchondroma and chondrosarcoma, Journal of Bone Oncology, Volume 58, 2026, 100761,ISSN 2212-1374, https://doi.org/10.1016/j.jbo.2026.100761

Hochhaus, A., le Coutre, P., Milojkovic, D. et al. ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors. Leukemia (2026). https://doi.org/10.1038/s41375-026-02965-8

Morath O, Wolfrum T, Crodel C, Hochhaus A, Ernst T, Rinke J. Dysregulation of HIF-1α-regulated and thrombo-inflammatory genes may contribute to thrombotic risk in patients with BCR::ABL1-negative myeloproliferative neoplasms. J Thromb Haemost. 2026 Apr 16:S1538-7836(26)00259-X. doi: 10.1016/j.jtha.2026.04.013. Epub ahead of print. PMID: 42000137

Kiefer L, Ciarlo G, Ostendorf F, Hintze E, Hübner J. Health literacy, nutrition, complementary medicine and their associations with life satisfaction in cancer patients: a cross-sectional study. BMC Cancer. 2026 Mar 13;26(1):453. doi: 10.1186/s12885-026-15848-z. PMID: 41820903; PMCID: PMC13063638

Stölzel F, Stelljes M, Beelen DW, Markiewicz M, Reményi P, Luft T, Ciceri F, Wagner-Drouet EM, Junghanss C, Scheid C, Patriarca F, Socié G, Hilgendorf I, Rambaldi A, Schaefer-Eckart K, Russo D, Wulf G, Glass B, Labussiere-Wallet H, Stuhler G, Bieniaszewska M, Casper J, Holler E, Benedetti F, Iori AP, Kunadt D, Mihajlović J, Schild B, Khan I, Li X, Bethge W. GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial. Haematologica. 2026 Jan 29. doi: 10.3324/haematol.2025.288770. Epub ahead of print. PMID: 41609025

Shumilov E, Wurm-Kuczera R, Kauer J, Wang M, Mazzeo P, Boyadzhiev H, Gebauer N, Holtick U, Hölscher A, Teichert M, Nierychlewska PM, Kimmich C, Berning P, Melchardt T, Zeremski V, Wirths C, Nakov P, Schultze-Florey C, Velazquez GF, Lesan V, Krämer I, Kaiser F, Vehling-Kaiser U, Ossami-Saidy A, Huber H, Behringer A, Bentz M, Scholz JK, Gödel P, Schnetzke U, Vucinic V, Shorb E, Ghandili S, Kerkhoff A, Scheich S, Aydin S, Mayer K, Bacher U, Wille K, Glass B, Oellerich T, Ayuk F, Heidel F, Thurner L, Lutz M, Hänel M, Scholz CW, Tometten M, Pott C, Dreger P, Mougiakakos D, Dietrich S, Derenzini E, Chapuy B, Tresckow BV, Pabst T, Müller F, Lenz G. Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma. Haematologica. 2026 Apr 2. doi: 10.3324/haematol.2025.300063. Epub ahead of print. PMID: 41924925

Cortes JE, Hughes TP, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Etienne G, Kim I, Andorsky DJ, Bombaci F, Issa GC, Takahashi N, Kapoor S, Jinwal R, Malek K, McCulloch T, Yau L, Larson RA, Hochhaus A. Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial. Blood. 2026 Mar 26;147(13):1433-1446. doi: 10.1182/blood.2025029210. PMID: 41397287

Grumt A, Huchel S, Keinki C, Mathies V, Käsmann L, Huebner J. Development of an Assessment Tool for YouTube Videos With Medical Content: A Focus on Nutrition and Cancer. Integr Cancer Ther. 2026 Jan-Dec;25:15347354261422762. doi: 10.1177/15347354261422762. Epub 2026 Mar 15. PMID: 41832899

Morath O, Lindig U, Katenkamp K, Gassler N, Haziri D, Auletta V, Bauerschlag D, Franiel T, Bergener M, Griessbach AS, Ernst T, Hochhaus A, Crodel CC. Diagnostic and therapeutic challenges in claudin 18.2-positive gastric cancer treated with zolbetuximab: Intrapatient heterogeneity or secondary loss of expression? J Cancer Res Clin Oncol. 2026 Mar 19;152(3):70. doi: 10.1007/s00432-026-06447-3. PMID: 41854734; PMCID: PMC13003056

Al-Sawaf O, Stumpf J, Zhang C, Simon F, Bosch F, Feyzi E, Ghia P, Gregor M, Kater AP, Lindström V, Mattsson M, Niemann CU, Staber PB, Tadmor T, Thornton P, Wendtner CM, Janssens A, Noesslinger T, Bohn JP, da Cunha-Bang C, Poulsen CB, Ranti J, Illmer T, Schoettker B, Böttcher S, Gaska T, Vandenberghe E, Clifford R, Benjamini O, Frustaci AM, Scarfò L, Sportoletti P, Schreurs J, Levin MD, van der Straaten H, van der Klift M, Tran H, de la Serna J, Loscertales J, Lindblad O, Bergendahl Sandstedt A, Goede J, Baumann M, Fink AM, Fischer K, Ritgen M, Kreuzer KA, Schneider C, Tausch E, Stilgenbauer S, Robrecht S, Eichhorst B, Hallek M; CLL17 Trial Investigators. Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia. N Engl J Med. 2026 Mar 12;394(11):1084-1096. doi: 10.1056/NEJMoa2515458. Epub 2025 Dec 6. PMID: 41358601

Lorenzen S, Goetze TO, Thuss-Patience PC, Riera-Knorrenschild J, Goekkurt E, Dechow TN, Ettrich TJ, Hofheinz RD, Luley KB, Pink D, Lindig U, Folprecht G, Schuch G, Bitzer M, Heinemann V, Angermeier S, Bolling C, Loose M, Junge S, Pauligk C, Al-Batran SE. First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial. Nat Commun. 2026 Feb 27;17(1):2072. doi: 10.1038/s41467-026-69622-7. PMID: 41760643; PMCID: PMC12948978

Kreher KL, Dörfler J, Büntzel J, Büntzel J, Hübner J. Reliability of Results from Randomized Studies and Systematic Reviews in Acupuncture: A Methodological Review for Acupuncture Against Symptoms of Breast Cancer Care. In Vivo. 2026 Mar-Apr;40(2):726-747. doi: 10.21873/invivo.14234. PMID: 41760339; PMCID: PMC12949905

Tharmaseelan H, Sgonina LM, Bühnen I, Schnetzke U, Meißner J, Sellmayr M, Beverungen D, Hellmuth JC, Puthenparambil J, Zamrik T, Ferdinandus J, Shumilov E, Kerkhoff A, Melchardt T, Bröckelmann PJ, Kobe C, Borchmann P, Von Tresckow B. Anti-programmed cell death protein 1-based salvage therapy for relapsed/refractory Hodgkin lymphoma: a multicenter real-world analysis. Haematologica. 2026 Feb 26. doi: 10.3324/haematol.2025.288996. Epub ahead of print. PMID: 4174288

Lauseker M, Sacha T, Klamova H, Yakoleva J, Lomaia E, Milojkovic D, Fabisch C, Nicolini FE, Olsson-Stromberg U, Zackova D, Lewandowski K, Ernst P, Castagnetti F, Hirschbühl K, Zupan I, Voskanyan A, Gołos A, Frietsch JJ, Gil J, Faber E, Krause SW, Parry A, Saussele S, Heibl S, Franke GN, Casado LF, Paczkowska E, Hebart H, Eder M, Anhut P, Trautmann-Grill K, Szczepanek E, Südhoff T, Patkowska E, Kiani A, Ernst T, Apperley J, Mayer J, Hochhaus A, Pfirrmann M, Brioli A. Development of a prognostic scoring system for chronic myeloid leukemia in blast phase. Leukemia. 2026 Apr;40(4):751-758. doi: 10.1038/s41375-026-02875-9. Epub 2026 Feb 19. PMID: 41714405; PMCID: PMC13056570

Sitte HH, Hübner J, Aust N, Weisshäupl V, Ernst E. Trials and tribulations of responsible people trying to uphold scientific standards. Res Integr Peer Rev. 2026 Feb 16;11(1):5. doi: 10.1186/s41073-026-00191-5. PMID: 4169274

Obstfelder E, Herrmann J, Vučinić V, Hochhaus A, Schnetzke U, Eigendorff F. Tisagenlecleucel yields superior patient-reported health-related quality of life compared to autologous stem cell transplantation in patients with relapsed/refractory large B-cell lymphomas. Ann Hematol. 2026 Feb 5;105(3):88. doi: 10.1007/s00277-026-06840-5. PMID: 41639434

Voigtländer S, Dörfler J, Hübner J. Acupuncture as treatment of cancer-therapy induced fatigue: a critical systematic review with a focus on the methodological assessment of blinding. J Cancer Res Clin Oncol. 2026 Jan 8;152(1):37. doi: 10.1007/s00432-025-06395-4. PMID: 41507508; PMCID: PMC12783427

Crodel CC, Kohnle C, Radsak MP, Nückel H, Jilg S, Hochhaus A, Heidel FH, Hübner J. Patient-reported outcomes regarding the use of complementary and alternative medicine (CAM) in BCR::ABL1-negative myeloproliferative neoplasias. J Cancer Res Clin Oncol. 2026 Jan 20;152(1):41. doi: 10.1007/s00432-025-06421-5. PMID: 41559233; PMCID: PMC12819938

Fleischmann M, Hansen O, Voigtländer D, Bechwar J, Schwietzer L-J, Bahr S, et al. Targeting MCL-1 and MAPK overcomes venetoclax resistance in FLT3-ITD-positive AML cells harbouring activating PTPN11 (SHP-2) mutations. Br J Haematol. 2026; 00: 1–11. https://doi.org/10.1111/bjh.70344

Hilgendorf, I. (2025). Impfungen bei immunsupprimierten Patienten. In: Schmoll, HJ. (eds) Kompendium Internistische Onkologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-46764-0_309-1

Ernst P, Lohse C, Lauseker M, Geißler J, le Coutre P, Brümmendorf TH, Saußele S, Burchert A, Franke GN, La Rosée P, Brioli A, Schenk T, Fabisch C, Ernst T, Mehlkop G, Hochhaus A. Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective. Leukemia. 2026 Jan;40(1):29-36. doi: 10.1038/s41375-025-02826-w. Epub 2025 Dec 19. PMID: 41419606; PMCID: PMC12789025

Bill M, Eckardt JN, Döhner K, Röhnert MA, Rausch C, Metzeler KH, Spiekermann K, Stasik S, Wurm AA, Sauer T, Scholl S, Schnetzke U, Hochhaus A, Crysandt M, Brümmendorf TH, Krug U, Wörmann B, Einsele H, Hiddemann W, Görlich D, Sauerland C, Steffen B, Neubauer A, Burchert A, Schäfer-Eckart K, Berdel WE, Schliemann C, Krause SW, Hänel M, Hanoun M, Kaufmann M, Fransecky L, Braess J, Schetelig J, Middeke JM, Bullinger L, Heuser M, Thol F, Serve H, Baldus CD, Platzbecker U, Müller-Tidow C, Válka J, Šrámek J, Weinbergerova B, Mayer J, Dumas PY, Bertoli S, Delabesse E, Récher C, Pigneux A, Herold T, Ganser A, Döhner H, Bornhäuser M, Thiede C, Röllig C. Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients. Leukemia. 2026 Jan;40(1):63-71. doi: 10.1038/s41375-025-02781-6. Epub 2025 Oct 27. PMID: 41145671; PMCID: PMC12789037

Salmon M, Naumann N, Rinke J, Meggendorfer M, Radia D, Pomfret M, Ernst T, Hochhaus A, Reiter A, Tapper WJ, White H, Cross NCP. Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genes. Leukemia. 2026 Jan;40(1):37-46. doi: 10.1038/s41375-025-02801-5. Epub 2025 Nov 18. PMID: 41254115; PMCID: PMC12789007

Truger M, Meggendorfer M, Walter W, Hutter S, Alsdorf W, Massenkeil G, Martens UM, Kern W, Hörst K, Kühn C, Reiter A, Hochhaus A, Haferlach T. Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing. Leukemia. 2026 Jan;40(1):55-62. doi: 10.1038/s41375-025-02820-2. Epub 2025 Dec 19. PMID: 41419605; PMCID: PMC12789012

Hochhaus A., Gale RP: 40 years of LEUKEMIA. Leukemia (2026) 40:1–2; https://doi.org/10.1038/s41375-025-02840-y

Fischer M, Büntzel J, Hübner J. Social and psychological effects of a stoma on the sexuality and self-image of patients. Int J Colorectal Dis. 2026 Jan 20;41(1):39. doi: 10.1007/s00384-026-05091-0. PMID: 41559477

Burchert A, Nicolini FE, le Coutre P, Saussele S, Hochhaus A, Tuere E, Metzelder SK, Pauck K, Garn H, Raifer H, Huber M, Gattermann N, Crysandt M, Schafhausen P, Bormann M, Radsak MP, Guerci-Bresler A, Illmer T, Goebeler ME, Herhaus P, Teichmann LL, Franke GN, Lang F, Krause SW, Möhle R, Klausmann M, Stegelmann F, Lutz C, Etienne G, Stoltefuß A, Göthert JR, Ernst T, Abu-Samra M, Höffkes HG, Neubauer A, Wang Y, Weiland P, Otto C, Kiessler L, Weber T, Kroning L, Nist A, Stiewe T, Hehlmann R, Aminossadati B, Wittenberg M, Winterstein K, Oellerich T, Lechner M, Pfirrmann M, Schade-Brittinger C, Klemm P, Michel C. Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX). Leukemia. 2026 Feb;40(2):410-417. doi: 10.1038/s41375-025-02859-1. Epub 2026 Jan 12. PMID: 41526617; PMCID: PMC12875868

Witt, N., Mathies, V. Ernährung in der Prähabilitation. Onkologie (2026). https://doi.org/10.1007/s00761-025-01896-w

Anika Wolff, Jutta Hübner, Jens Büntzel and Judith Büntzel: “Psychotropic Medicinal Plant Use in Oncology: A Dual-Cohort Analysis and Its Implications for Anesthesia and Perioperative Care”, Appl. Sci. 2026, 16(1), 481; https://doi.org/10.3390/app16010481

Dendorfer SM, Schmidt-Brücken K, Kramer M, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Hänel M, Hanoun M, Kaufmann M, Weinbergerova B, Schäfer-Eckart K, Sauer T, Neubauer A, Burchert A, Baldus CD, Mertová J, Jost E, Niemann D, Novák J, Krause SW, Scholl S, Hochhaus A, Held G, Szotkowski T, Rank A, Schmid C, Fransecky L, Kayser S, Schaich M, Fiebig F, Haake A, Schetelig J, Middeke JM, Stölzel F, Platzbecker U, Thiede C, Müller-Tidow C, Berdel WE, Ehninger G, Mayer J, Serve H, Bornhäuser M, Röllig C. Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy. Am J Hematol. 2026 Mar;101(3):512-520. doi: 10.1002/ajh.70160. Epub 2026 Jan 5. PMID: 41492073; PMCID: PMC12869000

Schenk T, Fabisch C, Ernst T, Ernst P, Saussele S, Žáčková D, Mayer J, Klamová H, Hochhaus A; German CML Study Group and the Czech Leukemia Study Group. Ponatinib for CML patients in routine clinical practice: the PONDEROSA study. Ann Hematol. 2026 Jan 15;105(1):9. doi: 10.1007/s00277-026-06788-6. PMID: 41535610; PMCID: PMC12804319

2025

A.-K. Köditz, A. Mehnert-Theuerkauf, U. Platzbecker, A. Hochhaus, M. Jentzsch, G.-N. Franke, I. Hilgendorf, J. Ernst: Therapieadhärenz bei Patienten mit Stammzelltransplantation bei einer hämatologischen Krebserkrankung (TASK) – eine bizentrische Beobachtungstudie. Forum 40, 426–428 (2025). https://doi.org/10.1007/s12312-025-01496-0

Cortes JE, Hughes TP, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Etienne G, Kim I, Andorsky D, Bombaci F, Issa GC, Takahashi N, Kapoor S, Jinwal R, Malek K, McCulloch T, Yau L, Larson RA, Hochhaus A. Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial. Blood. 2025 Dec 15:blood.2025029210. doi: 10.1182/blood.2025029210. Epub ahead of print. PMID: 41397287

Gale RP, Hochhaus A. Things that drive Editors crazy: jargon, unnecessary abbreviations, abusing decimals and a few more. Leukemia. 2025 Dec 10. doi: 10.1038/s41375-025-02838-6. Epub ahead of print. PMID: 4137259

Cuker A, Stauch T, Cooper N, Al-Samkari H, Michel M, Ghanima W, Urban P, Fronczek J, Foster M, Weill M, Zhang L, Hou M, Zander T, Sharif A, Sun J, Nath UK, Schutgens R, Rossi E, Deleu L, Červinek L, Yoon JH, Chang H, Ruchutrakool T, Iino M, Goto T, Zaja F; VAYHIT2 Investigators. Ianalumab plus Eltrombopag in Immune Thrombocytopenia. N Engl J Med. 2025 Dec 9. doi: 10.1056/NEJMoa2515168. Epub ahead of print. PMID: 41363800

Tintelnot J, Paschold L, Goekkurt E, Schultheiss C, Matschl U, Santos Cruz M, Bauer M, Wickenhauser C, Thuss-Patience P, Lorenzen S, Ettrich TJ, Riera-Knorrenschild J, Jacobasch L, Kretzschmar A, Kubicka S, Al-Batran SE, Reinacher-Schick A, Pink D, Bokemeyer C, Sinn M, Lindig U, Hinke A, Hegewisch-Becker S, Stein A, Binder M. Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy. Cancer Immunol Res. 2025 Feb 3;13(2):200-209. doi: 10.1158/2326-6066.CIR-24-0561. PMID: 39527097; PMCID: PMC11788649

Gerhardt F, Müller C, Venerito M, Chater J, Mohr R, Egerer M, Lindig U, Schindler A, Ebel S, Fischer J, Schwarz M, Gehring S, Berg T, van Bömmel F. Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer - real-world data from a multicenter German patient population. J Cancer Res Clin Oncol. 2025 Jun 18;151(6):191. doi: 10.1007/s00432-025-06239-1. PMID: 40533571; PMCID: PMC12176970

Hübner J: Was können und müssen wir aus den Erfolgsgeschichten der Alternativen Medizin lernen? Überzeugungskräfte, Über das Vertrauen in Wissenschaft (und Pseudowissenschaft), Herausgeber:innen: Mathis Lessau und Hans Christian Riechers; Kartoniert, Status: Publiziert, ISBN: 978-3-7705-6932-8, Publikation: 07 Nov 2025

Ulf Schnetzke , David Irvine, José Mário Mariz, P. Joy Ho. How I Treat: Improving Patient Outcomes With Real-World Evidence in R/R DLBCL. Medscape Medical Affairs, Novartis, Industry sponsored scientific communication. Content ID: FA-11397715. October 2025

Göllner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, Rohde C, Pabst C, Sauer T, Lerdrup M, Tavor S, Stölzel F, Herold S, Ehninger G, Köhler G, Pan KT, Urlaub H, Serve H, Dugas M, Spiekermann K, Vick B, Jeremias I, Berdel WE, Hansen K, Zelent A, Wickenhauser C, Müller LP, Thiede C, Müller-Tidow C. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. Nat Med. 2017 Jan;23(1):69-78. doi: 10.1038/nm.4247. Epub 2016 Dec 12. PMID: 27941792; PMCID: PMC6548550

Hentze, A., Keinki, C., Walter, S. et al. Demographic and biographical data from cancer patients of a German online self-help forum. J Public Health (Berl.) (2025). https://doi.org/10.1007/s10389-025-02608-9

Rauchfuß F, Schwenk L, Dondorf F, Rohland O, Ali-Deeb A, Hochhaus A, Settmacher U. Liver transplantation in well-selected patients with unresectable colorectal liver metastases. Liver Transpl. 2025 Sep 25. doi: 10.1097/LVT.0000000000000739. Epub ahead of print. PMID: 40990644

Käsmann L, Gurtner R, Rennollet R, Büntzel J, Micke O, Belka C, Pazos M, Mücke R, Rauch J, Hübner J. Complementary and Alternative Medicine (CAM) Use in Patients Undergoing Radiotherapy: Sex-specific Prevalence and Associations of Use Based on the S3 Guideline Complementary Medicine in Oncology Questionnaire. In Vivo. 2025 Sep-Oct;39(5):2969-2975. doi: 10.21873/invivo.14097. PMID: 40877141; PMCID: PMC12396048

Gale RP, Hochhaus A. Are real world data real world data? Leukemia. 2025 Oct;39(10):2311-2312. doi: 10.1038/s41375-025-02751-y. Epub 2025 Sep 11. PMID: 40935824

Nagel SN, Brintrup J, Ghannam Y, Stallmach A, Hochhaus A, Ripoll C, Cario H, Schrenk KG. Combined heterozygosity for the highly unstable variant hemoglobin Taybe, and α-thalassemia as a rare cause of hemolytic anemia. Ann Hematol. 2025 Sep 9. doi: 10.1007/s00277-025-06578-6. Epub ahead of print. PMID: 40924176

Curik N, Laznicka A, Krizkova J, Suchankova P, Vavrova A, Polivkova V, Pokorna E, Semerak P, Burda P, Kuzilkova D, Kalina T, Hochhaus A, Machova Polakova K. Venetoclax in combination with ponatinib for the treatment of asciminib-resistant chronic myeloid leukemia. Leukemia. 2025 Oct;39(10):2555-2558. doi: 10.1038/s41375-025-02732-1. Epub 2025 Aug 26. PMID: 40858806; PMCID: PMC12463652

Kemmner SF, Dörfler J, Huebner J. Cannabinoids for the prevention of chemotherapy-induced nausea and vomiting in oncological therapy: a systematic review. J Cancer Surviv. 2025 Aug 12. doi: 10.1007/s11764-025-01876-4. Epub ahead of print. PMID: 4079706

Bröckelmann PJ, Böll B, Molin D, Schneider G, Leppä S, Meissner J, Kamper P, Hutchings M, Christensen JH, Schnetzke U, Fuchs M, Jablonski J, Eichenauer DA, von Tresckow B, Klapper W, Kobe C, Borchmann P, Fosså A. Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone for advanced-stage Hodgkin lymphoma in older patients. Hemasphere. 2025 Aug 18;9(8):e70190. doi: 10.1002/hem3.70190. PMID: 40832013; PMCID: PMC12358935

Ciarlo G, Josfeld L, Muenstedt K, Micke O, Buentzel J, Zomorodbakhsch B, Klein M, Keinki C, Huebner J. Evidence-Based Medicine and Complementary and Alternative Medicine - Attitudes and Knowledge of German Medical Students. Cancer Invest. 2025 Aug 5:1-8. doi: 10.1080/07357907.2025.2543850. Epub ahead of print. PMID: 40764257

Limbrunner J, Doerfler J, Pietschmann K, Buentzel J, Scharpenberg M, Huebner J. The influence of antioxidant supplementation on adverse effects and tumor interaction during radiotherapy: a systematic review. Clin Exp Med. 2025 Jul 22;25(1):258. doi: 10.1007/s10238-025-01804-x. PMID: 40691411; PMCID: PMC12279893

Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, Lipton JH, Malhotra H, Niederwieser D, Radich J, Rousselot P, Saussele S, Schiffer CA, Silver R, Soverini S, Stenke L, Turkina A, Casado LF, Castagnetti F, Cervantes F, Clark RE, Cortes J, Deininger M, Hughes TP, Janssen J, Jiang Q, Kim DW, Larson RA, Mahon FX, Mauro M, Mayer J, Nicolini FE, Pane F, Rea D, Richter J, Rosti G, Saglio G, Hehlmann R. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025 Aug;39(8):1797-1813. doi: 10.1038/s41375-025-02664-w. Epub 2025 Jul 11. PMID: 40646132

Wolff H, Zomorodbakhsch B, Schnizer M, Keinki C, Hübner J. Evaluation of patient management of (radio-)chemotherapy-caused mucositis with the goal of enhancing patient treatment. J Cancer Res Clin Oncol. 2025 Jul 10;151(7):211. doi: 10.1007/s00432-025-06238-2. PMID: 40634631

Maschmeyer G, Fehm T, Loibl S, Dittrich R, Hilgendorf I. Onkopedia - What's New? Systemic Tumor Treatment in Pregnancy. Oncol Res Treat. 2025 Jul 2:1-25. doi: 10.1159/000547137. Epub ahead of print. PMID: 40602390

Seltmann A, Mayer K, Hahn-Ast C, Brioli A, Rüthrich MM, Brossart P, Hochhaus A, von Lilienfeld-Toal M. Sex-disaggregated analysis of pneumonia in patients with high-risk neutropenia. Oncol Res Treat. 2025 Jun 24:1-14. doi: 10.1159/000546911. Epub ahead of print. PMID: 40555220

Akhtar NM, Walter A, Katenkamp K, Chen Y, Lehmann T, Weschenfelder W, Spiegel C, Vogt M, Hofmann GO, Hochhaus A, Gaßler N, Clement JH and Schrenk KG (2025) MiR-221, miR-320a, miR133a, and miR-133b as potential biomarkers in leiomyosarcoma. Front. Oncol. 15:1577859. doi: 10.3389/fonc.2025.1577859

Weiss M, Hammersen J, Rudolphi S, Formann I, Träger K, Rücker FG, Grüner B, Allgöwer A, Birndt S, Fabisch C, Hochhaus A, Döhner K, La Rosée P, Stegelmann F. l. Prognostic Impact of COVID-19 Inflammation Score Response: A Sub-Group Analysis on Critically Ill Patients of the RuxCoFlam Trial. Life. 2025; 15(5):781. https://doi.org/10.3390/life15050781

Mauro MJ MD, Minami Y, Hochhaus A, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Cortes J, Abdo A, Fogliato LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Chee L, Garcia-Gutierrez V, Sasaki K, Boquimpani C, Kapoor S, Espurz-Abad N, Dhamal V, Rea D. Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL. Blood Adv. 2025 May 7:bloodadvances.2025016042. doi: 10.1182/bloodadvances.2025016042. Epub ahead of print. PMID: 40334072

Christian Keinki, Mariska-Alenka Klein, Lukas Käsmann, Karsten Münstedt, Jutta Hübner,
Patients’ information on side effects of cancer treatment and usage of complementary and alternative medicine – A cross-sectional study. Advances in Integrative Medicine, 2025, 100497, ISSN 2212-9588,https://doi.org/10.1016/j.aimed.2025.100497. (https://www.sciencedirect.com/science/article/pii/S2212958825000564)

Turkina A, Vinogradova O, Lomaia E, Shatokhina E, Shukhov O, Chelysheva E, Shikhbabaeva D, Nemchenko I, Petrova A, Bykova A, Siordiya N, Shuvaev V, Mikhailov I, Novikov F, Shulgina V, Hochhaus A, Ottmann O, Cortes J, Gale RP, Chilov G. Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemia. Ann Hematol. 2025 Apr 29. doi: 10.1007/s00277-025-06239-8. Epub ahead of print. PMID: 4029899

Morath O, Rinke J, Walter A, Crodel C, Meggendorfer M, Baer C, Hochhaus A, Ernst T. Molecular predictors of venous and arterial thrombotic events in patients with myelofibrosis. Ann Hematol. 2025 Apr 27. doi: 10.1007/s00277-025-06361-7. Epub ahead of print. PMID: 40287867

Zeremski V, Haage TR, Witte HM, Adolph L, Beer SA, Behre G, Jacobs B, Kahl C, Lalayanni C, Panse J, Papageorgiou S, Siakantaris MP, Schneider J, Schnetzke U, Schulz A, Vassilakopoulos TP, Walter J, Mougiakakos D. PFS24 as a prognostic milestone in patients with newly diagnosed primary CNS lymphoma. J Hematol Oncol. 2025 Apr 24;18(1):48. doi: 10.1186/s13045-025-01700-7. PMID: 40275355; PMCID: PMC12023625

Shumilov E, Scholz JK, Seib M, Mazzeo P, Wurm-Kuczera R, Vucinic V, Holtick U, Boyadzhiev H, Melchardt T, Hölscher AS, Schultze-Florey CR, Abdelhafez A, Velazquez GF, Ossami Saidy A, Lesan V, Schnetzke U, Kerkhoff A, Bacher U, Ghandili S, Aydilek E, Gebauer N, Weber T, Wulf GG, Glass B, Thurner L, Heidel FH, Schmid C, Viardot A, Hänel M, Dietrich S, Pabst T, Ayuk FA, von Tresckow B, Chapuy B, Pott C, Müller F, Lenz G. Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma. Blood Adv. 2025 Apr 16:bloodadvances.2024015719. doi: 10.1182/bloodadvances.2024015719. Epub ahead of print. PMID: 40238938

Nguyen HA, Doerfler J, Buentzel J, Keinki C, Huebner J. Assessing iIndications for herbal medicinal products: a comparative analysis of EMA monographs and database records. BMC Complement Med Ther. 2025 Apr 9;25(1):130. doi: 10.1186/s12906-025-04852-8. PMID: 40205417

Hochhaus A, Kim DW, Cortes JE, Sasaki K, Mauro MJ, Hughes TP, Breccia M, Talpaz M, Minami H, Goh YT, DeAngelo DJ, Lang F, Ottmann O, Heinrich MC, Gomez Garcia de Soria V, le Coutre P, Sanchez-Olle G, Cao M, Pognan N, Kapoor S, Hoch M, Rea D. Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results. Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02578-7. Epub ahead of print. PMID: 40204892

Cortes JE, Lang F, Rea D, Hochhaus A, Breccia M, Goh YT, Heinrich MC, Hughes TP, Janssen JJWM, le Coutre P, Minami H, Sasaki K, DeAngelo DJ, Sanchez-Olle G, Pognan N, Cao M, Hoch M, Mauro MJ. Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results. Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02592-9. Epub ahead of print. PMID: 40204896

Heyder C, Büntzel J, Boyadzhiev H, Stegmaier P, Zomorodbakhsch B, Heißner K, Stoll C, von Weikersthal LF, Czekay J, Rudolph I, Hübner J. Does anxiety influence the use of complementary or alternative medicine among cancer patients? J Cancer Res Clin Oncol. 2025 Mar 26;151(3):123. doi: 10.1007/s00432-025-06173-2. PMID: 4013367

Ruhnke L, Bill M, Zukunft S, Eckardt JN, Schäfer S, Stasik S, Hanoun M, Schroeder T, Fransecky L, Steffen B, Krause SW, Scholl S, Hochhaus A, Sauer T, Kraus S, Schäfer-Eckart K, Kaufmann M, Jost E, Brümmendorf T, Schliemann C, Mikesch JH, Krug U, Hänel M, Morgner A, Schaich M, Neubauer A, Repp R, Niemann D, Seggewiss-Bernhardt R, Meinhardt A, Kullmer J, Kaiser U, Blau W, Kiani A, Grigoleit GU, Giagounidis A, Wurm AA, Altmann H, Middeke JM, Schetelig J, Müller-Tidow C, Stölzel F, Baldus CD, Platzbecker U, Serve H, Bornhäuser M, Thiede C, Röllig C. Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia. Blood Adv. 2025 Mar 25;9(6):1392-1404. doi: 10.1182/bloodadvances.2024013304. PMID: 39504561

Fosså, A., Molin, D., Bröckelmann, P.J., Schneider, G., Schnetzke, U., Linderoth, J., Kamper, P.M.H., Leppä, S.M., Meissner, J., Schaub, V., Lia, K., Fuchs, M., Borchmann, P. and Böll, B. (2025), Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG–NLG phase II BVB trial. HemaSphere, 9: e70099. https://doi.org/10.1002/hem3.70099

Zibrova D, Ernst T, Hochhaus A, Heller R. The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling. Mol Cell Biochem. 2025 Mar;480(3):1627-1643. doi: 10.1007/s11010-024-05070-5. Epub 2024 Jul 15. PMID: 39009935; PMCID: PMC11842422

Jahns L, Hübner J, Mensger C, Mathies V. A Neutropenic Diet in Haemato-Oncological Patients Receiving High-Dose Therapy and Hematopoietic Stem Cell Transplantation: A Systematic Review. Nutrients. 2025; 17(5):768. https://doi.org/10.3390/nu17050768

Ruhe S, Orawa H, Huebner J, Büntzel J. Hidden Resources for Cancer Patients - Interactions between spirituality, religiosity and selected factors influencing patient's self-care. Oncology. 2025 Feb 3:1-27. doi: 10.1159/000543312. Epub ahead of print. PMID: 39900005

Nicole Erickson, Virpi Sulosaari, Erin Stella Sullivan, Alessandro Laviano, Annemieke van Ginkel-Res, Wineke Remijnse, Joost Wesseling, Ute Koepcke, Nina Weber, Jutta Huebner, Viktoria Mathies, Sebastian Theurich, Theres Fey: Nutrition Care in Cancer: An Overlooked Part of Patient-Centered Care, Seminars in Oncology Nursing, Volume 41, Issue 1, 2025, 151799, ISSN 0749-2081, https://doi.org/10.1016/j.soncn.2024.151799

Fleischmann M, Jentzsch M, Brioli A, Eisele F, Frietsch JJ, Eigendorff F, Tober R, Schrenk KG, Hammersen JF, Yomade O, Hilgendorf I, Hochhaus A, Scholl S, Schnetzke U. Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia. Ann Hematol. 2024 Oct 25. doi: 10.1007/s00277-024-06048-5. Epub ahead of print. Erratum in: Ann Hematol. 2024 Dec;103(12):6061. doi: 10.1007/s00277-024-06095-y. PMID: 39453477

Rötzer, I., Frank, M., von Grundherr, J. et al. Ernährungstherapeutische Besonderheiten bei Patienten mit einem Magenkarzinom. Onkologie 31, 206–212 (2025). https://doi.org/10.1007/s00761-024-01633-9

Gale RP, Hochhaus A. Mpox in people with haematological cancers. Leukemia. 2025 Feb;39(2):275. doi: 10.1038/s41375-024-02465-7. Epub 2024 Dec 13. PMID: 39672828

Röllig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Hänel M, Noppeney R, Hanoun M, Kaufmann M, Weinbergerova B, Schäfer-Eckart K, Sauer T, Neubauer A, Burchert A, Baldus CD, Mertová J, Jost E, Niemann D, Novák J, Krause SW, Scholl S, Hochhaus A, Held G, Szotkowski T, Rank A, Schmid C, Fransecky L, Kayser S, Schaich M, Kramer M, Fiebig F, Haake A, Schetelig J, Middeke JM, Stölzel F, Platzbecker U, Thiede C, Müller-Tidow C, Berdel WE, Ehninger G, Mayer J, Serve H, Bornhäuser M. Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia. J Clin Oncol. 2025 Jan;43(1):65-74. doi: 10.1200/JCO.24.00235. Epub 2024 Sep 16. PMID: 39284116

Xiong L, Beyer D, Liu N, Lehmann T, Neugebauer S, Schaeuble S, Sommerfeld O, Ernst P, Svensson CM, Nietzsche S, Scholl S, Bruns T, Gaßler N, Gräler MH, Figge MT, Panagiotou G, Bauer M, Press AT. Targeting protein kinase C-α prolongs survival and restores liver function in sepsis: Evidence from preclinical models. Pharmacol Res. 2025 Jan 4;212:107581. doi: 10.1016/j.phrs.2025.107581. Epub ahead of print. PMID: 39761839

Meren SS, Josfeld L, Bahlmann JC, Fischer von Weikersthal L, Männle H, Huebner J. Feelings of guilt among cancer patients and the usage of complementary or alternative medicine - A cross-sectional survey. Palliat Support Care. 2025 Jan 20;23:e21. doi: 10.1017/S1478951524001718. PMID: 39829247

Erickson N, Sulosaari V, Sullivan ES, Laviano A, van Ginkel-Res A, Remijnse W, Wesseling J, Koepcke U, Weber N, Huebner J, Mathies V, Theurich S, Fey T. Nutrition Care in Cancer: An Overlooked Part of Patient-Centered Care. Semin Oncol Nurs. 2025 Jan 10:151799. doi: 10.1016/j.soncn.2024.151799. Epub ahead of print. PMID: 39799089

Hübner J. Was können und müssen wir aus den Erfolgsgeschichten der Alternativen Medizin lernen; in Lessau M. Riechers H.C. (Hrsg.): Überzeugungskräfte; über das Vertrauen in Wissenschaft (und Pseudowissenschaft); Brill/Fink 2025

Moulis G, Chen F, Carli G, Ghanima W, Trautmann-Grill K, Stauch T, Schifferli A, Miah H, Rueter M, Ghiotto L, Tomasello R, Georgi A, McDonald V, Zaja F, Pettersen HH, Kühne T, Lozano ML, González-López TJ, Provan D, Michel M, Cooper N, Rodeghiero F. Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries. Haematologica. 2025 Dec 1;110(12):3094-3098. doi: 10.3324/haematol.2025.287408. Epub 2025 Jun 26. PMID: 40568720; PMCID: PMC12666275

2024

Huchel S, Grumt A, Keinki C, Buentzel J, Käsmann L, Huebner J. Quality Assessment of YouTube Videos on Complementary and Alternative Medicine (CAM) for Cancer Using a Newly Developed Tool. Integr Cancer Ther. 2024 Jan-Dec;23:15347354241293417 doi: 10.1177/15347354241293417

Hübner J, Wölfl H, Otto L, Grohmann E, Walter S, Keinki C. Patienteninitiierte Forschung in der Onkologie. Onkologie 2024(1); 89-95; https://doi.org/10.1007/s00761-024-01622-y

Heß M, Huebner J, Dawczynski C, Serzisko J, Erickson N., Micke O, Schnetzke U, Scholl S, Mathies V. Effect of cancer therapy on the uptake and supply of selected micronutrients in acute myeloid leukemia; Trace Elements Electrolytes 2024;41:89-96; doi 10.5414/TE500083

von Grundherr J, Elmers S, Koch B, Hail LA, Mann J, Escherich G, Bergelt C, Samland L, Jensen W, Vettorazzi E, Stark M, Valentini L, Baumann FT, Singer S, Reer R, Beller R, Calaminus G, Faber J, Classen CF, Gebauer J, Hilgendorf I, Koehler M, Puzik A, Salzmann N, Sander A, Schiffmann L, Sokalska-Duhme M, Schuster S, Kock-Schoppenhauer AK, Bokemeyer C, Sinn M, Stein A, Dwinger S, Salchow J. A Multimodal Lifestyle Psychosocial Survivorship Program in Young Cancer Survivors: The CARE for CAYA Program-A Randomized Clinical Trial Embedded in a Longitudinal Cohort Study. JAMA Netw Open. 2024 Mar 4;7(3):e242375. doi: 10.1001/jamanetworkopen.2024.2375. PMID: 38526495; PMCID: PMC10964114

Jilg S, Schwaab J, Sockel K, Crodel CC, Brueckl V, Stegelmann F, Jentzsch M, Sasca D, Moyses M, Fuhrmann S, Gundel D, Caduc M, Teichmann LL, Heidel F, Al-Ali HK, Petrides PE. MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients. Ann Hematol. 2024 Oct;103(10):4065-4077. doi: 10.1007/s00277-024-05908-4. Epub 2024 Jul 29. PMID: 39073589

Ritter M, Yomade O, Holtz BO, Deinhardt-Emmer S, McLean AL, Hartinger S, Bechwar J, Schwab M, Huss A, Mawrin C, Axer H, Schrenk KG, Reuken PA, Mäurer I. Chronic hepatitis E virus-induced spinal cord atrophy in a patient with chronic lymphatic leukemia: a case report and interdisciplinary management proposal. Front Immunol. 2024 Jul 26;15:1445944. doi: 10.3389/fimmu.2024.1445944. PMID: 39131153; PMCID: PMC11310032

Morath O, Crodel C, Rinke J, Sander I, Tekbas A, Meggendorfer M, Baer C, Hochhaus A, Ernst T. Molecular and Clinical Risk Factors Associated with Thrombosis and Bleeding in Myelofibrosis Patients. Hamostaseologie. 2024 Dec 21. doi: 10.1055/a-2410-8530. Epub ahead of print. PMID: 39708833

Gale RP, Hochhaus A. Mpox in people with haematological cancers. Leukemia. 2024 Dec 13. doi: 10.1038/s41375-024-02465-7. Epub ahead of print. PMID: 39672828

Shumilov E, Wurm-Kuczera R, Kerkhoff A, Wang M, Melchardt T, Holtick U, Bacher U, Staber PB, Mazzeo P, Leng C, Böckle D, Hölscher AS, Kauer J, Rotter N, Vucinic V, Rudzki JD, Nachbaur D, Bücklein VL, Schnetzke U, Krämer I, Wille K, Hasse A, von Tresckow B, Hänel M, Koenecke C, Velazquez GF, Viardot A, Schmid C, Thurner L, Wolf D, Subklewe M, Dreyling M, Dreger P, Dietrich S, Keller U, Jaeger U, Greil R, Pabst T, Lenz G, Chapuy B. Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study. Blood Adv. 2024 Dec 11:bloodadvances.2024014903. doi: 10.1182/bloodadvances.2024014903. Epub ahead of print. PMID: 39661985

Ernst T, Fall 1: 70-Jährige mit mehrfacher TKI-Intoleranz und kardiovaskulären Begleiterkrankungen. Thieme Case Report, Chronische myeloische Leukämie, August 2024; 1-12

Hochhaus A, Asciminib bewährt sich auch im Langzeitverlauf als effektive und verträgliche Therapie. Thieme Case Report, Chronische myeloische Leukämie, August 2024; 1-12

Salomo S, Hübner J. Development and implementation of a new part-time continuing education course in integrative oncology. GMS J Med Educ. 2024;41(5):Doc64. DOI: 10.3205/zma001719, URN: urn:nbn:de:0183-zma0017190

Hübner J., Wölfl, H., Otto, L. et al. Patienteninitiierte Forschung in der Onkologie. Onkologie (2024). https://doi.org/10.1007/s00761-024-01622-y

Ruhnke L, Bill M, Zukunft S, Eckardt JN, Schäfer S, Stasik S, Hanoun M, Schroeder T, Fransecky L, Steffen B, Krause SW, Scholl S, Hochhaus A, Sauer T, Kraus S, Schäfer-Eckart K, Kaufmann M, Jost E, Brümmendorf TH, Schliemann C, Mikesch JH, Krug U, Hänel M, Morgner A, Schaich M, Neubauer A, Repp R, Niemann D, Seggewiss-Bernhardt R, Meinhardt A, Kullmer J, Kaiser U, Blau W, Kiani A, Grigoleit GU, Giagounidis A, Wurm AA, Altmann H, Middeke JMM, Schetelig J, Müller-Tidow C, Stölzel F, Baldus CD, Platzbecker U, Serve H, Bornhäuser M, Thiede C, Röllig C. Validation of the Revised 2022 European LeukemiaNet Risk Stratification in Adult Patients with Acute Myeloid Leukemia. Blood Adv. 2024 Nov 6:bloodadvances.2024013304. doi: 10.1182/bloodadvances.2024013304. Epub ahead of print. PMID: 39504561

Saur FG, Keinki C, Cramer A, Buentzel J, Hübner J. Education and Communication on the Topic of Osteonecrosis of the Jaw When Taking Bone-Stabilizing Drugs. Clin Exp Dent Res. 2024 Dec;10(6):e70024. doi: 10.1002/cre2.70024. PMID: 39497340

Wickel J, Schnetzke U, Sayer-Klink A, Rinke J, Borie D, Dudziak D, Hochhaus A, Heger L, Geis C. Anti-CD19 CAR-T cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome. Cell Rep Med. 2024 Oct 17:101794. doi: 10.1016/j.xcrm.2024.101794. Epub ahead of print. PMID: 39447569

Elnahas M, Hübner J, Lang PM, Ahmadi E. Job Satisfaction Among First-Generation Migrant Physicians in Anesthesiology and Intensive Care Medicine in Germany. Healthcare. 2024; 12(21):2107. https://doi.org/10.3390/healthcare12212107

Gutsche LC, Dörfler J, Hübner J. Curcumin as a complementary treatment in oncological therapy: a systematic review. Eur J Clin Pharmacol. 2024 Oct 19. doi: 10.1007/s00228-024-03764-9. Epub ahead of print. PMID: 39425780

Krannich F, Mücke R, Büntzel J, Schomburg L, Micke O, Huebner J, Dörfler J. A systematic review of Selenium as a complementary treatment in cancer patients. Complement Ther Med. 2024 Oct 5:103095. doi: 10.1016/j.ctim.2024.103095. Epub ahead of print. PMID: 39374898

Sockel K, Neu A, Goeckenjan M, Ditschkowski M, Hilgendorf I, Kröger N, Ayuk FA, Stoelzel F, Middeke JM, Eder M, Bethge W, Finke J, Bertz H, Kobbe G, Kaufmann M, Platzbecker U, Beverungen D, Schmid C, von Bonin M, Egger-Heidrich K, Heberling L, Trautmann-Grill K, Teipel R, Bug G, Tischer J, Fraccaroli A, Fante M, Wolff D, Luft T, Winkler J, Schäfer-Eckart K, Scheid C, Holtick U, Klein S, Blau IW, Burchert A, Wulf G, Hasenkamp J, Schwerdtfeger R, Kaun S, Junghanss C, Wortmann F, Winter S, Neidlinger H, Theuser C, Beyersmann J, Bornhaeuser M, Schmeller S, Schetelig J. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study). Blood. 2024 Oct 3;144(14):1532-1542. doi: 10.1182/blood.2024024342. PMID: 39007722

Hochhaus, A., Geissler, J. Patientenbeteiligung im CML-Studiennetzwerk. Onkologie (2024). https://doi.org/10.1007/s00761-024-01598-9

Cortes JE, Jiang Q, Wang J, Weng J, Zhu H, Liu X, Hochhaus A, Kim DW, Radich J, Savona M, Martin-Regueira P, Sy O, Saglio G. Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to three months of imatinib therapy: final 5-year results from DASCERN. Haematologica. 2024 May 2. doi: 10.3324/haematol.2023.283428. Epub ahead of print. PMID: 38695123

Davitian K, Noack P, Eckstein K, Hübner J, Ahmadi E. Barriers of Ukrainian refugees and migrants in accessing German healthcare. BMC Health Serv Res. 2024 Sep 24;24(1):1112. doi: 10.1186/s12913-024-11592-x. PMID: 39317924

Stege H, Schneider S, Forschner A, Eigentler T, Nashan D, Huening S, Lehr S, Meiss F, Kaatz M, Kuchen R, Kaehler KC, Haist M, Grabbe S, Huebner J, Loquai C. Second opinion and self-efficacy in German skin cancer patients. J Dtsch Dermatol Ges. 2024 Sep 12. doi: 10.1111/ddg.15512. Epub ahead of print. PMID: 39263772

Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Zimmermann A, Mathas S, Zijlstra JM, Fosså A, Viardot A, Hertenstein B, Martin S, Giri P, Scholl S, Topp MS, Jung W, Vucinic V, Beck HJ, Kerkhoff A, Unger B, Rank A, Schroers R, Zum Büschenfelde CM, de Wit M, Trautmann-Grill K, Kamper P, Molin D, Kreissl S, Kaul H, von Tresckow B, Borchmann S, Behringer K, Fuchs M, Rosenwald A, Klapper W, Eich HT, Baues C, Zomas A, Hallek M, Dietlein M, Kobe C, Diehl V; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie; Nordic Lymphoma Group; Australasian Leukaemia and Lymphoma Group. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet. 2024 Jul 27;404(10450):341-352. doi: 10.1016/S0140-6736(24)01315-1. Epub 2024 Jul 3. PMID: 38971175

Dörfler, J., Hübner, J. Neuerungen in der aktualisierten S3-Leitlinie „Komplementärmedizin in der Behandlung von onkologischen PatientInnen“. Forum (2024). https://doi.org/10.1007/s12312-024-01367-0

Ernst P, Rinke J, Franke GN, Dicker F, Haferlach T, Ernst T, Hochhaus A. Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation. Leukemia. 2024 Sep;38(9):2037-2040. doi: 10.1038/s41375-024-02327-2. Epub 2024 Jul 4. PMID: 38965368; PMCID: PMC11347363

Klaus M, Kutschan S, Männle H, Hübner J, Dörfler J. Reflexology in oncological treatment - a systematic review. BMC Complement Med Ther. 2024 Jan 11;24(1):32. doi: 10.1186/s12906-023-04220-4. PMID: 38212747; PMCID: PMC10782728

Chronic myeloid leukemia. Second edition. Editor-en-chief (Germany) Rüdiger Hehlmann, translated by Li Weiming, Beijing: Academic Literature Press, 2024.3, ISBN 978-7-5235-1167-1, first published in English under the title Chronic Myeloid Leukemia (2nd Ed.), edited by Rüdiger Hehlmann, Copyright Rüdiger Hehlmann, 2021. This edition has been translated an published under licence from Springer Nature Switzerland AG. Matthew Salmon, Helen E. White, Nocholas C.P. Cross, and Andreas Hochhaus: 2021 update: Standardization of molecular surveillance in chronic myeloid leukemia

Gambacorti-Passerini C, Brümmendorf TH, Abruzzese E, Kelly KR, Oehler VG, García-Gutiérrez V, Hjorth-Hansen H, Ernst T, Leip E, Purcell S, Luscan G, Viqueira A, Giles FJ, Hochhaus A. Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial. Leukemia. 2024 Aug 20. doi: 10.1038/s41375-024-02372-x. Epub ahead of print. PMID: 39164407

Baden D, Zukunft S, Hernandez G, Wolgast N, Steinhauser S, Pohlmann A, Schliemann C, Mikesch JH, Steffen B, Sauer T, Hanoun M, Schafer-Eckart K, Krause SW, Hanel M, Einsele H, Jost E, Brummendorf TH, Scholl S, Hochhaus A, Neubauer A, Burchert A, Kaufmann M, Niemann D, Schaich M, Blau W, Kiani A, Gorner M, Kaiser U, Kullmer J, Weber T, Berdel WE, Ehninger G, Muller-Tidow C, Platzbecker U, Serve H, Bornhauser M, Rollig C, Baldus CD, Fransecky L, Vol. 109 No. 8 (2024): August, 2024, https://haematologica.org/article/view/haematol.2024.285225

Dörfler J, Freuding M, Zaiser C, Büntzel J, Keinki C, Käsmann L, Hübner J. Umbrella review: Summary of findings for acupuncture as treatment for radiation-induced xerostomia. Head Neck. 2023 Apr;45(4):1026-1044. doi: 10.1002/hed.27297. Epub 2023 Feb 13. PMID: 36779370

Viktoria Mathies, Oliver Krings, Christian Keinki, Oliver Micke, and Jutta Hübner.Vitamin D deficiency in cancer care: Information, diagnosis, and supplementation from the patients’ point of view . 2023; 40: 143-151. doi: 10.5414/TE500060.

Hübner J, Keinki C, Münstedt K. Alternativmedizin in der Uroonkologie [Alternative medicine in uro-oncology]. Urologie. 2023 Jan;62(1):34-40. German. doi: 10.1007/s00120-022-01990-6. Epub 2022 Dec 1. PMID: 36454273

Cramer A., Keinki, C., Saur, F. et al. eHealth literacy, internet and eHealth service usage: a survey among a German municipality. J Public Health (Berl.) (2023). https://doi.org/10.1007/s10389-023-01997-z

Brandt F, Schneider N, Altmann U, Strauß B, Hübner J, Keinki C. Psychometrische Eigenschaften des Qualiskope-A zur Messung der Patientenzufriedenheit mit der ambulant-ärztlichen Behandlung: Einsatz in der Onkologie und Übertragbarkeit auf die stationäre Versorgung [Psychometric Properties of the Qualiskope-A for Measuring Patient Satisfaction with Outpatient Medical Treatment: Use in Oncology and Transferability to Inpatient Care]. Gesundheitswesen. 2023 Aug;85(8-09):732-740. German. doi: 10.1055/a-2016-7948. Epub 2023 Apr 7. PMID: 37028417; PMCID: PMC11248893

Schütt J, Brinkert K, Plis A, Schenk T, Brioli A. Unraveling the complexity of drug resistance mechanisms to SINE, T cell-engaging therapies and CELMoDs in multiple myeloma: a comprehensive review. Cancer Drug Resist. 2024 Jun 26;7:26. doi: 10.20517/cdr.2024.39. PMID: 39050883; PMCID: PMC11267153

Haematolymphoid Tumours. WHO Classification of Tumours, 5th Edition, Volume 11; 2024; ISBN-13 978-92-832-4520-9; IARC Publications Website - Haematolymphoid Tumours (who.int)

Schneider N, Altmann U, Brandt F, Hübner J, Strauss B, Keinki C. A web-based knowledge database to provide evidence-based information to cancer patients: Utilization within the PIKKO study. Support Care Cancer. 2024 Jul 17;32(8):521. doi: 10.1007/s00520-024-08725-7. PMID: 39017937; PMCID: PMC1125498

Zibrova D, Ernst T, Hochhaus A, Heller R. The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling. Mol Cell Biochem. 2024 Jul 15. doi: 10.1007/s11010-024-05070-5. Epub ahead of print. PMID: 39009935

Ma Y, Nenkov M, Berndt A, Abubrig M, Schmidt M, Sandhaus T, Huber O, Clement JH, Lang SM, Chen Y, Gaßler N. The Diagnostic Value of ACSL1, ACSL4, and ACSL5 and the Clinical Potential of an ACSL Inhibitor in Non-Small-Cell Lung Cancer. Cancers (Basel). 2024 Mar 16;16(6):1170. doi: 10.3390/cancers16061170. PMID: 38539505; PMCID: PMC10969076

Schnetzke U, Fischer M, Röllig C, Scherag A, Altmann H, Stölzel F, Alakel N, Bornhäuser M, Hochhaus A, Scholl S. Validating genetic variants in innate immunity linked to infectious events in acute myeloid leukemia post-induction chemotherapy. Genes Immun. 2024 Jul 9. doi: 10.1038/s41435-024-00285-4. Epub ahead of print. PMID: 38982248

Efficace F, Mahon FX, Richter J, Piciocchi A, Cipriani M, Nicolini FE, Mayer J, Zackova D, Janssen JJWM, Panayiotidis P, Vestergaard H, Koskenvesa P, Almeida A, Hjorth-Hansen H, Martinez-Lopez J, Olsson-Strömberg U, Hochhaus A, Berger MG, Etienne G, Klamova H, Faber E, Rousselot P, Pfirrmann M, Saussele S. Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial. Leukemia. 2024 Jul 10. doi: 10.1038/s41375-024-02341-4. Epub ahead of print. PMID: 38987274

Morath O, Hoffmann J, Schilling K, Hochhaus A, Rachow T, Lang SM. Venous and Arterial Thromboembolism in Lung Cancer Patients: A Retrospective Analysis. Journal of Clinical Medicine. 2024; 13(13):3773. https://doi.org/10.3390/jcm13133773

Isfort S, von Bubnoff N, Al-Ali HK, Becker H, Götze T, le Coutre P, Griesshammer M, Moskwa C, Wohn L, Riedel J, Palandri F, Manz K, Hochhaus A, Döhner K, Heidel FH. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN). Ann Hematol. 2024 Jul 5. doi: 10.1007/s00277-024-05867-w. Epub ahead of print. PMID: 38967662

Ernst P, Rinke J, Franke GN. et al. Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation. Leukemia (2024). https://doi.org/10.1038/s41375-024-02327-2

Gale RP, Jiang Q, Apperley JF, Hochhaus A. Is there really an accelerated phase of chronic myeloid leukaemia? Leukemia. 2024 Jun 25. doi: 10.1038/s41375-024-02316-5. Epub ahead of print. PMID: 38918562

Oliinyk D, Will A, Schneidmadel FR, Böhme M, Rinke J, Hochhaus A, Ernst T, Hahn N, Geis C, Lubeck M, Raether O, Humphrey SJ, Meier F. µPhos: a scalable and sensitive platform for high-dimensional phosphoproteomics. Mol Syst Biol. 2024 Jun 21. doi: 10.1038/s44320-024-00050-9. Epub ahead of print. PMID: 38907068

Curik N, Laznicka A, Polivkova V, Krizkova J, Pokorna E, Semerak P, Suchankova P, Burda P, Hochhaus A, Machova Polakova K. Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations. Leukemia. 2024 Jun;38(6):1415-1418. doi: 10.1038/s41375-024-02248-0. Epub 2024 Apr 13. PMID: 38615117; PMCID: PMC11147753

Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, Andorsky D, Issa GC, Larson RA, Bombaci F, Kapoor S, McCulloch T, Malek K, Yau L, Ifrah S, Hoch M, Cortes JE, Hughes TP; ASC4FIRST Investigators. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med. 2024 Sep 12;391(10):885-898. doi: 10.1056/NEJMoa2400858. Epub 2024 May 31. PMID: 38820078

Mahon FX, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, Mayer J, Hjorth-Hansen H, Janssen JJWM, Mustjoki S, Martinez-Lopez J, Vestergaard H, Ehrencrona H, Machová Poláková K, Olsson-Strömberg U, Ossenkoppele G, Berger MG, Etienne G, Dengler J, Brümmendorf TH, Burchert A, Réa D, Rousselot P, Nicolini FE, Hofmann WK, Richter J, Saussele S; EURO-SKI Investigators; Investigators. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. J Clin Oncol. 2024 Jun 1;42(16):1875-1880. doi: 10.1200/JCO.23.01647. Epub 2024 Mar 12. PMID: 38471049

Ritschel ML, Hübner J, Wurm-Kuczera R, Büntzel J. Phytotherapy known and applied by head-neck cancer patients and medical students to treat oral discomfort in Germany: an observational study. J Cancer Res Clin Oncol. 2023 May;149(5):2057-2070. doi: 10.1007/s00432-022-04200-0. Epub 2022 Jul 23. PMID: 35870011; PMCID: PMC10097744

Therapie-Handbuch Onkologie und Hämatologie. Praxishandbuch. Hubert Serve, David Zurmeyer (Herausgeber). Komplementärmedizin (Hübner J) Buch | Softcover. XXII, 504 Seiten. 2024 | 2., erweiterte und aktualisierte Auflage. Urban & Fischer in Elsevier (Verlag). 978-3-437-21011-2 (ISBN)

Beksac M, Eikema DJ, Koster L, Hulin C, Poiré X, Hamladji RM, Gromek T, Bazarbachi A, Ozkurt ZN, Pabst T, Ben Othman T, Finke J, Pirogova O, Wu D, Hayat A, Hilgendorf I, Tholouli E, de Wreede LC, Schönland S, Garderet L, Drozd-Sokolowska J, Raj K, Hayden PJ, Yakoub-Agha I, McLornan DP. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2024 Apr;59(4):526-533. doi: 10.1038/s41409-023-02160-8. Epub 2024 Jan 31. PMID: 38297040; PMCID: PMC10994834

Schulz F, Jäger P, Tischer J, Fraccaroli A, Bug G, Hausmann A, Baermann BN, Tressin P, Hoelscher A, Kasprzak A, Nachtkamp K, Schetelig J, Hilgendorf I, Germing U, Dietrich S, Kobbe G. Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies. Cancers (Basel). 2024 Jan 26;16(3):532. doi: 10.3390/cancers16030532. PMID: 38339283; PMCID: PMC10854830

Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, Hochhaus A, Lang F, Heinrich MC, Breccia M, Deininger M, Goh YT, Janssen JJWM, Talpaz M, de Soria VGG, le Coutre P, DeAngelo DJ, Damon A, Cacciatore S, Polydoros F, Agrawal N, Rea D. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia. 2024 May 16. doi: 10.1038/s41375-024-02278-8. Epub ahead of print. PMID: 38755421

Eigendorff F, Filimonova I, Scholl S, Sayer-Klink A, Rummler S, Kunert C, Pietschmann K, Wittig A, Hochhaus A, Schnetzke U. Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed/refractory large B-cell lymphoma: findings from a German monocentric study. J Cancer Res Clin Oncol. 2024 May 1;150(5):224. doi: 10.1007/s00432-024-05765-8. PMID: 38693452; PMCID: PMC11062962

Hofinger J, Kaesmann L, Buentzel J, Scharpenberg M, Huebner J. Systematic assessment of the influence of quality of studies on mistletoe in cancer care on the results of a meta-analysis on overall survival. J Cancer Res Clin Oncol. 2024 Apr 29;150(4):219. doi: 10.1007/s00432-024-05742-1. PMID: 38679615; PMCID: PMC11056339

Baden D, Zukunft S, Hernandez G, Wolgast N, Steinhauser S, Pohlmann A, Schliemann C, Mikesch JH, Steffen B, Sauer T, Hanoun M, Schafer-Eckart K, Krause SW, Hanel M, Einsele H, Jost E, Brummendorf TH, Scholl S, Hochhaus A, Neubauer A, Burchert A, Kaufmann M, Niemann D, Schaich M, Blau W, Kiani A, Gorner M, Kaiser U, Kullmer J, Weber T, Berdel WE, Ehninger G, Muller-Tidow C, Platzbecker U, Serve H, Bornhauser M, Rollig C, Baldus CD, Fransecky L. Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens. Haematologica. 2024 Apr 24. doi: 10.3324/haematol.2024.285225. Epub ahead of print. PMID: 38654660

Masetti M, Al-Batran SE, Goetze TO, Thuss-Patience P, Knorrenschild JR, Goekkurt E, Folprecht G, Ettrich TJ, Lindig U, Luley KB, Pink D, Dechow T, Sookthai D, Junge S, Loose M, Pauligk C, Lorenzen S. Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy. Int J Cancer. 2024 Jun 15;154(12):2142-2150. doi: 10.1002/ijc.34894. Epub 2024 Mar 6. PMID: 38447003

Curik N, Laznicka A, Polivkova V, Krizkova J, Pokorna E, Semerak P, Suchankova P, Burda P, Hochhaus A, Machova Polakova K. Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations. Leukemia. 2024 Apr 13. doi: 10.1038/s41375-024-02248-0. Epub ahead of print. PMID: 38615117

Eichenauer DA, Heger JM, Kruschel I, Kutsch N, Gödel P, Garcia Borrega J, Schnetzke U, Böll B, Neumann MA, Gebel C, Pralong A, Borchmann P, Voltz R, Wedding U, Simon ST. Specialized palliative care in patients with haematological malignancies receiving chimeric antigen receptor T-cell therapy. Br J Haematol. 2024 Mar 24. doi: 10.1111/bjh.19434. Epub ahead of print. PMID: 38522848

Hübner J: Komplementäre Onkologie. Verlag: Urban & Fischer in Elsevier, ISBN: ISBN 978-3-437-15076-0; eISBN 978-3-437-05413-6

Brioli A, Lomaia E, Fabisch C, Sacha T, Klamova H, Morozova E, Golos A, Ernst P, Olsson-Stromberg U, Zackova D, Nicolini FE, Bao H, Castagnetti F, Patkowska E, Mayer J, Hirschbühl K, Podgornik H, Paczkowska E, Parry A, Ernst T, Voskanyan A, Szczepanek E, Saussele S, Franke GN, Kiani A, Faber E, Krause S, Casado LF, Lewandowski K, Eder M, Anhut P, Gil J, Südhoff T, Hebart H, Heibl S, Pfirrmann M, Hochhaus A, Lauseker M. Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry. Leukemia. 2024 Mar 28. doi: 10.1038/s41375-024-02204-y. Epub ahead of print. PMID: 38548962

Kantarjian H, Branford S, Breccia M, Cortes J, Haddad FG, Hochhaus A, Hughes T, Issa GC, Jabbour E, Nicolini FE, Sasaki K, Xavier-Mahon F. Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia? Leukemia. 2024 Mar 26. doi: 10.1038/s41375-024-02229-3. Epub ahead of print. PMID: 38531949

Fleischmann M, Bechwar J, Voigtländer D, Fischer M, Schnetzke U, Hochhaus A, Scholl S. Synergistic Effects of the RARalpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation. Cancers. 2024; 16(7):1311. https://doi.org/10.3390/cancers16071311

Benesova A, De Santis S, Polivkova V, Pecherkova P, Krizkova J, Suchankova P, Monaldi C, Klamova H, Srbova D, Zizkova H, Hochhaus A, Soverini S, Machova Polakova K. Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia. Am J Hematol. 2024 Apr;99(4):759-762. doi: 10.1002/ajh.27232. Epub 2024 Feb 5. PMID: 38314531

Mahon FX, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, Mayer J, Hjorth-Hansen H, Janssen JJWM, Mustjoki S, Martinez-Lopez J, Vestergaard H, Ehrencrona H, Machová Poláková K, Olsson-Strömberg U, Ossenkoppele G, Berger MG, Etienne G, Dengler J, Brümmendorf TH, Burchert A, Réa D, Rousselot P, Nicolini FE, Hofmann WK, Richter J, Saussele S; EURO-SKI Investigators. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. J Clin Oncol. 2024 Mar 12:JCO2301647. doi: 10.1200/JCO.23.01647. Epub ahead of print. PMID: 38471049

Smith BD, Brümmendorf TH, Roboz GJ, Gambacorti-Passerini C, Charbonnier A, Viqueira A, Leip E, Purcell S, Goldman EH, Giles F, Ernst T, Hochhaus A, Rosti G. Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study. Leuk Res. 2024 Apr;139:107481. doi: 10.1016/j.leukres.2024.107481. Epub 2024 Mar 11. PMID: 38484432

Lübke J, Christen D, Schwaab J, Kaiser A, Naumann N, Shoumariyeh K, Jentzsch M, Sockel K, Schaffrath J, Ayuk FA, Stelljes M, Hilgendorf I, Sala E, Kaivers J, Schönland S, Wittke C, Hertenstein B, Radsak M, Kaiser U, Brückl V, Kröger N, Brümmendorf TH, Hofmann WK, Klein S, Jost E, Reiter A, Panse J. Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries. Leukemia. 2024 Apr;38(4):810-821. doi: 10.1038/s41375-024-02186-x. Epub 2024 Mar 6. PMID: 38448757; PMCID: PMC10997505

Hochhaus A, Hörst K, Kühn C, Kvasnicka HM, Reiter A: Genetic alterations in myeloproliferative and myelodysplastic/myeloproliferative neoplasms – a practical guide to WHO-HAEM5. Medizinische Genetik, vol. 36, no. 1, 2024, pp. 31-38. https://doi.org/10.1515/medgen-2024-2003

Benesova A, De Santis S, Polivkova V, Pecherkova P, Krizkova J, Suchankova P, Monaldi C, Klamova H, Srbova D, Zizkova H, Hochhaus A, Soverini S, Machova Polakova K. Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia. Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27232. Epub ahead of print. PMID: 38314531

Jabbour E, Apperley J, Cortes J, Rea D, Deininger M, Abruzzese E, Chuah C, DeAngelo DJ, Hochhaus A, Lipton JH, Mauro M, Nicolini F, Pinilla-Ibarz J, Rosti G, Rousselot P, Shah NP, Talpaz M, Vorog A, Ren X, Kantarjian H. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024 Jan 29. doi: 10.1038/s41375-024-02159-0. Epub ahead of print. PMID: 38287132

Zeidler J, Kutschan S, Dörfler J, Büntzel J, Huebner J. Impact of nutrition counseling on nutrition status in patients with head and neck cancer undergoing radio- or radiochemotherapy: a systematic review. Eur Arch Otorhinolaryngol. 2024 Jan 4. doi: 10.1007/s00405-023-08375-1. Epub ahead of print. PMID: 38175263

Knauft J, Schenk T, Ernst T, Schnetzke U, Hochhaus A, La Rosée P, Birndt S. Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis. Leukemia. 2024 Jan 18. doi: 10.1038/s41375-024-02135-8. Epub ahead of print. PMID: 38238443

2023

Dreger P, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner E, Wulf G, Marks R, Penack O, Schnetzke U, Koenecke C, von Bonin M, Stelljes M, Glass B, Baldus CD, Vucinic V, Mougiakakos D, Topp M, Schroers R, Wolff D, Thomas S, Kröger N, Bethge WA; German Lymphoma Alliance (GLA); German Stem Cell Transplantation Registry (DRST). Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience. Bone Marrow Transplant. 2023 Feb;58(2):229-232. doi: 10.1038/s41409-022-01867-4. Epub 2022 Nov 22. PMID: 36418916; PMCID: PMC9902271

Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindström V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Nösslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, van der Klift M, Jäger U, Leys MBL, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink JC, Widmer A, Simon F, De Silva N, Fink AM, Bahlo J, Fischer K, Wendtner CM, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Levin MD, van Oers M, Geisler C, Stilgenbauer S, Hallek M; GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. N Engl J Med. 2023 May 11;388(19):1739-1754. doi: 10.1056/NEJMoa2213093. PMID: 37163621

Derigs P, Bethge WA, Krämer I, Holtick U, von Tresckow B, Ayuk F, Penack O, Vucinic V, von Bonin M, Baldus C, Mougiakakos D, Wulf G, Schnetzke U, Stelljes M, Fante M, Schroers R, Kroeger N, Dreger P; German Lymphoma Alliance and the German Registry for Stem Cell Transplantation. Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis. Transplant Cell Ther. 2023 Dec;29(12):750-756. doi: 10.1016/j.jtct.2023.09.008. Epub 2023 Sep 13. PMID: 37709204

Rivera D, Cui W, Gao J, Peker D, Zhang QY, Dewar R, Qiu L, Konoplev S, Hu Z, Sasaki K, Hu A, E S, Liu M, Fang H, Wang W, Tang G, Apperley JF, Hochhaus A, Cortes JE, Khoury JD, Medeiros LJ, Jabbour E, Hu S. Aleukemic Chronic Myeloid Leukemia without Neutrophilia and Thrombocytosis at Initial Presentation: a Report from the BCR::ABL1 Pathology Group. Mod Pathol. 2023 Dec 15:100406. doi: 10.1016/j.modpat.2023.100406. Epub ahead of print. PMID: 38104892

Tubío-Santamaría N, Jayavelu AK, Schnoeder TM, Eifert T, Hsu CJ, Perner F, Zhang Q, Wenge DV, Hansen FM, Kirkpatrick JM, Jyotsana N, Lane SW, von Eyss B, Deshpande AJ, Kühn MWM, Schwaller J, Cammann C, Seifert U, Ebstein F, Krüger E, Hochhaus A, Heuser M, Ori A, Mann M, Armstrong SA, Heidel FH. Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia. Mol Cancer. 2023 Dec 4;22(1):196. doi: 10.1186/s12943-023-01907-7. PMID: 38049829; PMCID: PMC10694946

Fleischmann M, Fischer M, Schnetzke U, Fortner C, Kirkpatrick J, Heidel FH, Hochhaus A, Scholl S. Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance. Cells. 2021 Nov 3;10(11):2992. doi: 10.3390/cells10112992. PMID: 34831215; PMCID: PMC8616352

Shalgouny M, Bertz-Lepel J, Fischer V Weikersthal L, Herbin J, Meier-Höfig M, Mücke R, Rohe U, Stauch T, Stoll C, Troeltzsch D, Wittmann S, Kurz O, Naumann R, Huebner J. Introducing a standardized assessment of patients' interest in and usage of CAM in routine cancer care: chances and risks from patients' and physicians' point of view. J Cancer Res Clin Oncol. 2023 Dec;149(18):16575-16587. doi: 10.1007/s00432-023-05182-3. Epub 2023 Sep 16. PMID: 37715831; PMCID: PMC10645655

Rosti G, Brümmendorf TH, Gjertsen BT, Giraldo-Castellano P, Castagnetti F, Gambacorti-Passerini C, Ernst T, Zhao H, Kuttschreuter L, Purcell S, Giles FJ, Hochhaus A. Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study. Leukemia. 2024 Jan;38(1):126-135. doi: 10.1038/s41375-023-02080-y. Epub 2023 Nov 25. PMID: 38007586; PMCID: PMC10776383

Lorenzen S, Götze TO, Thuss-Patience P, Biebl M, Homann N, Schenk M, Lindig U, Heuer V, Kretzschmar A, Goekkurt E, Haag GM, Riera-Knorrenschild J, Bolling C, Hofheinz RD, Zhan T, Angermeier S, Ettrich TJ, Siebenhuener AR, Elshafei M, Bechstein WO, Gaiser T, Loose M, Sookthai D, Kopp C, Pauligk C, Al-Batran SE; AIO and SAKK Study Working Groups. Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial. J Clin Oncol. 2023 Nov 14:JCO2300975. doi: 10.1200/JCO.23.00975. Epub ahead of print. PMID: 37963317

Aldenhoff, F. Aschenbrenner, E. Baum, M. Baumann, W. Bertram, V. Borger, K. Brass, S. Bushuven, A. Conrad, G. Danzer, U. Dittmer, G. Döller, A. Eggert, D. Eichenberger zur Bonsen, A. Encke, M.R. Fischer, U. Förstermann |R. Frankenberger, S. Frantz |C. Friedrich, M. Frosch, W. Georg, T. Greschik, O. Gröne, C. Groß, N. Halama, A. Hasenburg, R. Hecker, S. C. Herpertz, M. Herrmann, H. Hildebrandt, K. Hofmann, J. Holst, G. Hörl, J. Hübner, C. Jassoy, G. Jonitz, J. Jünger, K. Kemmritz, U. Koch-Gromus, I. B. Kopp, S. Krieger, T.-T. Lâm, F. Lammert, H. Lang, M. Leuzinger-Bohleber, G. Matheis, E. D. Munz, A. Mutschler, E. Nagel, G. Nettekoven, T. Niedenthal, F. Niroomand, N. Ouédraogo, F. Paulsen, U. Repschläger, B. Salzberger, T. Schäfer, B. Schlegelberger, S. Schramm, M. Schütz, R. Seifert, M. Sievers, A. Spaic, A. Stallmach, G. Stöcker, R. Strametz, M.-J. Sturm, S. Taubner, U. Teichert, U. Teichgräber, A. Thater, P. Tinnemann, G. Trabert, B. Vajen, B. Vajen, H. Vatter, E. von Hirschhausen, S. Weinbrenner, J. Weis, C. Witte, W. Wohlgemuth: Heilkunst Reloaded, MWV Medizinisch Wissenschaftliche Verlagsgesellschaft; 1. Edition (23. Oktober 2023), ISBN-10 : ‎ 3954668262, ISBN-13 ‏: ‎ 978-3954668267

Josfeld L, Huebner J; Working Group Prevention and Integrative Oncology in the German Cancer Society. Development and analysis of quality assessment tools for different types of patient information - websites, decision aids, question prompt lists, and videos. BMC Med Inform Decis Mak. 2023 Jun 21;23(1):111. doi: 10.1186/s12911-023-02204-5. PMID: 37344772; PMCID: PMC10283325

Möller J, Josfeld L, Keinki C, Zieglowski N, Büntzel J, Hübner J. The quality of German - language patient decision aids for oncological patients on the internet. BMC Med Inform Decis Mak. 2023 Aug 18;23(1):161. doi: 10.1186/s12911-023-02259-4. PMID: 37596582; PMCID: PMC10436558

Pouyiourou M, Kraft BN, Wohlfromm T, Stahl M, Kubuschok B, Löffler H, Hacker UT, Hübner G, Weiss L, Bitzer M, Ernst T, Schütt P, Hielscher T, Delorme S, Kirchner M, Kazdal D, Ball M, Kluck K, Stenzinger A, Bochtler T, Krämer A. Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial. Nat Commun. 2023 Oct 24;14(1):6761. doi: 10.1038/s41467-023-42400-5. PMID: 37875494; PMCID: PMC10598029

Cross NCP, Ernst T, Branford S, Cayuela JM, Deininger M, Fabarius A, Kim DDH, Machova Polakova K, Radich JP, Hehlmann R, Hochhaus A, Apperley JF, Soverini S. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia. 2023 Oct 4. doi: 10.1038/s41375-023-02048-y. Epub ahead of print. PMID: 37794101

Cale RP, Hochhaus A: "Oppenheimer" ia a reminder to physicians, scientist to act to prevent nuclear war. The cancer letter, Sept. 29.2023, Vol 49, issute 36

Shalgouny M, Bertz-Lepel J, Fischer V Weikersthal L, Herbin J, Meier-Höfig M, Mücke R, Rohe U, Stauch T, Stoll C, Troeltzsch D, Wittmann S, Kurz O, Naumann R, Huebner J. Introducing a standardized assessment of patients' interest in and usage of CAM in routine cancer care: chances and risks from patients' and physicians' point of view. J Cancer Res Clin Oncol. 2023 Sep 16. doi: 10.1007/s00432-023-05182-3. Epub ahead of print. PMID: 37715831

Lauseker M, Hehlmann R, Hochhaus A, Saußele S. Survival with chronic myeloid leukaemia after failing milestones. Leukemia. 2023 Sep 19. doi: 10.1038/s41375-023-02028-2. Epub ahead of print. PMID: 37726340

Eckardt JN, Bill M, Rausch C, Metzeler K, Spiekermann K, Stasik S, Sauer T, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Krug U, Wörmann B, Hiddemann W, Görlich D, Sauerland C, Steffen B, Einsele H, Neubauer A, Burchert A, Schäfer-Eckart K, Berdel WE, Schliemann C, Krause SW, Hänel M, Hanoun M, Kaufmann M, Fransecky L, Braess J, Ruhnke L, Schetelig J, Middeke JM, Serve H, Baldus CD, Platzbecker U, Müller-Tidow C, Bornhäuser M, Herold T, Thiede C, Röllig C. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European leukemia net risk classification. Leukemia. 2023 Sep 7. doi: 10.1038/s41375-023-02016-6. Epub ahead of print. PMID: 37679502

Hoppe C, Büntzel J, Paradies K, Rösler M, Hübner J; Working Group Prevention and Integrative Oncology of the German Cancer Society. Psychosocial effects of the corona pandemic on people with cancer: a qualitative study. J Cancer Res Clin Oncol. 2023 Oct;149(13):11031-11039. doi: 10.1007/s00432-023-04970-1. Epub 2023 Jun 20. PMID: 37340188; PMCID: PMC10465636

Hammersen J, Birndt S, Döhner K, Reuken P, Stallmach A, Sauerbrey P, La Rosée F, Pfirrmann M, Fabisch C, Weiss M, Träger K, Bremer H, Russo S, Illerhaus G, Drömann D, Schneider S, La Rosée P, Hochhaus A. The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial. Leukemia. 2023 Sep;37(9):1879-1886. doi: 10.1038/s41375-023-01979-w. Epub 2023 Jul 28. PMID: 37507425; PMCID: PMC10457200

Isfort S, Manz K, Teichmann LL, Crysandt M, Burchert A, Hochhaus A, Saussele S, Kiani A, Göthert JR, Illmer T, Schafhausen P, Al-Ali HK, Stegelmann F, Hänel M, Pfeiffer T, Giagounidis A, Franke GN, Koschmieder S, Fabarius A, Ernst T, Warnken-Uhlich M, Wolber U, Kohn D, Pfirrmann M, Wolf D, Brümmendorf TH; German CML study group. Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study. Ann Hematol. 2023 Aug 18. doi: 10.1007/s00277-023-05394-0. Epub ahead of print. PMID: 37592092

Eifert T, Hsu CJ, Becker AL, Graessle S, Horne A, Bemmann F, Zhang Q, Heuser M, Vasioukhin V, Scholl S, Hochhaus A, Siegerist F, Endlich N, Bullinger L, Lane SW, Haas S, Schnoeder TM, Heidel FH. Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia. Leukemia. 2023 Aug 16. doi: 10.1038/s41375-023-02005-9. Epub ahead of print. PMID: 37587260

Schrenk KG, Weschenfelder W, Spiegel C, Agaimy A, Stöhr R, Hartmann A, Gaßler N, Drescher R, Freesmeyer M, Malouhi A, Bürckenmeyer F, Aschenbach R, Teichgräber U, Kögler C, Vogt M, Hofmann GO, Hochhaus A. Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma. J Cancer Res Clin Oncol. 2023 Aug;149(9):5493-5496. doi: 10.1007/s00432-022-04496-y. Epub 2022 Dec 5. PMID: 36469155; PMCID: PMC10356868

Staupe H, Buentzel J, Keinki C, Buentzel J, Huebner J. Systematic analysis of mistletoe prescriptions in clinical studies. J Cancer Res Clin Oncol. 2023 Aug;149(9):5559-5571. doi: 10.1007/s00432-022-04511-2. Epub 2022 Dec 9. PMID: 36481925; PMCID: PMC10356894

Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D. Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors. J Cancer Res Clin Oncol. 2023 Aug;149(9):6247-6262. doi: 10.1007/s00432-022-04562-5. Epub 2023 Jan 28. PMID: 36707445; PMCID: PMC10356870

Keck M, Hübner J, Büntzel J. "I do not hear you!": hearing-impaired cancer patients report their communication experiences. J Cancer Res Clin Oncol. 2023 Aug;149(9):6557-6567. doi: 10.1007/s00432-023-04634-0. Epub 2023 Feb 13. PMID: 36780054; PMCID: PMC9924207

Schmidt A, Bernhardt C, Bürkle D, Fries S, Hannig CV, Jentsch-Ullrich K, Josting A, Kreher S, Reiser M, Steinmetz HT, Tesch H, Terner S, Schulte A, Crodel CC, Palandri F, Heidel FH. Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany. J Cancer Res Clin Oncol. 2023 Aug;149(10):7197-7206. doi: 10.1007/s00432-023-04669-3. Epub 2023 Mar 8. PMID: 36884118; PMCID: PMC10374473

Hübner J: Kommentar zu "Tumortherapie: Beipackzettel gehen am Patienten vorbei". Dtsch Med Wochenschr 2023; 148; 2023. Thieme; 877-878

Hack V, Josfeld L, Hübner J, Keinki C, Büntzel J. Decision-making by cancer patients and the role of a counselling facility for complementary and alternative medicine: a cohort study. J Cancer Res Clin Oncol. 2023 Jul;149(7):2903-2913. doi: 10.1007/s00432-022-04178-9. Epub 2022 Jul 11. PMID: 35819526; PMCID: PMC10314849

Colditz C, Keinki C, Huebner J. Self-help management of patients undergoing chemotherapy: analysis of the online forum of the women's self-help association against cancer. Breast Cancer. 2023 Jul 7. doi: 10.1007/s12282-023-01481-2. Epub ahead of print. PMID: 37420142

Halwas N, Griebel L, Huebner J. eHealth literacy, Internet and eHealth service usage: a survey among cancer patients and their relatives. J Cancer Res Clin Oncol. 2017 Nov;143(11):2291-2299. doi: 10.1007/s00432-017-2475-6. Epub 2017 Jul 11. PMID: 28699035

Schaefer C, Hübner J: Leitlinien zur Förderung der Patientenbeteiligung und -Information. Günster et al. (Hrsg.) Versorgungs-Report Leitlinien - Evidenz für die Praxis. ISBN: 978-3-95466-800-7

Boesenecker SJ, Mathies V, Buentzel J, Huebner J. How can counselling by family physicians on nutrition and physical activity be improved: trends from a survey in Germany. J Cancer Res Clin Oncol. 2023 Jul;149(7):3335-3347. doi: 10.1007/s00432-022-04233-5. Epub 2022 Aug 6. PMID: 35932301; PMCID: PMC10314832

Boesenecker SJ, Mathies V, Buentzel J, Huebner J. Nutrition and physical activity in cancer patients: a survey on their information sources. J Cancer Res Clin Oncol. 2022 Aug 22. doi: 10.1007/s00432-022-04282-w. Epub ahead of print. PMID: 35994117

Keinki C, Ahmadi E, Kastrati K, Zomorodbakhsch B, Hübner J; Working Group Prevention and Integrative Oncology of the German Cancer Society (PRIO). Cancer Patient Motives and Expectations on Non-medical Practitioners. In Vivo. 2022 Sep-Oct;36(5):2505-2513. doi: 10.21873/invivo.12986. PMID: 36099132; PMCID: PMC946393

Hoppe C, Büntzel J, Paradies K, Rösler M, Hübner J; Working Group Prevention and Integrative Oncology of the German Cancer Society. Psychosocial effects of the corona pandemic on people with cancer: a qualitative study. J Cancer Res Clin Oncol. 2023 Jun 20. doi: 10.1007/s00432-023-04970-1. Epub ahead of print. PMID: 37340188

Georgi JA, Stasik S, Eckardt JN, Zukunft S, Hartwig M, Röllig C, Middeke JM, Oelschlägel U, Krug U, Sauer T, Scholl S, Hochhaus A, Brümmendorf TH, Naumann R, Steffen B, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Hänel M, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Müller-Tidow C, Platzbecker U, Berdel WE, Serve H, Ehninger G, Bornhäuser M, Schetelig J, Kroschinsky F, Thiede C; Study Alliance Leukemia (SAL). UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome. Blood Cancer J. 2023 May 26;13(1):88. doi: 10.1038/s41408-023-00858-y. PMID: 37236968; PMCID: PMC1022002

Chen Y, Möbius S, Riege K, Hoffmann S, Hochhaus A, Ernst T, Rudolph KL. Genetic separation of chronic myeloid leukemia stem cells from normal hematopoietic stem cells at single-cell resolution. Leukemia. 2023 May 26. doi: 10.1038/s41375-023-01929-6. Epub ahead of print. PMID: 37237078

Supplement to: Eichhorst B, Niemann CU, Kater AP, et al. First-line venetoclax combinations in chronic lymphocytic
leukemia. N Engl J Med 2023;388:1739-54. DOI: 10.1056/NEJMoa2213093

Kühnel C, Salomo S, Pagiatakis H, Hübner J, Seifert P, Freesmeyer M, Gühne F. Medical Students’ and Radiology Technician Trainees’ eHealth Literacy and Hygiene Awareness—Asynchronous and Synchronous Digital Hand Hygiene Training in a Single-Center Trial. Healthcare. 2023; 11(10):1475. https://doi.org/10.3390/healthcare11101475

Wurschi GW, Güllmar D, Gaßler N, Clement J, Kesselmeier M, Müller-Wurschi JJ, Settmacher U, Mothes H, Helfritzsch H, Liebe Y, Franiel T, Mäurer MA, Ernst T, Nicolay NH, Wittig A. Planning adaptive treatment by longitudinal response assessment implementing MR imaging, liquid biopsy and analysis of microenvironment during neoadjuvant treatment of rectal cancer (PRIMO). Medicine (Baltimore). 2023 Apr 25;102(17):e33575. doi: 10.1097/MD.0000000000033575. PMID: 37115093; PMCID: PMC10146036

Hübner J, Keinki C, Büntzel J. Komplementäre und alternative Medizin – eine Option bei chronischen Schmerzpatienten? [Complementary and alternative medicine-An option for chronic pain patients?]. Schmerz. 2023 May 8. German. doi: 10.1007/s00482-023-00719-4. Epub ahead of print. PMID: 37154977

Hinze A, Rinke J, Crodel CC, Möbius S, Schäfer V, Heidel FH, Hochhaus A, Ernst T. Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms. Br J Haematol. 2023 Jul;202(2):308-317. doi: 10.1111/bjh.18834. Epub 2023 May 4. PMID: 37139709

Hauptmann M, Kutschan S, Hübner J, Dörfler J. Bioenergy therapies as a complementary treatment: a systematic review to evaluate the efficacy of bioenergy therapies in relieving treatment toxicities in patients with cancer. J Cancer Res Clin Oncol. 2023 Jun;149(6):2607-2619. doi: 10.1007/s00432-022-04362-x. Epub 2022 Sep 27. PMID: 36166091; PMCID: PMC10129966

Keinki C, Rudolph I, Wozniak T, Pietsch R, Margolina M, Garcia I, Mayr-Welschlau K, Schmidt T, Hübner J. A virtual dance sport class for cancer patients: the trainer perspective. J Cancer Res Clin Oncol. 2023 Mar;149(3):1079-1083. doi: 10.1007/s00432-022-03913-6. Epub 2022 Mar 7. PMID: 35253086; PMCID: PMC9984500

Bargehr B, Fischer von Weikersthal L, Junghans C, Zomorodbakhsch B, Stoll C, Prott FJ, Fuxius S, Micke O, Hübner J, Büntzel J, Hoppe C. Sense of coherence and its context with demographics, psychological aspects, lifestyle, complementary and alternative medicine and lay aetiology. J Cancer Res Clin Oncol. 2023 Apr 20. doi: 10.1007/s00432-023-04760-9. Epub ahead of print. PMID: 37079052

Mickoleit F, Jörke C, Richter R, Rosenfeldt S, Markert S, Rehberg I, Schenk AS, Bäumchen O, Schüler D, Clement JH. Long-Term Stability, Biocompatibility, and Magnetization of Suspensions of Isolated Bacterial Magnetosomes. Small. 2023 Feb 17:e2206244. doi: 10.1002/smll.202206244. Epub ahead of print. PMID: 36799182

Réa D, Boquimpani C, Mauro MJ, Minami Y, Allepuz A, Maheshwari VK, D'Alessio D, Wu Y, Lawrance R, Narbutas S, Sharf G, Hochhaus A. Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial. Leukemia. 2023 May;37(5):1060-1067. doi: 10.1038/s41375-023-01888-y. Epub 2023 Apr 14. PMID: 37069326

Wagenknecht A, Dörfler J, Freuding M, Josfeld L, Huebner J. Homeopathy effects in patients during oncological treatment: a systematic review. J Cancer Res Clin Oncol. 2023 May;149(5):1785-1810. doi: 10.1007/s00432-022-04054-6. Epub 2022 Jun 22. PMID: 35731274; PMCID: PMC10097733

Retzlaff T, Dörfler J, Kutschan S, Freuding M, Hübner J. The benefits of vitamin A as a complementary treatment for oncology patients: a systematic review. J Cancer Res Clin Oncol. 2023 May;149(5):2157-2177. doi: 10.1007/s00432-022-04224-6. Epub 2022 Aug 16. PMID: 35972692

Brandt F, Schneider N, Altmann U, Strauß B, Hübner J, Keinki C. Psychometrische Eigenschaften des Qualiskope-A zur Messung der Patientenzufriedenheit mit der ambulant-ärztlichen Behandlung: Einsatz in der Onkologie und Übertragbarkeit auf die stationäre Versorgung [Psychometric Properties of the Qualiskope-A for Measuring Patient Satisfaction with Outpatient Medical Treatment: Use in Oncology and Transferability to Inpatient Care]. Gesundheitswesen. 2023 Apr 7. German. doi: 10.1055/a-2016-7948. Epub ahead of print. PMID: 3702841

Frietsch JJ, Flossdorf S, Beck JF, Kröger N, Fleischhauer K, Dreger P, Schetelig J, Bornhäuser M, Hochhaus A, Hilgendorf I. Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany. Br J Haematol. 2023 Apr;201(2):308-318. doi: 10.1111/bjh.18610. Epub 2022 Dec 27. PMID: 36573337

Hauptmann L, Midic D, Eigendorff F, Malouhi A, Theis B, Kißler H, Rödel J, Prims F, Hochhaus A, Scholl S, Schnetzke U. Staphylococcus intermedius infection with splenic abscesses in a patient with acute lymphoblastic leukemia. Ann Hematol. 2023 Apr 4. doi: 10.1007/s00277-023-05208-3. Epub ahead of print. PMID: 37014448

Hochhaus A, Ströbel P, Höffken K: Myeloproliferative Neoplasien – eine heterogene Entität mit vielen Ähnlichkeiten. Onkologie 29, 278–280 (2023), https://doi.org/10.1007/s00761-023-01330-z

Siebert R, Schuh A, Ott G, Cree IA, Du MQ, Ferry J, Hochhaus A, Naresh KN, Solary E, Khoury JD. Response to the Comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH) on the 5th edition of the World Health Organization classification of haematolymphoid tumors. Leukemia. 2023 May;37(5):1170-1172. doi: 10.1038/s41375-023-01872-6. Epub 2023 Mar 27. PMID: 36973349

Tober R, Schnetzke U, Fleischmann M, Yomade O, Schrenk K, Hammersen J, Glaser A, Thiede C, Hochhaus A, Scholl S: Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia. J Cancer Res Clin Oncol. 2023 Apr;149(4):1569-1583. doi: 10.1007/s00432-022-03995-2. Epub 2022 May 18. PMID: 35583829; PMCID: PMC10020242

Mauro MJ, Hughes TP, Kim DW, Rea D, Cortes JE, Hochhaus A, Sasaki K, Breccia M, Talpaz M, Ottmann O, Minami H, Goh YT, DeAngelo DJ, Heinrich MC, Gómez-García de Soria V, le Coutre P, Mahon FX, Janssen JJWM, Deininger M, Shanmuganathan N, Geyer MB, Cacciatore S, Polydoros F, Agrawal N, Hoch M, Lang F. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia. 2023 May;37(5):1048-1059. doi: 10.1038/s41375-023-01860-w. Epub 2023 Mar 22. PMID: 36949155

Kröger N., Gagelmann N, Hilgendorf I: Allogene Stammzelltransplantation bei myeloproliferativen Neoplasien. Onkologie 2023, 29: 339–345, https://doi.org/10.1007/s00761-023-01329-6

Hübner J, Prott FJ, Büntzel J, Micke O, Keinki C: Wer zahlt für komplementäre und alternative Medizin? Forum https://doi.org/10.1007/s12312-023-01187-8, published online 15 March 2023

Keinki C, Rudolph I, Wozniak T, Pietsch R, Margolina M, Garcia I, Mayr-Welschlau K, Schmidt T, Hübner J: A virtual dance sport class for cancer patients: the trainer perspective. J Cancer Res Clin Oncol. 2023 Mar;149(3):1079-1083. doi: 10.1007/s00432-022-03913-6. Epub 2022 Mar 7. PMID: 35253086; PMCID: PMC9984500

DiNardo CD, Hochhaus A, Frattini MG, Yee K, Zander T, Krämer A, Chen X, Ji Y, Parikh NS, Choi J, Wei AH: A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome. J Cancer Res Clin Oncol. 2023 Mar;149(3):1145-1158. doi: 10.1007/s00432-022-03983-6. Epub 2022 Mar 30. PMID: 35353219

Stegelmann F, Teichmann LL, Heidel FH, Crodel CC, Ernst T, Kreil S, Reiter A, Otten S, Schauer S, Körber RM, Kricheldorf K, Isfort S, Döhner H, Brümmendorf TH, Griesshammer M, Döhner K, Koschmieder S: Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN). Leukemia. 2023 Feb 24. doi: 10.1038/s41375-023-01837-9. Epub ahead of print. PMID: 36828867

Giebel S, Labopin M, Schroeder T, Swoboda R, Maertens J, Bourhis JH, Grillo G, Salmenniemi U, Hilgendorf I, Kröger N, Poiré X, Cornelissen JJ, Arat M, Savani B, Spyridonidis A, Nagler A, Mohty M: Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2023 Jan 10. doi: 10.1002/ajh.26825. Epub ahead of print. PMID: 36626592

Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D: Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors. J Cancer Res Clin Oncol. 2023 Jan 28. doi: 10.1007/s00432-022-04562-5. Epub ahead of print. PMID: 36707445

Ernst T, Hochhaus A: Chronische myeloische Leukämie. Onkologie 29, 305–314 (2023), https://doi.org/10.1007/s00761-022-01290-w

Späth C, Peter N, Opitz B, Florschütz A, Reifenrath K, Zojer N, Scholl S, Pönisch W, Heyn S, Vucinic V, Hochhaus A, Aul C, Giagounidis A, Balleisen L, Oldenkott B, Staib P, Kiehl M, Schütte W, Naumann R, Eimermacher H, Dörken B, Sauerland C, Lengfelder E, Hiddemann W, Wörmann B, Müller-Tidow C, Serve H, Schliemann C, Hehlmann R, Berdel WE, Pfirrmann M, Krug U, Hoffmann VS: Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study. Ann Hematol. 2023 Jan 25. doi: 10.1007/s00277-023-05087-8. Epub ahead of print. PMID: 36695874

Goldmann M, Schmidt F, Cseresnyés Z, Orasch T, Jahreis S, Hartung S, Figge MT, von Lilienfeld-Toal M, Heinekamp T, Brakhage AA: The Lipid Raft-Associated Protein Stomatin Is Required for Accumulation of Dectin-1 in the Phagosomal Membrane and for Full Activity of Macrophages against Aspergillus fumigatus. mSphere. 2023 Jan 31:e0052322. doi: 10.1128/msphere.00523-22. Epub ahead of print. PMID: 36719247

Giesen N, Sprute R, Rüthrich M, Khodamoradi Y, Mellinghoff SC, Beutel G, Lueck C, Koldehoff M, Hentrich M, Sandherr M, von Bergwelt-Baildon M, Wolf HH, Hirsch HH, Wörmann B, Cornely OA, Köhler P, Schalk E, von Lilienfeld-Toal M: COVID-19 guideline panel of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy. Eur J Cancer. 2021 Apr;147:154-160. doi: 10.1016/j.ejca.2021.01.033. Epub 2021 Feb 10. PMID: 33676266; PMCID: PMC7874914

Schuster FS, Nyvlt P, Heeren P, Spies C, Adam MF, Schenk T, Brunkhorst FM, Janka G, La Rosée P, Lachmann C, Lachmann G: Differential Diagnosis of Hyperferritinemia in Critically Ill Patients. J Clin Med. 2022 Dec 27;12(1):192. doi: 10.3390/jcm12010192. PMID: 36614993; PMCID: PMC9821140

Ruhnke L, Röllig C, Herold S, Sauer T, Brandts CH, Steffen B, Schäfer-Eckart K, Krause SW, Hänel M, Reichle A, Scholl S, Neubauer A, Mikesch JH, Schetelig J, Stölzel F, Kramer M, Haake A, Frimmel J, Krämer A, Schlenk R, Platzbecker U, Serve H, Baldus CD, Müller-Tidow C, Aust D, Bornhäuser M, Ehninger G, Thiede C: Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial. Haematologica. 2023 Feb 9. doi: 10.3324/haematol.2022.281636. Epub ahead of print. PMID: 36779591

Mickoleit F, Jörke C, Richter R, Rosenfeldt S, Markert S, Rehberg I, Schenk AS, Bäumchen O, Schüler D, Clement JH: Long-Term Stability, Biocompatibility, and Magnetization of Suspensions of Isolated Bacterial Magnetosomes. Small 2023, DOI: 10.1002/smll.202206244

Brioli A, Gengenbach L, Mancuso K, Binder M, Ernst T, Heidel FH, Stauch T, Zamagni E, Hilgendorf I, Hochhaus A, Engelhardt M, von Lilienfeld-Toal M. Pomalidomide combinations are a safe and effective option after daratumumab failure. J Cancer Res Clin Oncol. 2023 Aug;149(9):6569-6574. doi: 10.1007/s00432-023-04637-x. Epub 2023 Feb 13. PMID: 36781500; PMCID: PMC10356885

Heidel FH., Crodel CC, Kreipe HH: Primäre Myelofibrose. Onkologie 29, 315–322 (2023), https://doi.org/10.1007/s00761-022-01253-1

Dörfler J, Freuding M, Zaiser C, Büntzel J, Keinki C, Käsmann L, Hübner J: Umbrella review: Summary of findings for acupuncture as treatment for radiation-induced xerostomia. Head Neck. 2023 Feb 13. doi: 10.1002/hed.27297. Epub ahead of print. PMID: 36779370

Keck M, Hübner J, Büntzel J. "I do not hear you!": hearing-impaired cancer patients report their communication experiences. J Cancer Res Clin Oncol. 2023 Feb 13. doi: 10.1007/s00432-023-04634-0. Epub ahead of print. PMID: 36780054

Radich JP, Wall M, Branford S, Campbell CD, Chaturvedi S, DeAngelo DJ, Deininger M, Guinney J, Hochhaus A, Hughes TP, Kantarjian HM, Larson RA, Li S, Maegawa R, Mishra K, Obourn V, Pinilla-Ibarz J, Purkayastha D, Sadek I, Saglio G, Shrestha A, White BS, Druker BJ: Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis. Haematologica. 2023 Feb 2. doi: 10.3324/haematol.2022.281878. Epub ahead of print. PMID: 36727397

Hochhaus A, Réa D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, Kim D, Abdo A, Fogliatto LM, le Coutre P, Sasaki K, Kim D, Saussele S, Annunziata M, Chaudhri N, Chee L, García-Gutiérrez V, Kapoor S, Allepuz A, Quenet S, VBédoucha V, Mauro MJ: Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia 37, 617–626 (2023) https://doi.org/10.1038/s41375-023-01829-9

Rummelt C, Grishina O, Schmoor C, Crysandt M, Heuser M, Götze KS, Schlenk RF, Döhner K, Salih HR, Heil G, Müller-Tidow C, Brugger W, Kündgen A, De Wit M, Giagounidis A, Scholl S, Neubauer A, Krauter J, Bug G, Al-Ali HK, Wäsch R, Becker H, May AM, Duyster J, Hackanson B, Ganser A, Döhner H, Lübbert M.:Activity of decitabine combined with all-trans retinoic acid in oligoblastic AML: Results from a randomized 2x2 phase II trial (DECIDER). Haematologica. 2023 Jan 5. doi: 10.3324/haematol.2022.282258. Epub ahead of print. PMID: 36601981

Kayser S, Kramer M, Martínez-Cuadrón D, Grenet J, Metzeler KH, Sustkova Z, Luskin MR, Brunner AM, Elliott MA, Gil C, Marini SC, Ráčil Z, Cetkovsky P, Novak J, Perl AE, Platzbecker U, Stölzel F, Ho AD, Thiede C, Stone RM, Röllig C, Montesinos P, Schlenk RF, Levis MJ: Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study. Haematologica. 2022 Apr 1;107(4):836-843. doi: 10.3324/haematol.2021.278645. PMID: 34348451; PMCID: PMC8968900

Ernst T, Hochhaus A: Chronische myeloische Leukämie. Onkologie 29, 305–314 (2023). https://doi.org/10.1007/s00761-022-01290-w

Krege S, Hübner J: Integrative Medizin in der Uroonkologie. Die Urologie | Ausgabe 1/2023

Hübner J, Keinki C, Münstedt K: Alternativmedizin in der Uroonkologie. Die Urologie | Ausgabe 1/2023

Bauer-Büntzel C, Büntzel J, Zomorodbakhsch B, Keinki C: Phytotherapie in der Uroonkologie. Die Urologie | Ausgabe 1/2023

Schmidt L, Mathies V, von Grundherr J: Praxisrelevante Ernährungsempfehlungen in der Uroonkologie. Die Urologie | Ausgabe 1/2023

Niederwieser D, Lan T, Krahl R, Heinicke T, Maschmeyer G, Al‑Ali HK, Schwind S, Jentzsch M, Cross M, Kahl C, Wolf HH, Sayer H, Schulze A, Dreger P,· Hegenbart U, · Krämer A, Junghanss C, · Mügge LO, Hähling D, Hirt C, Späth C, Peter N, Opitz B, · Florschütz A, Reifenrath K, Zojer N, Scholl S, · Pönisch W, Heyn S, Vucinic V, Hochhaus A, Aul C, Giagounidis A, Balleisen L, Oldenkott B, Staib P, Kiehl M, Schütte W, Naumann R, Eimermacher H, Dörken B, Sauerland C, Lengfelder E, Hiddemann W, Wörmann B, Muller‑Tidow C, Serve H, Schliemann C, Hehlmann R, E. Berdel WE, Pfirrmann M, Utz Krug39,44 · Hoffmann VS: Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study. Ann Hematol (2023). https://doi.org/10.1007/s00277-023-05087-8

Hochhaus A, Ott G, Siebert R: WHO-Klassifikation 2022 chronischer myeloproliferativer Erkrankungen. Onkologie 2023, 29:287–295https://doi.org/10.1007/s00761-023-01308-x

Huebner J, Muecke R, Micke O, Prott FJ, Josfeld L, Büntzel J, Büntzel J; Working Group Prevention, Integrative Oncology of the German Cancer Society. Lay etiology concepts of cancer patients do not correlate with their usage of complementary and/or alternative medicine. J Cancer Res Clin Oncol. 2023 Aug;149(9):6067-6074. doi: 10.1007/s00432-022-04528-7. Epub 2023 Jan 18. PMID: 36653538; PMCID: PMC10356643

Mathies V, Schmidt L, Reudelsterz C, Hübner J. (2023): Ernährung bei besonderen Folgeerscheinungen der Tumorerkrankung. In: Schmoll, HJ. (eds) Kompendium Internistische Onkologie . Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-46764-0_341-1

Kouka M, Landgraf J, Büntzel J, Kaftan H, Böger D, Mueller A, Schultze-Mosgau S, Ernst T, Guntinas-Lichius O: Sterberisiko für Mundhöhlen- und Oropharynxkarzinome in Thüringen: eine bevölkerungsbasierte Analyse [Mortality risk for oral and oropharyngeal carcinomas in Thuringia: a population-based analysis]. Laryngorhinootologie. 2023 Jan 5. German. doi: 10.1055/a-1976-9815. Epub ahead of print. PMID: 36603817

Appel TM, Stein C, Brandt C, Rödel J, Frietsch JJ, Miethke J, Hochhaus A, Hilgendorf I. Isolation of Hafnia paralvei co-harbouring blaNDM-1 and blaVIM-1 in a woman who underwent allogeneic hematopoietic stem cell transplantation. Infection. 2023 Aug;51(4):1161-1164. doi: 10.1007/s15010-022-01976-8. Epub 2023 Jan 3. PMID: 36595211; PMCID: PMC10352390

Hübner J, Münstedt K, Micke O, Prott FJ, Schmidt T, Büntzel J, Keinki C. Komplementäre oder alternative Medizin in der Onkologie : Chancen oder Risiken? [Complementary or alternative medicine in oncology : Chances or risks?]. Inn Med (Heidelb). 2023 Jan;64(1):3-9. German. doi: 10.1007/s00108-022-01452-3. Epub 2023 Jan 3. PMID: 36594968

2022

Hess G, Hüttmann A, Witzens-Harig M, Dreyling MH, Keller U, Marks R, Ernst T, Pott C, Viardot A, Frontzek F, Trautmann M, Ruckes C, Deuster O, Rosenwald A, Theobald M, Lenz G. A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial. Br J Haematol. 2022 Aug;198(3):482-491. doi: 10.1111/bjh.18161. Epub 2022 Apr 1. PMID: 35362552

Koschmieder S, Isfort S, Wolf D, Heidel FH, Hochhaus A, Schafhausen P, Griesshammer M, Wolleschak D, Platzbecker U, Döhner K, Jost PJ, Parmentier S, Schaich M, von Bubnoff N, Stegelmann F, Maurer A, Crysandt M, Gezer D, Kortmann M, Franklin J, Frank J, Hellmich M, Brümmendorf TH; German Study Group for Myeloproliferative Neoplasms (GSG-MPN). Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group. Ann Hematol. 2022 Dec 23. doi: 10.1007/s00277-022-05080-7. Epub ahead of print. PMID: 36564535

Wittwer A, Sponholz K, Frietsch JJ, Linke P, Kropp P, Hochhaus A, Hilgendorf I. Psychosocial distress in young adults surviving hematological malignancies: a pilot study. J Cancer Res Clin Oncol. 2023 Aug;149(9):5655-5663. doi: 10.1007/s00432-022-04527-8. Epub 2022 Dec 17. PMID: 36527483; PMCID: PMC10356626

Wu JMF, Bekfani T, Hinze A, Westphal JG, Steinacker B, Zeller M, Hartmann C, Möbius-Winkler S, Hochhaus A, Schulze PC, Ernst T. Clonal haematopoiesis of indeterminate potential-related mutations and outcome in dilated and ischaemic cardiomyopathy. ESC Heart Fail. 2022 Dec;9(6):3954-3960. doi: 10.1002/ehf2.14115. Epub 2022 Aug 18. PMID: 35979940

Cortes JE, Hochhaus A, Takahashi N, Larson RA, Issa GC, Bombaci F, Ramscar N, Ifrah S, Hughes TP. Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. Future Oncol. 2022 Dec 16. doi: 10.2217/fon-2022-0923. Epub ahead of print. PMID: 36524980

Kastrati K, Mathies V, Kipp AP, Huebner J. Patient-reported experiences with side effects of kidney cancer therapies and corresponding information flow. J Patient Rep Outcomes. 2022 Dec 16;6(1):126. doi: 10.1186/s41687-022-00533-z. PMID: 36525162; PMCID: PMC9758261

Schrenk KG, Weschenfelder W, Spiegel C, Agaimy A, Stöhr R, Hartmann A, Gaßler N, Drescher R, Freesmeyer M, Malouhi A, Bürckenmeyer F, Aschenbach R, Teichgräber U, Kögler C, Vogt M, Hofmann GO, Hochhaus A. Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma. J Cancer Res Clin Oncol. 2022 Dec 5. doi: 10.1007/s00432-022-04496-y. Epub ahead of print. PMID: 36469155

Stein A, Paschold L, Tintelnot J, Goekkurt E, Henkes SS, Simnica D, Schultheiss C, Willscher E, Bauer M, Wickenhauser C, Thuss-Patience P, Lorenzen S, Ettrich T, Riera-Knorrenschild J, Jacobasch L, Kretzschmar A, Kubicka S, Al-Batran SE, Reinacher-Schick A, Pink D, Sinn M, Lindig U, Hiegl W, Hinke A, Hegewisch-Becker S, Binder M. Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial. JAMA Oncol. 2022 Aug 1;8(8):1150-1158. doi: 10.1001/jamaoncol.2022.2228. PMID: 35737383; PMCID: PMC9227706

Vogel A, Sterneck M, Vondran F, Waidmann O, Klein I, Lindig U, Nadalin S, Settmacher U, Tacke F, Schlitt HJ, Wege H. Der Einsatz der immunonkologischen Therapie beim hepatozellulären Karzinom im Kontext der Lebertransplantation Eine interdisziplinäre Risiko-Nutzen-Abwägung [The use of immuno-oncologic therapy in hepatocellular carcinoma in the context of liver transplantation. An interdisciplinary benefit/risk assessment]. Z Gastroenterol. 2022 Feb;60(2):184-191. German. doi: 10.1055/a-1649-8643. Epub 2021 Oct 20. PMID: 34670296

Hübner J, Keinki C, Münstedt K: Alternativmedizin in der Uroonkologie. Urologie (2022). https://doi.org/10.1007/s00120-022-01990-6

Drexler U, Dörfler J, von Grundherr J, Erickson N, Hübner J: Fasting during cancer treatment: a systematic review. Qual Life Res (2022). https://doi.org/10.1007/s11136-022-03300-1

Dreger P, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner E, Wulf G, Marks R, Penack O, Schnetzke U, Koenecke C, von Bonin M, Stelljes M, Glass B, Baldus CD, Vucinic V, Mougiakakos D, Topp M, Schroers R, Wolff D, Thomas S, Kröger N, Bethge WA; German Lymphoma Alliance (GLA); German Stem Cell Transplantation Registry (DRST). Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience. Bone Marrow Transplant. 2022 Nov 22. doi: 10.1038/s41409-022-01867-4. Epub ahead of print. PMID: 36418916

Brüggemann M, Pott C, Stübig T, Kneba M, Hochhaus A (2022). Marker für minimale Resterkrankung: Minimal Residual Disease. In: Schmoll, HJ. (eds) Kompendium Internistische Onkologie . Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-46764-0_153-1

Brioli A, Wyrwa A, Rüddel U, Yomade O, Lindig U, Franz W, Wacker HH, Gaßler N, Schweyer S, Chung HY, Axer H, Witte OW, Hochhaus A, Schrenk KG. Mutations in the plasma cell clone identify mechanism of polyneuropathy in a case of POEMS syndrome associated with Castleman disease and multiple myeloma. Ann Hematol. 2022 Nov 19. doi: 10.1007/s00277-022-05032-1. Epub ahead of print. PMID: 36401620

Henß H, Hübner J: Kompendium Seltene Tumoren. 2022; Zuckschwerdt (Verlag), 978-3-86371-353-9 (ISBN)

Festerling L, Buentzel J, Fischer von Weikersthal L, Junghans C, Zomorodbakhsch B, Stoll C, Prott FJ, Fuxius S, Micke O, Richter A, Sallmann D, Huebner J, Hoppe C. Resilience in cancer patients and how it correlates with demographics, psychological factors, and lifestyle. J Cancer Res Clin Oncol. 2022 Nov 18. doi: 10.1007/s00432-022-04480-6. Epub ahead of print. PMID: 36396875

Hehlmann R, Lauseker M, Voskanyan A, Fabarius A, Haferlach C, Hochhaus A, Saußele S: Impact of emerging ACA on survival in chronic myeloid leukemia (CML). Leukemia 36, 2544–2547 (2022). https://doi.org/10.1038/s41375-022-01681-3

Hübner J. Integrative oncology-the best from one world. J Cancer Res Clin Oncol. 2022 Dec;148(12):3225-3226. doi: 10.1007/s00432-022-04168-x. Epub 2022 Jul 1. PMID: 35776195; PMCID: PMC9587103

Hübner J, Dörfler J, Liebl C, Käsmann L: Answer to Commentary on “Systematic review about complementary medical hyperthermia in oncology” by Liebl et al.. Clin Exp Med (2022). https://doi.org/10.1007/s10238-022-00901-5

Maschmeyer G, Loibl S, Fehm T, Hilgendorf I, Dittrich R: Management onkologischer Erkrankungen in der Schwangerschaft. Forum (2022). https://doi.org/10.1007/s12312-022-01134-z

Hanoun M, Ruhnke L, Kramer M, Hanoun C, Schäfer-Eckart K, Steffen B, Sauer T, Krause SW, Schliemann C, Mikesch JH, Kaufmann M, Hänel M, Jost E, Brümmendorf TH, Fransecky L, Kraus S, Einsele H, Niemann D, Neubauer A, Kullmer J, Seggewiss-Bernhard R, Görner M, Held G, Kaiser U, Scholl S, Hochhaus A, Reinhardt HC, Platzbecker U, Baldus CD, Müller-Tidow C, Bornhäuser M, Serve H, Röllig C; Study Alliance Leukemia (SAL). Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry. J Cancer Res Clin Oncol. 2022 Sep 28. doi: 10.1007/s00432-022-04356-9. Epub ahead of print. PMID: 36167894

Gavriilaki E, Labopin M, Sakellari I, Salmenniemi U, Yakoub-Agha I, Potter V, Berceanu A, Rambaldi A, Hilgendorf I, Kröger N, Mielke S, Zuckerman T, Sanz J, Busca A, Ozdogu H, Anagnostopoulos A, Savani B, Giebel S, Bazarbachi A, Spyridonidis A, Nagler A, Mohty M. Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP). Bone Marrow Transplant. 2022 Sep 22. doi: 10.1038/s41409-022-01830-3. Epub ahead of print. PMID: 36138068

Baron von Osthoff M, Watzlaw-Schmidt U, Lehmann T, Hübner J. Patientengruppenspezifische Datenhoheitsbedürfnisse und Akzeptanz der elektronischen Patientenakte [Patient group-specific data sovereignty needs and acceptance of electronic health records]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022 Sep 23. German. doi: 10.1007/s00103-022-03589-w. Epub ahead of print. PMID: 36149472

Münstermann J, Hübner J, Büntzel J. Can Cancer Education Programs Improve Health Literacy Among Deaf and Hard of Hearing Patients: a Systematic Review. J Cancer Educ. 2022 Sep 19. doi: 10.1007/s13187-022-02222-3. Epub ahead of print. PMID: 36117200

Hübner J, Welter S, Ciarlo G, Käsmann L, Ahmadi E, Keinki C. Patient activation, self-efficacy and usage of complementary and alternative medicine in cancer patients. Med Oncol. 2022 Sep 7;39(12):192. doi: 10.1007/s12032-022-01796-8. PMID: 36071252

Kunadt D, Stasik S, Metzeler KH, Röllig C, Schliemann C, Greif PA, Spiekermann K, Rothenberg-Thurley M, Krug U, Braess J, Krämer A, Hochhaus A, Scholl S, Hilgendorf I, Brümmendorf TH, Jost E, Steffen B, Bug G, Einsele H, Görlich D, Sauerland C, Schäfer-Eckart K, Krause SW, Hänel M, Hanoun M, Kaufmann M, Wörmann B, Kramer M, Sockel K, Egger-Heidrich K, Herold T, Ehninger G, Burchert A, Platzbecker U, Berdel WE, Müller-Tidow C, Hiddemann W, Serve H, Stelljes M, Baldus CD, Neubauer A, Schetelig J, Thiede C, Bornhäuser M, Middeke JM, Stölzel F; A. M. L. Cooperative Group (AMLCG), Study Alliance Leukemia (SAL). Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation. J Hematol Oncol. 2022 Sep 5;15(1):126. doi: 10.1186/s13045-022-01339-8. PMID: 36064577

Kantarjian HM, Jabbour E, Deininger M, Abruzzese E, Apperley J, Cortes J, Chuah C, DeAngelo DJ, DiPersio J, Hochhaus A, Lipton J, Nicolini FE, Pinilla-Ibarz J, Rea D, Rosti G, Rousselot P, Shah NP, Talpaz M, Srivastava S, Ren X, Mauro M: Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. Am J Hematol. 2022; 97( 11): 1419- 1426. doi:10.1002/ajh.26686

Ott KU, Keinki C, Kaesmann L, Hübner J: Education of complementary and alternative medicine in adult education centers in Germany: a web-based survey. Wien Med Wochenschr (2022). https://doi.org/10.1007/s10354-022-00951-0

Wu JMF, Bekfani T, Hinze A, Westphal JG, Steinacker B, Zeller M, Hartmann C, Möbius-Winkler S, Hochhaus A, Schulze PC, Ernst T. Clonal haematopoiesis of indeterminate potential-related mutations and outcome in dilated and ischaemic cardiomyopathy. ESC Heart Fail. 2022 Aug 18. doi: 10.1002/ehf2.14115. Epub ahead of print. PMID: 35979940

Tabatabai J, Schnitzler P, Prifert C, Schiller M, Weissbrich B, von Lilienfeld-Toal M, Teschner D, Jordan K, Müller-Tidow C, Egerer G, Giesen N. Parainfluenza virus infections in patients with hematological malignancies or stem cell transplantation: Analysis of clinical characteristics, nosocomial transmission and viral shedding. PLoS One. 2022 Jul 29;17(7):e0271756. doi: 10.1371/journal.pone.0271756. PMID: 35905071; PMCID: PMC9337657

Soverini S, De Santis S, Martelli M, Monaldi C, Castagnetti F, Gugliotta G, Papayannidis C, Mancini M, Bruno S, Venturi C, Machova Polakova K, Ernst T, Maar D, Corner A, Cavo M. Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia. Leukemia. 2022 Jul 30. doi: 10.1038/s41375-022-01660-8. Epub ahead of print. PMID: 35908105

Einsele H, Steutel H, Eichhorst B, Göbeler ME, Hochhaus A, Nickel L, von Messling V, Deggerich A, Nettekoven G. [Klinische Studien in der Hämatologie und Onkologie]. Oncol Res Treat. 2022 Jul 22;45 Suppl 1:6-32. German. doi: 10.1159/000525371. Epub ahead of print. PMID: 35871514

Heilfort L, Kutschan S, Dörfler J, Freuding M, Büntzel J, Münstedt K, Hübner J (2022): A Systematic Review of the Benefit of B-Vitamins as a Complementary Treatment in Cancer Patients, Nutrition and Cancer, DOI: 10.1080/01635581.2022.2098348

Stege, H.; Schneider, S.; Forschner, A.; Eigentler, T.; Nashan, D.; Huening, S.; Meiss, F.; Lehr, S.; Kaatz, M.; Kuchen, R.; Kaehler, K.C.; Haist, M.; Huebner, J.; Loquai, C. eHealth Literacy in German Skin Cancer Patients. Int. J. Environ. Res. Public Health 2022, 19, 8365. https://doi.org/10.3390/ijerph19148365

Liebl CM, Kutschan S, Dörfler J, Käsmann L, Hübner J. Systematic review about complementary medical hyperthermia in oncology. Clin Exp Med. 2022 Jun 29:1–47. doi: 10.1007/s10238-022-00846-9. Epub ahead of print. PMID: 35767077; PMCID: PMC9244386

CiteStein A, Paschold L, Tintelnot J, Goekkurt E, Henkes SS, Simnica D, Schultheiss C, Willscher E, Bauer M, Wickenhauser C, Thuss-Patience P, Lorenzen S, Ettrich T, Riera-Knorrenschild J, Jacobasch L, Kretzschmar A, Kubicka S, Al-Batran SE, Reinacher-Schick A, Pink D, Sinn M, Lindig U, Hiegl W, Hinke A, Hegewisch-Becker S, Binder M. Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial. JAMA Oncol. 2022 Jun 23. doi: 10.1001/jamaoncol.2022.2228. Epub ahead of print. PMID: 35737383

Wagenknecht A, Dörfler J, Freuding M, Josfeld L, Huebner J. Homeopathy effects in patients during oncological treatment: a systematic review. J Cancer Res Clin Oncol. 2022 Jun 22. doi: 10.1007/s00432-022-04054-6. Epub ahead of print. PMID: 35731274

Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A Jr, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22. PMID: 35732829; PMCID: PMC9214472

Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22. PMID: 35732831; PMCID: PMC9252913

Brioli A, Nägler TM, Yomade O, Rüthrich MM, Scholl S, Frietsch JJ, Hilgendorf I, Ernst T, Sayer HG, Hochhaus A, Mügge LO, von Lilienfeld-Toal M. Sex-disaggregated analysis of biology, treatment tolerability and outcome of Multiple Myeloma in a German cohort. Oncol Res Treat. 2022 Jun 15. doi: 10.1159/000525493. Epub ahead of print. PMID: 35705004

Salmon M, White HE, Zizkova H, Gottschalk A, Motlova E, Cerveira N, Colomer D, Coriu D, Franke GN, Gottardi E, Izzo B, Jurcek T, Lion T, Schäfer V, Venturi C, Vigneri P, Zawada M, Zuna J, Hovorkova L, Koblihova J, Klamova H, Markova MS, Srbova D, Benesova A, Polivkova V, Zackova D, Mayer J, Roeder I, Glauche I, Ernst T, Hochhaus A, Polakova KM, Cross NCP. Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy. Leukemia. 2022 Jul;36(7):1879-1886. doi: 10.1038/s41375-022-01612-2. Epub 2022 Jun 8. PMID: 35676453; PMCID: PMC9252903

Zomorodbakhsch, B., Hübner, J. Cannabis bei Krebs – für welchen Einsatz haben wir Evidenz?. Onkologie (2022). https://doi.org/10.1007/s00761-022-01197-6

Ernst P, Schnöder TM, Huber N, Perner F, Jayavelu AK, Eifert T, Hsu CJ, Tubío-Santamaría N, Crodel CC, Ungelenk M, Hübner CA, Clement JH, Hochhaus A, Heidel FH. Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms. Leukemia. 2022 Jul;36(7):1843-1849. doi: 10.1038/s41375-022-01611-3. Epub 2022 Jun 2. PMID: 35654819; PMCID: PMC9252905

Brümmendorf TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, le Coutre P, Garcia-Gutierrez V, Chuah C, Kota V, Lipton JH, Rousselot P, Mauro MJ, Hochhaus A, Hurtado Monroy R, Leip E, Purcell S, Yver A, Viqueira A, Deininger MW; BFORE study investigators. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022 Jul;36(7):1825-1833. doi: 10.1038/s41375-022-01589-y. Epub 2022 May 28. PMID: 35643868; PMCID: PMC9252917

Scholl S, Eich H, Höffken K: Akute Leukämien. Onkologie 28, 453–454 (2022). https://doi.org/10.1007/s00761-022-01168-x

Scholl S: Primär- und Rezidivtherapie akuter Leukämien. Onkologie 28, 455–458 (2022). https://doi.org/10.1007/s00761-022-01167-y

Fleischmann M, Schnetzke U, Hochhaus, A, Scholl S: Ziele und Optionen der palliativen Therapie der akuten myeloischen Leukämie. Onkologie 28, 483–491 (2022). https://doi.org/10.1007/s00761-022-01151-6

White HE, Salmon M, Albano F, Andersen CSA, Balabanov S, Balatzenko G, Barbany G, Cayuela JM, Cerveira N, Cochaux P, Colomer D, Coriu D, Diamond J, Dietz C, Dulucq S, Engvall M, Franke GN, Gineikiene-Valentine E, Gniot M, Gómez-Casares MT, Gottardi E, Hayden C, Hayette S, Hedblom A, Ilea A, Izzo B, Jiménez-Velasco A, Jurcek T, Kairisto V, Langabeer SE, Lion T, Meggyesi N, Mešanović S, Mihok L, Mitterbauer-Hohendanner G, Moeckel S, Naumann N, Nibourel O, Oppliger Leibundgut E, Panayiotidis P, Podgornik H, Pott C, Rapado I, Rose SJ, Schäfer V, Touloumenidou T, Veigaard C, Venniker-Punt B, Venturi C, Vigneri P, Vorkinn I, Wilkinson E, Zadro R, Zawada M, Zizkova H, Müller MC, Saussele S, Ernst T, Machova Polakova K, Hochhaus A, Cross NCP. Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. Leukemia. 2022 Jul;36(7):1834-1842. doi: 10.1038/s41375-022-01607-z. Epub 2022 May 25. PMID: 35614319; PMCID: PMC9252906

Fendler A., de Vries EGE, GeurtsvanKessel, CH, Haanen JB, Wörmann B, Turajlic S, Lilienfeld-Toal M: COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nat Rev Clin Oncol 19, 385–401 (2022). https://doi.org/10.1038/s41571-022-00610-8

Tober R, Schnetzke U, Fleischmann M, Yomade O, Schrenk K, Hammersen J, Glaser A, Thiede C, Hochhaus A, Scholl S. Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia. J Cancer Res Clin Oncol. 2022 May 18. doi: 10.1007/s00432-022-03995-2. Epub ahead of print. PMID: 35583829

Eckardt JN, Stölzel F, Kunadt D, Röllig C, Stasik S, Wagenführ L, Jöhrens K, Kuithan F, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Herbst R, Hänel M, Hanoun M, Kaiser U, Kaufmann M, Rácil Z, Mayer J, Kroschinsky F, Berdel WE, Ehninger G, Serve H, Müller-Tidow C, Platzbecker U, Baldus CD, Schetelig J, Bornhäuser M, Thiede C, Middeke JM. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. J Hematol Oncol. 2022 May 13;15(1):60. doi: 10.1186/s13045-022-01267-7. PMID: 35562747

Frietsch JJ, Miethke J, Linke P, Crodel CC, Schnetzke U, Scholl S, Hochhaus A, Hilgendorf I. Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma. Bone Marrow Transplant. 2022 Jul;57(7):1164-1170. doi: 10.1038/s41409-022-01701-x. Epub 2022 May 10. PMID: 35538141; PMCID: PMC9262709

Hochhaus, A., Ernst, T. Weißes Blut. Onkologe (2022). https://doi.org/10.1007/s00761-022-01135-6

Fleischmann M, Schnetzke U, Hochhaus A, Zomorodbakhsch B, Foller S, Rengsberger M, Hartmann M, Huebner J: Ziele und Optionen der palliativen Therapie der akuten myeloischen Leukämie. Onkologe (2022). https://doi.org/10.1007/s00761-022-01151-6

Wolf CPJG, Rachow T, Ernst T, Hochhaus A, Zomorodbakhsch B, Foller S, Rengsberger M, Hartmann M, Huebner J. Complementary and alternative medicine (CAM) supplements in cancer outpatients: analyses of usage and of interaction risks with cancer treatment. J Cancer Res Clin Oncol. 2022 May;148(5):1123-1135. doi: 10.1007/s00432-021-03675-7. Epub 2021 Jul 6. PMID: 34228225

Hoang TNM, Cseresnyés Z, Hartung S, Blickensdorf M, Saffer C, Rennert K, Mosig AS, von Lilienfeld-Toal M, Figge MT. Invasive aspergillosis-on-chip: A quantitative treatment study of human Aspergillus fumigatus infection. Biomaterials. 2022 Apr;283:121420. doi: 10.1016/j.biomaterials.2022.121420. Epub 2022 Feb 24. PMID: 35245733

Goldmann M, Schmidt F, Cseresnyés Z, Orasch T, Jahreis S, Hartung S, Figge MT, von Lilienfeld-Toal M, Heinekamp T, Brakhage AA: The lipid raft-associated protein stomatin is required for accumulation of dectin-1 in the phagosomal membrane and for full activity of macrophages against Aspergillus fumigatus. bioRxiv preprint DOI: https://doi.org/10.1101/2022.02.25.481948, Posted: February 25, 2022, Version 1

DiNardo CD, Hochhaus A, Frattini MG, Yee K, Zander T, Krämer A, Chen X, Ji Y, Parikh NS, Choi J, Wei AH. A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome. J Cancer Res Clin Oncol. 2022 Mar 30. doi: 10.1007/s00432-022-03983-6. Epub ahead of print. PMID: 35353219

Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner-Drouet EM, Wulf GG, Marks R, Penack O, Schnetzke U, Koenecke C, von Bonin M, Stelljes M, Glass B, Baldus CD, Vucinic V, Mougiakakos D, Topp MS, Fante MA, Schroers R, Bayir LM, Borchmann P, Buecklein V, Hanoun C, Thomas S, Beelen DW, Lengerke C, Kroeger N, Dreger P. GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. Blood. 2022 Mar 22:blood.2021015209. doi: 10.1182/blood.2021015209. Epub ahead of print. PMID: 35316325

Saglio G, Rosti G, Hehlmann R, Hochhaus A, Gale RP. Prof. Michele Baccarani, August 16, 1942 to December 20, 2021: a gifted life in haematology. Bone Marrow Transplant. 2022 Mar 16. doi: 10.1038/s41409-022-01636-3. Epub ahead of print. PMID: 35297405

O'Hagan Henderson S, Glaser A, Frietsch JJ, Hochhaus A, Hilgendorf I. The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm. Ann Hematol. 2022 Apr;101(4):919-920. doi: 10.1007/s00277-021-04655-0. Epub 2021 Sep 1. PMID: 34471943; PMCID: PMC8913527

Schaffrath J, Brummer C, Wolff D, Holtick U, Kröger N, Bornhäuser M, Kraus S, Hilgendorf I, Blau IW, Penack O, Wittke C, Steiner N, Nachbaur D, Thurner L, Hindah H, Zeiser R, Maier CP, Bethge W, Müller LP. High mortality of COVID-19 early after allogeneic stem cell transplantation - a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Transplant Cell Ther. 2022 Mar 13:S2666-6367(22)00158-0. doi: 10.1016/j.jtct.2022.03.010. Epub ahead of print. PMID: 35296445; PMCID: PMC8918088

Fendler A, de Vries EGE, GeurtsvanKessel CH, GeurtsvanKessel CH, Haanen JB, Wörmann B, Turajlic S, von Lilienfeld-Toal M: COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nat Rev Clin Oncol (2022). https://doi.org/10.1038/s41571-022-00610-8

Keinki C, Rudolph I, Wozniak T, Pietsch R, Margolina M, Garcia I, Mayr-Welschlau K, Schmidt T, Hübner J. A virtual dance sport class for cancer patients: the trainer perspective. J Cancer Res Clin Oncol. 2022 Mar 7. doi: 10.1007/s00432-022-03913-6. Epub ahead of print. PMID: 35253086

Saglio G, Rosti G, Hehlmann R, Hochhaus A, Gale RP: Prof. Michele Baccarani. August 16, 1942 to December 20, 2021: a gifted life in haematology. Leukemia (2022). https://doi.org/10.1038/s41375-022-01525-0

Topp MS, Eradat H, Florschütz A, Hochhaus A, Wrobel T, Walewski J, Knopinska-Posluszny W, Kanate AS, Lech-Maranda E, Brunnberg U, Chitra S, Nielsen TG, Sellam G, Shivhare M, Lossos IS. Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma. J Cancer Res Clin Oncol. 2022 Feb 18. doi: 10.1007/s00432-021-03847-5. Epub ahead of print. PMID: 35182224

Fleischmann M, Scholl S, Frietsch JJ, Hilgendorf I, Schrenk K, Hammersen J, Prims F, Thiede C, Hochhaus A, Schnetzke U. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia. J Cancer Res Clin Oncol. 2022 Nov;148(11):3191-3202. doi: 10.1007/s00432-022-03930-5. Epub 2022 Jan 31. PMID: 35099591; PMCID: PMC9508061

Hochhaus A, Krause M, Schmidberger H. Molekulare Onkologie. Onkologe 28, 92–94 (2022). https://doi.org/10.1007/s00761-022-01095-x

Hübner J, Ciarlo G, Dubois C, Münstedt K, Micke O, Büntzel J, Klein M, Josfeld L, Keinki C. Komplementär- und alternativmedizinische Angebote von Lehrpraxen für Allgemeinmedizin [Complementary and Alternative Medicine Offers of Teaching Practices for General Medicine]. Gesundheitswesen. 2022 Jan 11. German. doi: 10.1055/a-1690-6631. Epub ahead of print. PMID: 35016252

Januzzi JL, Garasic JM, Kasner SE, McDonald V, Petrie MC, Seltzer J, Mauro M, Croce K, Berman E, Deininger M, Hochhaus A, Pinilla-Ibarz J, Nicolini F, Kim DW, DeAngelo DJ, Kantarjian H, Xu J, Hall T, Srivastava S, Naranjo D, Cortes J. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. J Hematol Oncol. 2022 Jan 6;15(1):1. doi: 10.1186/s13045-021-01221-z. PMID: 34991679

Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, Röllig C, Krug U, Krämer A, Scholl S, Hochhaus A, Brümmendorf TH, Naumann R, Petzold A, Mulet-Lazaro R, Valk PJM, Steffen B, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Hänel M, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Herold S, Stölzel F, Sockel K, von Bonin M, Müller-Tidow C, Platzbecker U, Berdel WE, Serve H, Ehninger G, Bornhäuser M, Schetelig J, Thiede C; Study Alliance Leukemia (SAL). CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood. 2022 Jan 6;139(1):87-103. doi: 10.1182/blood.2020009680. PMID: 34320176

2021

Publikationen aus dem Jahr 2021

Hoffmeister L, Huebner J, Keinki C, Muenstedt K. Education of non-medical practitioners in Germany-an analysis of course subjects of specialized schools. Wien Med Wochenschr. 2021 Dec 13. English. doi: 10.1007/s10354-021-00896-w. Epub ahead of print. PMID: 34902098

Retzlaff D, Dörfler J, Kutschan S, Freuding M, Büntzel J, Hübner J (2021) The Vitamin E Isoform α-Tocopherol is Not Effective as a Complementary Treatment in Cancer Treatment: A Systematic Review, Nutrition and Cancer, DOI: 10.1080/01635581.2021.2014905

Hochhaus A, Ernst T: TKI discontinuation in CML: how do we make more patients eli gi ble ? How do we increase the chances of a suc cessful treatment - free remission? Hematology 2021, ASH Education Program, 106-112

Josfeld L, Krüger L, Büntzel J, Zomorodbakhsch B, · Hübner J: Self-efficacy in relation to the use of complementary and alternative medicine, lifestyle choices and cancer aetiology. J Cancer Res Clin Oncol (2021). https://doi.org/10.1007/s00432-021-03857-3

Middeke JM, Metzeler KH, Röllig C, Kramer M, Eckardt JN, Stasik S, Greif PA, Spiekermann K, Rothenberg-Thurley M, Krug U, Braess J, Kraemer A, Hochhaus A, Brümmendorf TH, Naumann R, Steffen B, Einsele H, Schaich M, Burchert A, Neubauer A, Görlich D, Sauerland CM, Schaefer-Eckart K, Schliemann C, Krause SW, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Kaufmann M, Kunadt D, Woermann B, Sockel K, von Bonin M, Herold T, Müller-Tidow C, Platzbecker U, Berdel WE, Serve H, Baldus CD, Ehninger G, Schetelig J, Hiddemann W, Bornhäuser M, Stölzel F, Thiede C. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: Results from a large multicenter study. Blood Adv. 2021 Nov 18:bloodadvances.2021004934. doi: 10.1182/bloodadvances.2021004934. Epub ahead of print. PMID: 34794176

Walter RB, Hochhaus A, Gale RP: Elihu H. Estey, MD: leukemia expert, statistician, and gentle soul (July 15, 1946–October 8, 2021). Leukemia (2021). https://doi.org/10.1038/s41375-021-01467-z

Fleischmann M, Schnetzke U, Hochhaus A, Scholl S. Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives. Cancers (Basel). 2021 Nov 16;13(22):5722. doi: 10.3390/cancers13225722. PMID: 34830877

Vogel J, Zomorodbakhsch B, Thomas Stauch T, Josfeld L, Hübner J: The role of the general practitioner in cancer care in general and with respect to complementary and alternative medicine for patients with cancer. European Journal of Cancer Care, Received: 26 May 2021 Revised: 10 August 2021 Accepted: 4 October 2021, DOI: 10.1111/ecc.13533

O'Hagan Henderson S, Frietsch JJ, Hilgendorf I, Hochhaus A, Köhne CH, Casper J. Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms. J Cancer Res Clin Oncol. 2021 Oct 21. doi: 10.1007/s00432-021-03836-8. Epub ahead of print. PMID: 34674031

Schnoeder TM, Schwarzer A, Jayavelu AK, Hsu CJ, Kirkpatrick J, Döhner K, Perner F, Eifert T, Huber N, Arreba-Tutusaus P, Dolnik A, Assi SA, Nafria M, Jiang L, Dai YT, Chen Z, Chen SJ, Kellaway SG, Ptasinska A, Ng ES, Stanley EG, Elefanty AG, Buschbeck M, Bierhoff H, Brodt S, Matziolis G, Fischer KD, Hochhaus A, Chen CW, Heidenreich O, Mann M, Lane SW, Bullinger L, Ori A, Eyss BV, Bonifer C, Heidel F. PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. Blood. 2021 Oct 25:blood.2021012778. doi: 10.1182/blood.2021012778. Epub ahead of print. PMID: 34695195

Hübner, J., Stoll, C. & Keinki, C. Immunstimulanzien aus der Naturheilkunde und ihr Einsatz bei Neoplasien. Onkologe 27, 1125–1130 (2021). https://doi.org/10.1007/s00761-021-01040-4

Hübner, J., Stoll, C. & Keinki, C. Immunstimulanzien aus der Naturheilkunde und ihr Einsatz bei Neoplasien. Onkologe (2021). https://doi.org/10.1007/s00761-021-01040-4

Hübner J, Beckmann M , Follmann M, Nothacker M, Prott FJ, Wörmann B: Komplementärmedizin in der Behandlung von onkologisch erkrankten Patienten; Dtsch Arztebl Int 2021; 118: 654-9; DOI: 10.3238/arztebl.m2021.0277

Gale RP, Hochhaus A, Cross NCP, Harrison CJ: HGNC nomenclature for fusion genes. Leukemia (2021). https://doi.org/10.1038/s41375-021-01437-5

Mühleck, R., Scholl, S., Hilgendorf, I. et al. Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy. J Cancer Res Clin Oncol 148, 2539–2548 (2022). https://doi.org/10.1007/s00432-021-03821-1

Reuken PA, Rüthrich MM, Hochhaus A, Hammersen J, Bauer M, La Rosée P, La Rosée F, Stallmach A: The impact of specific cytokine directed treatment on severe COVID-19. Leukemia. 2021 Sep 7:1–3. doi: 10.1038/s41375-021-01411-1. Epub ahead of print. PMID: 34493799; PMCID: PMC8422045.

Döhner H, Malcovati L, Ossenkoppele GJ, Hochhaus A, Maria Vannucchi A, Bullinger L, Cervantes F, Craddock C, de Witte T, Döhner K, Dombret H, Fenaux P, Geissler J, Germing U, Guilhot F, Harrison C, Hellström-Lindberg E, Passamonti F, Sierra J, Skoda R, Wierzbowska A. The EHA Research Roadmap: Malignant Myeloid Diseases. Hemasphere. 2021 Aug 26;5(9):e635. doi: 10.1097/HS9.0000000000000635. PMID: 34476345; PMCID: PMC8389885

Heinicke T, Krahl R, Kahl C, Cross M, Scholl S, Wolf HH, Hähling D, Hegenbart U, Peter N, Schulze A, Florschütz A, Schmidt V, Reifenrath K, Zojer N, Junghanss C, Sayer HG, Maschmeyer G, Späth C, Hochhaus A, Fischer T, Al-Ali HK, Niederwieser D. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials. Ann Hematol. 2021 Sep;100(9):2387-2398. doi: 10.1007/s00277-021-04565-1. Epub 2021 Jul 7. PMID: 34232360

O'Hagan Henderson S, Glaser A, Frietsch JJ, Hochhaus A, Hilgendorf I. The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm. Ann Hematol. 2021 Sep 1. doi: 10.1007/s00277-021-04655-0. Epub ahead of print. PMID: 34471943

Stasik S, Eckardt JN, Kramer M, Röllig C, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause S, Herbst R, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Rácil Z, Platzbecker U, Berdel WE, Mayer J, Serve H, Müller-Tidow C, Ehninger G, Bornhäuser M, Schetelig J, Middeke JM, Thiede C; Study Alliance Leukemia (SAL). Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. Blood Adv. 2021 Sep 14;5(17):3279-3289. doi: 10.1182/bloodadvances.2021004631. PMID: 34459887

Hübner J, Münstedt K, Micke O, Prott FJ,Schmidt T, Büntzel J: Zentrale Empfehlungen und Statements der S3-Leitlinie zur komplementären Medizin für Patient*innen mit onkologischen Erkrankungen – Teil 2. Onkologe 27, 917–921 (2021). https://doi.org/10.1007/s00761-021-00990-z

Réa D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L, García-Gutiérrez V, Cortes JE, Aimone P, Allepuz A, Quenet S, Bédoucha V, Hochhaus A. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021 Nov 25;138(21):2031-2041. doi: 10.1182/blood.2020009984. PMID: 34407542

Cortes J, Apperley JF, Lomaia E, Moiraghi B, Undurraga MS, Pavlovsky C, Chuah C, Sacha T, Lipton JH, Schiffer CA, McCloskey J, Hochhaus A, Rousselot P, Rosti G, de Lavallade H, Turkina A, Rojas C, Arthur C, Maness LJ, Talpaz M, Mauro MJ, Hall T, Lu V, Srivastava S, Deininger MW. Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia: A Randomized, Open-Label Phase 2 Clinical Trial. Blood. 2021 Aug 18:blood.2021012082. doi: 10.1182/blood.2021012082. Epub ahead of print. PMID: 34407543

Hoppe C, Freuding M, Büntzel J, Münstedt K, Hübner J: Clinical efficacy and safety of oral and intravenous vitamin C use in patients with malignant diseases. J Cancer Res Clin Oncol (2021). https://doi.org/10.1007/s00432-021-03759-4

Schnetzke U: Aggressives B-Zell-Lymphom: Registerstudien bestätigen die Wirksamkeit von CAR-T-Zell-Therapien. Kompass Onkol 2021. doi: 10.1159/000518702

Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, Röllig C, Krug U, Krämer A, Scholl S, Hochhaus A, Brümmendorf TH, Naumann R, Petzold A, Mulet-Lazaro R, Valk PJM, Steffen B, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Hänel M, Noppeney R, Kaiser U, Baldus C, Kaufmann M, Herold S, Stölzel F, Sockel K, von Bonin M, Müller-Tidow C, Platzbecker U, Berdel WE, Serve H, Ehninger G, Bornhäuser M, Schetelig J, Thiede C. CEBPA Mutations in 4708 Patients with Acute Myeloid Leukemia - Differential Impact of bZIP and TAD Mutations on Outcome. Blood. 2021 Jul 28:blood.2020009680. doi: 10.1182/blood.2020009680. Epub ahead of print. PMID: 34320176

Ruhe J, Schnetzke U, Kentouche K, Prims F, Baier M, Herfurth K, Schlosser M, Busch M, Hochhaus A, Wolf G. Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine. Ann Hematol. 2021 Jul 26. doi: 10.1007/s00277-021-04584-y. Epub ahead of print. PMID: 34309715

Fleischmann M, Schnetzke U, Frietsch JJ, Sayer HG, Schrenk K, Hammersen J, Glaser A, Hilgendorf I, Hochhaus A, Scholl S. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia. J Cancer Res Clin Oncol. 2021 Jul 23. doi: 10.1007/s00432-021-03733-0. Epub ahead of print. PMID: 34297206

Hübner J, Münstedt K, Micke O, Prott FJ, Schmidt T, Büntzel J: Zentrale Empfehlungen und Statements der S3-Leitlinie zur komplementären Medizin für Patient*innen mit onkologischen Erkrankungen – Teil 1. Onkologe 27, 795–801 (2021). https://doi.org/10.1007/s00761-021-00989-6

Gericke M., Geitel, Jörke C, Clement JH, Heinze T: Reactive Nanoparticles Derived from Polysaccharide Phenyl Carbonates. Molecules 2021, 26, 4026. https://doi.org/10.3390/molecules26134026

Hübner J, Mücke R, Micke O, Keinki C: Komplementärmedizin in der Uroonkologie. Urologe 60, 953–962 (2021). https://doi.org/10.1007/s00120-021-01584-8

Gremmler L, Kutschan S, Dörfler J, Büntzel J, Büntzel J, Hübner J. Proteolytic Enzyme Therapy in Complementary Oncology: A Systematic Review. Anticancer Res. 2021 Jul;41(7):3213-3232. doi: 10.21873/anticanres.15108. Epub 2021 Jul 5. PMID: 34230116

Krüger WH, Hirt C, Basara N, Sayer HG, Behre G, Fischer T, Grobe N, Maschmeyer G, Niederwieser D, Dölken G. Allogeneic stem cell transplantation for mantle cell lymphoma--final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO). Ann Hematol. 2014 Sep;93(9):1587-97. doi: 10.1007/s00277-014-2087-z. Epub 2014 Apr 30. PMID: 24782119

Wolf CPJG, Rachow T, Ernst T, Hochhaus A, Zomorodbakhsch B, Foller S, Rengsberger M, Hartmann M, Huebner J. Complementary and alternative medicine (CAM) supplements in cancer outpatients: analyses of usage and of interaction risks with cancer treatment. J Cancer Res Clin Oncol. 2021 Jul 6. doi: 10.1007/s00432-021-03675-7. Epub ahead of print. PMID: 34228225

von Lilienfeld-Toal M, Rieger C, Giesen N. et al. Impfung gegen SARS-CoV-2 bei Krebspatienten. Onkologe 27, 691–696 (2021). https://doi.org/10.1007/s00761-021-00972-1

Mickoleit F, Jörke C, Geimer S, Maier D, Müller JP, Demut J, Gräfe C, Schüler D, Clement JH. 2021. Biocompatibility, uptake and subcellular localization of bacterial magnetosomes in mammalian cells. Nanoscale Advances: https://doi.org/10.1039/D0NA01086C

Middeke JM, Teipel R, Röllig C, Stasik S, Zebisch A, Sill H, Kramer M, Scholl S, Hochhaus A, Jost E, Brümmendorf TH, Naumann R, Steffen B, Serve H, Altmann H, Kunzmann V, Einsele H, Parmentier S, Schaich M, Burchert A, Neubauer A, Schliemann C, Berdel WE, Sockel K, Stölzel F, Platzbecker U, Ehninger G, Bornhäuser M, Schetelig J, Thiede C; Study Alliance Leukemia (SAL). Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis. Leuk Lymphoma. 2021 Jun;62(6):1432-1440. doi: 10.1080/10428194.2020.1864354. Epub 2021 Jan 5. PMID: 33399480

Petr Vitek P, Koscielny S, Büssing A, Hübner J, Büntzel J. Religiosität und Spiritualität als Ressourcen in der Betreuung von Patienten mit Kopf-Hals-Tumoren; Laryngorhinootologie 2021; DOI: 10.1055/a-1516-4589

Büssing A, Recchia DR, Hübner J, Walter S, Büntzel J, Büntzel J. Tumor patients' fears and worries and perceived changes of specific attitudes, perceptions and behaviors due to the COVID-19 pandemic are still relevant. J Cancer Res Clin Oncol. 2021 Jun;147(6):1673-1683. doi: 10.1007/s00432-021-03573-y. Epub 2021 Mar 6. PMID: 33675401; PMCID: PMC7936591

Welter S, Keinki C, Ahmadi E, Huebner J. Lay Etiology, Self-Efficacy and Patient Activation Among Cancer Patients. Cancer Invest. 2021 Mar;39(3):219-228. doi: 10.1080/07357907.2021.1878528. Epub 2021 Feb 2. PMID: 33475001

Baier L, Hübner J, Kerschbaum E, Erickson N. Krebsdiäten: patientenzentrierte Kommunikationsstrategien; Onkologe 2021; 27:148–153

Männle H, Momm F, Hübner J, Münstedt K. Do breast cancer patients adapt CAM methods according to the therapeutic situation? Complement Ther Clin Pract. 2021 May;43:101305. doi: 10.1016/j.ctcp.2021.101305. Epub 2021 Jan 23. PMID: 33516058

Giesen N, Sprute R, Rüthrich M, Khodamoradi Y, Mellinghoff SC, Beutel G, Lueck C, Koldehoff M, Hentrich M, Sandherr M, von Bergwelt-Baildon M, Wolf HH, Hirsch HH, Wörmann B, Cornely OA, Köhler P, Schalk E, von Lilienfeld-Toal M; COVID-19 guideline panel of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy. Eur J Cancer. 2021 Apr;147:154-160. doi: 10.1016/j.ejca.2021.01.033. Epub 2021 Feb 10. PMID: 33676266; PMCID: PMC7874914

Schmoll HJ; Lindner LH, Reichardt P, Heißner K, Kopp HG, Kessler T, Mayer-Steinacker R, Rüssel J, Egerer G, Crysandt M, Kasper B, Niederwieser D, Kunitz A, MD12; Eigendorff E, Petersen I, Steighardt J, Cygon F, Meinert F, Stein A: Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021;7(2):255-262. doi:10.1001/jamaoncol.2020.6564

Eyre TA, Caillard S, Finel H, Boumendil A, Kothari J, Zimmermann H, Trappe RU, De Wilde V, Tholouli E, Kanfer E, Broom A, Damaj G, Bargetzi M, Kozák T, Hilgendorf I, Crawley C, Kerre T, Trněný M, Bachy E, Robinson S, Montoto S. Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplant. 2021 Apr 16. doi: 10.1038/s41409-021-01270-5. Epub ahead of print. PMID: 33864020

Schrickel L, Heidel FH, Sadjadian P, Becker T, Kolatzki V, Hochhaus A, Griesshammer M, Wille K; German Study Group MPN, GSG-MPN. Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety. J Cancer Res Clin Oncol. 2021 May;147(5):1481-1491. doi: 10.1007/s00432-020-03430-4. Epub 2020 Nov 2. PMID: 33140210

Graf La Rosée, H.-C. Bremer, F. La Rosée, P. Mohm, A. Hochhaus, I. Gehrke, B. Kumle, A. Benzing & S. Russo: Interdisziplinäres COVID-Board bei SARS-CoV-2-getriggerter hyperferritinämischer Inflammation. MedKlin IntensivmedNotfmed2021, 116:138–145, https://doi.org/10.1007/s00063-020-00750-8

Brioli A, Manz K, Pfirrmann M, Hänel M, Schwarzer AC, Prange-Krex G, Fabisch C, Knop S, Illmer T, Krammer-Steiner B, Hochhaus A, von Lilienfeld-Toal M, Mügge LO. Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN). J Cancer Res Clin Oncol. 2020 Mar;146(3):749-759. doi: 10.1007/s00432-019-03101-z. Epub 2019 Dec 2. PMID: 31788741

Büntzel J, Walter S, Hellmund H, Klein M, Hübner J, Vitek P, Büntzel J, Koscielny S, Sesterhenn AM, Büssing A. Auswirkungen der COVID-19-Pandemie auf die Versorgung von HNO-Tumoren – die Patientenperspektive [Oncology Services for Patients with Head Neck Cancer during Corona-Times - Patients' Perspective]. Laryngorhinootologie. 2021 Feb;100(2):104-110. German. doi: 10.1055/a-1327-4234. Epub 2020 Dec 14. PMID: 33316831

Ciarlo G, Ahmadi E, Welter S, Hübner J. Factors influencing the usage of complementary and alternative medicine by patients with cancer. Complement Ther Clin Pract. 2021 Apr 15;44:101389. doi: 10.1016/j.ctcp.2021.101389. Epub ahead of print. PMID: 33932731

Christiansen N, Walter S, Zomorodbakhsch B, Sartakhti EA, Hübner J. Assessment of Self-Efficacy as a Way to Help Identify Cancer Patients Who Might Benefit from Self-Help Group Attendance? Cancer Invest. 2021 Feb;39(2):133-143. doi: 10.1080/07357907.2020.1867996. Epub 2021 Jan 6. PMID: 33356618

Josfeld L, Keinki C, Pammer C, Zomorodbakhsch B, Hübner J. Cancer patients' perspective on shared decision-making and decision aids in oncology. J Cancer Res Clin Oncol. 2021 Jun;147(6):1725-1732. doi: 10.1007/s00432-021-03579-6. Epub 2021 Mar 7. PMID: 33682014; PMCID: PMC8076112

Morkramer L, Geitner M, Boeger D, Buentzel J, · Kaftan H, · Mueller AH,·Ernst T, · Guntinas‑Lichius O: Systemic therapy for recurrent and/or metastatic head and neck cancer: a population-based healthcare research study in Thuringia, Germany. J Cancer Res Clin Oncol (2021). https://doi.org/10.1007/s00432-021-03535-4

Büntzel J, Micke O, Klein M, Büntzel J, Walter S, Keinki C, Huebner J. Take care or "German Angst"? Lessons from cancer care during COVID-19 pandemic in spring 2020. J Cancer Res Clin Oncol (2021) 147:2093–2105. doi: 10.1007/s00432-020-03492-4. Epub ahead of print. PMID: 33387036; PMCID: PMC7776312

Römer M, Dörfler J, Huebner J. The use of ketogenic diets in cancer patients: a systematic review. Clin Exp Med. 2021 Apr 3. doi: 10.1007/s10238-021-00710-2. Epub ahead of print. PMID: 33813635

Hoppe C, Kutschan S, Dörfler J, Büntzel J, Büntzel J, Huebner J. Zinc as a complementary treatment for cancer patients: a systematic review. Clin Exp Med. 2021 May;21(2):297-313. doi: 10.1007/s10238-020-00677-6. Epub 2021 Jan 26. PMID: 33496846; PMCID: PMC8053661

Keinki C, Momberg A, Clauß K, Bozkurt G, Hertel E, Freuding M, Josfeld L, Huebner J. Effect of question prompt lists for cancer patients on communication and mental health outcomes-A systematic review. Patient Educ Couns. 2021 Jan 15:S0738-3991(21)00039-2. doi: 10.1016/j.pec.2021.01.012. Epub ahead of print. PMID: 33593643

Wiese F, Kutschan S, Doerfler J, Mathies V, Buentzel J, Buentzel J, Huebner J. Green tea and green tea extract in oncological treatment: A systematic review. Int J Vitam Nutr Res. 2021 Feb 17:1-13. doi: 10.1024/0300-9831/a000698. Epub ahead of print. PMID: 33593083

Thieser S, Dörfler J, Rudolph I, Wozniak T, Schmidt T, Hübner J. Influence of ballroom dancing on fatigue, body image, self-efficacy, and endurance of cancer patients and their partners. Med Oncol. 2021 Jan 28;38(2):15. doi: 10.1007/s12032-021-01459-0. PMID: 33507443; PMCID: PMC7843482

Sonneborn-Papakostopoulos M, Dubois C, Mathies V, Heß M, Erickson N, Ernst T, Huebner J. Quality of life, symptoms and dietary habits in oncology outpatients with malnutrition: A cross-sectional study. Med Oncol. 2021 Feb 4;38(2):20. doi: 10.1007/s12032-021-01460-7. PMID: 33543336; PMCID: PMC7862192

Eckardt JN, Stasik S, Kramer M, Röllig C, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Herbst R, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Rácil Z, Platzbecker U, Berdel WE, Mayer J, Serve H, Müller-Tidow C, Ehninger G, Stölzel F, Kroschinsky F, Schetelig J, Bornhäuser M, Thiede C, Middeke JM. Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia. Cancers (Basel). 2021 Apr 26;13(9):2095. doi: 10.3390/cancers13092095. PMID: 33926021

Wolf CPJG, Rachow T, Ernst T, Hochhaus A, Zomorodbakhsch B, Foller S, Rengsberger M, Hartmann M, Hübner J. Interactions in cancer treatment considering cancer therapy, concomitant medications, food, herbal medicine and other supplements. J Cancer Res Clin Oncol. 2021 Apr 17. doi: 10.1007/s00432-021-03625-3. Epub ahead of print. PMID: 33864520

Dufter SA, Hübner J, Ahmadi E, Zomorodbakhsch B. Traits of cancer patients and CAM usage. J Cancer Res Clin Oncol. 2021 Dec;147(12):3685-3692. doi: 10.1007/s00432-021-03605-7. Epub 2021 Apr 2. PMID: 33811274

Ernst P, Heidel FH. Molecular Mechanisms of Senescence and Implications for the Treatment of Myeloid Malignancies. Cancers (Basel). 2021 Feb 4;13(4):612. doi: 10.3390/cancers13040612. PMID: 33557090; PMCID: PMC7913823

Palandri F, Palumbo GA, Elli EM, Polverelli N, Benevolo G, Martino B, Abruzzese E, Tiribelli M, Tieghi A, Latagliata R, Cavazzini F, Bergamaschi M, Binotto G, Crugnola M, Isidori A, Caocci G, Heidel F, Pugliese N, Bosi C, Bartoletti D, Auteri G, Cattaneo D, Scaffidi L, Trawinska MM, Stella R, Ciantia F, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Iurlo A, Vianelli N, Cavo M, Breccia M, Bonifacio M. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. Blood Cancer J. 2021 Jan 7;11(1):4. doi: 10.1038/s41408-020-00392-1. PMID: 33414394; PMCID: PMC7791065

Polverelli N, Elli EM, Abruzzese E, Palumbo GA, Benevolo G, Tiribelli M, Bonifacio M, Tieghi A, Caocci G, D'Adda M, Bergamaschi M, Binotto G, Heidel FH, Cavazzini F, Crugnola M, Pugliese N, Bosi C, Isidori A, Bartoletti D, Auteri G, Latagliata R, Gandolfi L, Martino B, Scaffidi L, Cattaneo D, D'Amore F, Trawinska MM, Stella R, Markovic U, Catani L, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Vianelli N, Breccia M, Russo D, Cavo M, Iurlo A, Palandri F. Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2020 Nov 21. doi: 10.1111/bjh.17192. Epub ahead of print. PMID: 33222197

Benevolo G, Elli EM, Bartoletti D, Latagliata R, Tiribelli M, Heidel FH, Cavazzini F, Bonifacio M, Crugnola M, Binotto G, D'Addio A, Tieghi A, Bergamaschi M, Caocci G, Polverelli N, Bossi E, Auteri G, Carmosino I, Catani L, Cuneo A, Krampera M, Lanza F, Lemoli RM, Vianelli N, Breccia M, Palumbo GA, Cavo M, Palandri F. Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. Hematol Oncol. 2021 Feb 15. doi: 10.1002/hon.2843. Epub ahead of print. PMID: 33590502

Heidel FH, Platzbecker U. The Genomic Landscape of Myeloid Malignancies: Options for Pan-myeloid Therapies? Hemasphere. 2021 Feb 10;5(3):e537. doi: 10.1097/HS9.0000000000000537. PMID: 33604515; PMCID: PMC7886402

Palandri F, Tiribelli M, Breccia M, Bartoletti D, Elli EM, Benevolo G, Martino B, Cavazzini F, Tieghi A, Iurlo A, Abruzzese E, Pugliese N, Binotto G, Caocci G, Auteri G, Cattaneo D, Trawinska MM, Stella R, Scaffidi L, Polverelli N, Micucci G, Masselli E, Crugnola M, Bosi C, Heidel FH, Latagliata R, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Cavo M, Vianelli N, Bonifacio M, Palumbo GA. Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. Cancer. 2021 Apr 1. doi: 10.1002/cncr.33541. Epub ahead of print. PMID: 33794557

Loncarevic IF, Toepfer S, Hubold S, Klingner S, Kanitz L, Ellinger T, Steinmetzer K, Ernst T, Hochhaus A, Ermantraut E. Ultra-precise quantification of mRNA targets across a broad dynamic range with nanoreactor beads. PLoS One. 2021 Mar 18;16(3):e0242529. doi: 10.1371/journal.pone.0242529. PMID: 33735175

Frietsch JJ, Hunstig F, Wittke C, Junghanss C, Franiel T, Scholl S, Hochhaus A, Hilgendorf I. Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity. Bone Marrow Transplant. 2021 Jan;56(1):101-109. doi: 10.1038/s41409-020-0984-4. Epub 2020 Jun 30. PMID: 32606455; PMCID: PMC7796857

Hinze A, Rinke J, Hochhaus A, Ernst T. Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation. Ann Hematol. 2021 Feb;100(2):581-584. doi: 10.1007/s00277-020-04152-w. Epub 2020 Jun 23. PMID: 32577845; PMCID: PMC7817602

Pulewka K, Strauss B, Hochhaus A, Hilgendorf I. Clinical, social, and psycho-oncological needs of adolescents and young adults (AYA) versus older patients following hematopoietic stem cell transplantation. J Cancer Res Clin Oncol. 2021 Apr;147(4):1239-1246. doi: 10.1007/s00432-020-03419-z. Epub 2020 Oct 14. PMID: 33052515

Radich JP, Hochhaus A, Masszi T. et al. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia (2021). https://doi.org/10.1038/s41375-021-01205-5

Schäfer V, White HE, Gerrard G, Möbius S, Saussele S, Franke GN, Mahon FX, Talmaci R, Colomer D, Soverini S, Machova Polakova K, Cross NCP, Hochhaus A, Ernst T. Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network. J Cancer Res Clin Oncol. 2021 Mar 7. doi: 10.1007/s00432-021-03569-8. Epub ahead of print. PMID: 33677711

Richter F, Mapfumo P, Martin L, Solomun JI, Hausig F, Frietsch JJ, Ernst T, Hoeppener S, Brendel JC & Traeger A: Improved gene delivery to K-562 leukemia cells by lipoic acid modified block copolymer micelles. J Nanobiotechnol 19, 70 (2021). https://doi.org/10.1186/s12951-021-00801-y

Wagner-Drouet E, Teschner D, Wolschke C, Schäfer-Eckart K, Gärtner J, Mielke S, Schreder M, Kobbe G, Hilgendorf I, Klein S et al. Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-ELISpot Assay after Hematopoietic Stem Cell Transplantation. Diagnostics 2021, 11, 312. https://doi.org/10.3390/diagnostics11020312

Schrenk KG: Systemtherapie von Sarkomen. Ärzteblatt THÜRINGEN · 2/2021, 13-15

Vogt M, Langenberg J, Schüle S, Aschenbach R, Schrenk KG, Hofmann GO: Die strukturierte Tumornachsorge bei Sarkomen – zehn Jahre nach der Therapie. Ärzteblatt THÜRINGEN · 2/2021, 16-19

Henn S, Hübner J, Schäfer S, Uhde A, Zorn A: Erfassung regionaler Unterschiede in der Krebsprävention in Thüringen: der Krebspräventionsinfrastruktur-Index. Forum 2021 · 36:67–68, https://doi.org/10.1007/s12312-020-00877-x, Online publiziert: 11. Januar 2021 © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021

Rachow T, Schiffl H, Lang SM. Risk of lung cancer and renin-angiotensin blockade: a concise review. J Cancer Res Clin Oncol. 2021 Jan;147(1):195-204. doi: 10.1007/s00432-020-03445-x. Epub 2020 Nov 24. PMID: 33231730; PMCID: PMC7684567

Brioli A., Hochhaus A. (2021) Immune Checkpoint Blockade. In: Offermanns S., Rosenthal W. (eds) Encyclopedia of Molecular Pharmacology. Springer, Cham. https://doi.org/10.1007/978-3-030-21573-6_10053-1

Voigt M, Sinn K, Malouhi A, Gecks T, Zinke J, Hilgendorf I, Scholl S, Hochhaus A, Schnetzke U. HHV-6 encephalitis in a non-transplanted adult acute myeloid leukemia patient. Ann Hematol. 2021 Jan 14. doi: 10.1007/s00277-021-04409-y. Epub ahead of print. PMID: 33443593

Lennart J. Gresing, Patricia Radon, Ralf P. Friedrich, Diana Zahn, Martin Raasch, Alexander S. Mosig, Silvio Dutz, Christoph Alexiou, Frank Wiekhorst, Andreas Hochhaus, Joachim H. Clement: Negatively charged magnetic nanoparticles pass the blood-placenta barrier under continuous flow conditions in a time-dependent manner. Journal of Magnetism and Magnetic Materials, Volume 521, Part 2, 2021, 167535, ISSN 0304-8853, https://doi.org/10.1016/j.jmmm.2020.167535. (http://www.sciencedirect.com/science/article/pii/S0304885320325026)

Schüle S, Gampe M, Lindig U, Pelli M, Settmacher U: Gastrointestinale Stromatumore (GIST). ÄRZTEBLAT 26 T THÜRINGEN · 1/2021, 25-27

Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Boquimpani C, Pasquini R, Clark RE, Viviane Dubruille, Flinn IW, Kyrcz-Krzemien S, Medras E, Zanichelli M, Bendit I, Cacciatore S, Titorenko K, Aimone P, Saglio G, Hochhaus A: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia (2021). https://doi.org/10.1038/s41375-020-01111-2

Middeke JM, Teipel R, Röllig C, Stasik S, Zebisch A, Sill H, Kramer M, Scholl S, Hochhaus A, Jost E, Brümmendorf TH, Naumann R, Steffen B, Serve H, Altmann H, Kunzmann V, Einsele H, Parmentier S, Schaich M, Burchert A, Neubauer A, Schliemann C, Berdel WE, Sockel K, Stölzel F, Platzbecker U, Ehninger G, Bornhäuser M, Schetelig J, Thiede C; Study Alliance Leukemia (SAL). Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis. Leuk Lymphoma. 2021 Jan 5:1-15. doi: 10.1080/10428194.2020.1864354. Epub ahead of print. PMID: 33399480.

2020

Publikationen aus dem Jahr 2020

Gruhn B, Brodt G, Wittig S, Ernst T, Ernst J. Molecular remission using three monoclonal antibodies followed by allogeneic bone marrow transplantation in an infant with refractory ALL. Ann Hematol. 2020 May;99(5):1133-1134. doi: 10.1007/s00277-020-03957-z. Epub 2020 Feb 18. PMID: 32067128

Tintelnot J, Goekkurt E, Binder M, Thuss-Patience P, Lorenzen S, Knorrenschild JR, Kretzschmar A, Ettrich T, Lindig U, Jacobasch L, Pink D, Al-Batran SE, Hinke A, Hegewisch-Becker S, Nilsson S, Bokemeyer C, Stein A. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217). BMC Cancer. 2020 Jun 1;20(1):503. doi: 10.1186/s12885-020-06958-3. PMID: 32487035; PMCID: PMC7268753

Sinn M, Liersch T, Riess H, Gellert K, Stübs P, Waldschmidt D, Lammert F, Maschmeyer G, Bechstein W, Bitzer M, Denzlinger C, Hofheinz R, Lindig U, Ghadimi M, Hinke A, Striefler JK, Pelzer U, Bischoff S, Bahra M, Oettle H. CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results. Eur J Cancer. 2020 Oct;138:172-181. doi: 10.1016/j.ejca.2020.06.032. Epub 2020 Sep 2. PMID: 32890813

Giesen N, Sprute R, Rüthrich M, Khodamoradi Y, Mellinghoff SC, Beutel G, Lueck C, Koldehoff M, Hentrich M, Sandherr M, von Bergwelt-Baildon M, Wolf HH, Hirsch HH, Wörmann B, Cornely OA, Köhler P, Schalk E, von Lilienfeld-Toal M. Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Eur J Cancer. 2020 Nov;140:86-104. doi: 10.1016/j.ejca.2020.09.009. Epub 2020 Sep 21. PMID: 33068941; PMCID: PMC7505554

Schmitz C, Rekowski J, Müller SP, Farsijani N, Hertenstein B, Franzius C, von Verschuer U, La Rosée P, Freesmeyer M, Wilop S, Krohn T, Raghavachar A, Ganser A, Bengel FM, Prange-Krex G, Kroschinsky F, Kotzerke J, Giagounidis A, Dührsen U, Hüttmann A: Impact of complete surgical resection on outcome in aggressive non-Hodgkin lymphoma treated with immunochemotherapy. Cancer Med. 2020 Nov;9(22):8386-8396. doi: 10.1002/cam4.3448. Epub 2020 Sep 14. PMID: 32926763; PMCID: PMC7666729

Hübner J, Keinki C, Zomorodbakhsch B. Onkologe 2020; https://doi.org/10.1007/s00761-019-00699-0

Hübner J, Steinhaußen J, Busch St, Liebers St, Laubscher U, Büntzel J, Keinki C. Onkologische Versorgung in strukturschwachen Regionen. Eine Aufgabe für Medizin, Politik und Gesellschaft; Forum 2020; 35:31–36

Hübner J, Keinki C, Zomorodbakhsch B. Bedrohliche Situationen durch komplementäre und alternative Medizin; Onkologe 2020; 26:169–177

Schneider N, Bäcker A, Brenk-Franz K, Keinki C, Hübner J, Brandt F, von der Winkel G, Hager L, Strauss B, Altmann U. Patient information, communication and competence empowerment in oncology (PIKKO) – evaluation of a supportive care intervention for overall oncological patients. Study protocol of a nonrandomized controlled trial; BMC Med Res Meth 2020:20:120

Keinki C, Zomorodbakhsch B, Hübner J. Antwort auf den Leserbrief von Helmut Kiene, Institut für angewandte Erkenntnistheorie und medizinische Methodologie; Onkologe 2020;26:566–568

Heller T, Kloos C , Mueller N, Roemelt J, Keinki C, Wolf G, Mueller UA, Huebner J. Complementary and alternative medicine is positively associated with religiousness/spirituality; J Complement Integr Med 2020; 20180023; doi.org/10.1515/jcim-2018-0023

Walter S, Keinki C, Hübner J. Therapieentscheidungen in der Onkologie Gratwanderung zwischen Ehrlichkeit und Hoffnung, Lebenszeit und Lebensqualität; HNO 2020; 68:492–497

Hübner J. Komplementäre Medizin in der Uroonkologie; Urologe 2020;59:695-699

Hübner J. Angst vor der Isolation; DÄB 2020;117(25):1266

Eisfeld H, Schmidt T, Muenstedt K, Guntinas-Lichius O, Micke O, Huebner J. Need for information and use of complementary and alternative medicine in oncologic patients: A cross-sectional study at a German tertiary care hospital; Trace Elements Electrolytes. 2020; 37: 45-54. doi: 10.5414/TEX01606.

Keinki C, Meyer H, Bozkurt G, Müller N, Römelt J, Müller UA, Hübner J. Salvation Expectations of Patients of Medicine, Complementary and Alternative Medicine and Religion; J Religion Health 2020, DOI 10.1007/s10943-020-01074-9

Männle H, Hübner J, Münstedt K. Beekeepers who tolerate bee stings are not protected against SARS-CoV-2 infections; Toxicon 2020;187:279–284

Zomorodbakhsch B, Keinki C, Seilacher E, Huebner J. Cancer Patients Numeracy and Preferences for Information Presentation—a Survey Among German Cancer Patients; J Cancer Educ 2020; 35:22–27

Büssing A, Hübner J, Walter S, Gießler W, Büntzel J. Tumor Patients´ Perceived Changes of Specific Attitudes, Perceptions, and Behaviors Due to the COVID-19 Pandemic and Its Relation to Reduced Wellbeing. Front. Psychiatry 2020;11:574314.doi: 10.3389/fpsyt.2020.574314

Scheerer B, Hübner J, Sanchez H, Buchholz D, Schmunz J, Traeger W, Selig L, Blumers A, Neubauer S, Heinemann V, Erickson N. Wissenschaftsbasierte Entwicklung von patientenorientierten Rezeptideen in der Onkologie (PRIO); Forum 2020, 35: 408–410

Steinau P, Walter S, Hübner J, Büntzel J. Subjektive Bedeutung des Riechverlusts nach Laryngektomie; HNO 2020; https://doi.org/10.1007/s00106-020-00956-4

Kowalski C, Hübner J. Patient-reported outcome measures – Reif für die Routine; Forum 2020;35:401-405

Hübner J, Poeck J, Keinki C, Salomo S. Digital communication for patient care – a new approach; Oncol Res Treat 2020;43(suppl 4):238

Hübner J. S3 guideline project: Complementary and alternative medicine; Oncol Res Treat 2020;43(suppl 4):15

Heß M, Schüle S, Lindig U, Ernst T, Diebolder H, Liebusch AK, Mathies V, Huebner J: Cancer and malnutrition – study of the nutritional status of patients on oncological wards versus their personal-reflection. Ernahrungs Umschau 2020; 67(11): 206–12.

Büntzel J, Walter S, Hellmund H, Klein M, Hübner J, Vitek P, Büntzel J, Koscielny S, Sesterhenn AM, Büssing A. Auswirkgungen der Covid-19_Pandemie auf die Versorgung von HNO-Tumoren – die Patientenperspektive; Laryngo-Rhino-Otol. 2020 doi10.1055/a-1327-4234

Brioli A, vom Hofe F, Rucci P, Ernst T, Yomade O, Hilgendorf I, Scholl S, Sayer H, Mügge LO, Hochhaus A, von Lilienfeld-Toal M: Melphalan 200 mg/m2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients. Bone Marrow Transplant (2020). https://doi.org/10.1038/s41409-020-01170-0

Jayavelu AK, Schnöder TM, Perner F, Herzog C, Meiler A, Krishnamoorthy G, Huber N, Mohr J, Edelmann-Stephan B, Austin R, Brandt S, Palandri F, Schröder N, Isermann B, Edlich F, Sinha AU, Ungelenk M, Hübner CA, Zeiser R, Rahmig S, Waskow C, Coldham I, Ernst T, Hochhaus A, Jilg S, Jost PJ, Mullally A, Bullinger L, Mertens PR, Lane SW, Mann M & Heidel FH: Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Nature (2020). https://doi.org/10.1038/s41586-020-2968-3

Gresing LJ, Radon P, Friedrich RP, Zahn D, Raasch M, Mosig AS, Dutz S, Alexiou C, Wiekhorst F, Hochhaus A, Clement JH: Negatively charged magnetic nanoparticles pass the blood-placenta barrier under continuous flow conditions in a time-dependent manner. Journal of Magnetism and Magnetic Materials, Available online 10 November 2020, 167535, https://doi.org/10.1016/j.jmmm.2020.167535

Rummelt C, Gorantla SP, Meggendorfer M, Charlet A, Endres C, Döhner K, Heidel FH, Fischer T, Haferlach T, Duyster J, von Bubnoff N. Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo. Leukemia. 2020 Nov 4. doi: 10.1038/s41375-020-01077-1. Epub ahead of print. PMID: 33149267

Rinke J, Hochhaus A, Ernst T: CML - Not only BCR-ABL1 matters. Best Pract Res Clin Haematol. 2020 Sep;33(3):101194. doi: 10.1016/j.beha.2020.101194. Epub 2020 Jun 7. PMID: 33038988

Miller P, Sperling AS, Gibson CJ, Viswanathan K, Castellano CA, McConkey ME, Ceremsak JJ, Taylor MS, Birndt S, Perner F, Arnason JE, Agrawal M, Schram A, Nikiforow S, Pihan G, Hasserjian RP, Aster JC, La Rosée P, Morgan EA, Berliner N, Ebert BL: Contribution of Clonal Hematopoiesis to Adult-Onset Hemophagocytic Lymphohistiocytosis. Blood. 2020 Sep 22:blood.2020008206. doi: 10.1182/blood.2020008206. Epub ahead of print. PMID: 32961550

Ernst P, Press AT, Fischer M, Günther V, Gräfe C, Clement JH, Ernst T, Schubert US, Wotschadlo J, Lehmann M, Enzensperger C, Bauer M, Hochhaus A:Polymethine Dye-Functionalized Nanoparticles for Targeting CML Stem Cells. Molecular Therapy – Oncolytics, Volume 18, 25 September 2020, Pages 372-381. https://doi.org/10.1016/j.omto.2020.07.007

Eisfeld H, Kircher S, Rosenwald A, Anagnostopoulos I, Werner M, Gaßler N, Wolf G, Lehmkuhl L, Teichgräber U, Gühne F, Darr A, Freesmeyer M, Weschenfelder W, Hofmann G, Dalkilic R, Kalff R, Hochhaus A, Schrenk KG: Revealing the true face behind the mask of ALK-positive anaplastic large cell lymphoma (ALCL) [published online ahead of print, 2020 Sep 8]. Ann Hematol. 2020;10.1007/s00277-020-04247-4. doi:10.1007/s00277-020-04247-4 PMID: 32895754

La Rosée F, La Rosée P: Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies. [published online ahead of print, 2020 Aug 20]. Acta Haematol. 2020;1-3. doi:10.1159/000510770. PMID: 32818929

Wörmann B, Rüthrich M, Einsele H, Tamm I, de Wit M, Trümper L, von Lilienfel-Toal M: COVID-19 un Onkologie. Anpassungsfähiges System. Perspektiven der Onkologie 2/2020 I Deutsches Ärzteblatt. DOI: 10.3238/ PersOnko.20200817.07

Rachow T, Lamik T, Kalkreuth J, Kurze S, Wagner K , Stier P , Hammersen F, Rüthrich M, Winkelmann N, Klink A, Hilgendorf I, Hermann B , Lang S, Hochhaus A, von Lilienfeld-Toal M: Detection of community-acquired respiratory viruses in allogeneic stem-cell transplant recipients and controls-A prospective cohort study [published online ahead of print, 2020 Jul 13]. Transpl Infect Dis. 2020;e13415. doi:10.1111/tid.13415. PMID: 32779843

Büntzel J, Klein M, Keinki C, Walter S, Büntzel J, Hübner J. Oncology services in corona times: a flash interview among German cancer patients and their physicians [published online ahead of print, 2020 May 15]. J Cancer Res Clin Oncol. 2020;146(10):2713-2715. doi:10.1007/s00432-020-03249-z. PMID: 32415341

Kutschan S, Freuding M, Keinki C, Huebner J. Recommendations on complementary and alternative medicine within S3 guidelines in oncology: systematic quality assessment of underlying methodology. J Cancer Res Clin Oncol. 2020;146(9):2419-2425. doi:10.1007/s00432-020-03238-2. PMID: 32394053

Rosenfeldt S, Mickoleit F, Jörke C, Clement JC, Markert S, Jérôme V, Schwarzinger S, Freitag R, Schüler D, Uebe R, Schenk AS: Towards standardized purification of bacterial magnetic nanoparticles for future in vivo applications [published online ahead of print, 2020 Jul 25]. Acta Biomater. 2020;S1742-7061(20)30428-1. doi:10.1016/j.actbio.2020.07.042. PMID: 32721577

Wolff D, Herzberg PY, Herrmann A, Pavletic SZ, Heussner P, Mumm F, Höfer C, Hilgendorf I, Hemmati PG, Holler E, Greinix H, Mitchell SA: Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease-results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health [published online ahead of print, 2020 Jul 31]. Bone Marrow Transplant. 2020;10.1038/s41409-020-01017-8. doi:10.1038/s41409-020-01017-8 Copy. PMID: 32737446

Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Sebastien Rinaldetti S, Kohlbrenner K, Haferlach C, Schlegelberger B, Fabarius A, Seifarth W, Spieß B, Wuchter P, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Burchert A, Brümmendorf TH, Hasford J, Hochhaus A, Saußele S, Baccarani M, SAKK and the German CML Study Group: High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia. 2020;34(8):2074-2086. doi:10.1038/s41375-020-0826-9. PMID: 32382082

Pfirrmann M, Clark RE, Prejzner W, Lauseker M, Baccarani M, Saussele S, Guilhot F, Heibl S, Hehlmann R, Faber E, Turkina A, Ossenkoppele G, Höglund M, Zaritskey A, Griskevicius L, Olsson-Strömberg U, Everaus H, Koskenvesa P, Labar B, Sacha T, Zackova D, Cervantes F, Colita A, Zupan I, Bogdanovic A, Castagnetti F, Guilhot J, Hasford J, Hochhaus A, Hoffmann VS: The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2020;34(8):2138-2149. doi:10.1038/s41375-020-0931-9. PMID: 32601376

Kaiser A, Schmidt M, Huber O, Frietsch J , Scholl S, Heidel F, Hochhaus A, Müller J, Ernst T: SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders. Leukemia. 2020;34(8):2206-2216. doi:10.1038/s41375-020-0803-3. PMID: 32214204

Rinke J, Chase A, Cross NCP, Hochhaus A, Ernst T: EZH2 in Myeloid Malignancies. Cells 9, no. 7: 1639

Schiffl H, Al-Nemnem E, Lang SM. Proton-pump inhibitors and chronic kidney disease: Hidden consequences of an inappropriate drug use?. Saudi J Kidney Dis Transpl. 2020;31(2):312-319. doi:10.4103/1319-2442.284005. PMID: 32394903

Lang SM, Rachow T: Molekulare therapeutische Stratifizierung des nichtkleinzelligen Lungenkarzinoms. Onkologe, https://doi.org/10.1007/s00761-020-00787-6. © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2020

Lang, S.M., Al-Nemnem, E. and Schiffl, H. (2020) Anti-Tuberculosis Drug Induced Liver Injury and Ursodeoxycholic Acid. Journal of Tuberculosis Research, 8, 66-72. https://doi.org/10.4236/jtr.2020.82007

Lang SM: Pneumonitis als gravierende Nebenwirkung bei Asthmapatienten unter Immuntherapie. Kompass Pneumol https://doi.org/10.1159/000509167

Heidel F, Hochhaus A: Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation. Leukemia. 2020;34(7):1723-1725. doi:10.1038/s41375-020-0898-6. PMID: 32528040

Butt E, Stempfle K, Lister L , Wolf F , Kraft M, Herrmann AB, Viciano CP, Weber C, Hochhaus A, Ernst T, Hoffmann C, Zernecke A, Frietsch JJ: Phosphorylation-Dependent Differences in CXCR4-LASP1-AKT1 Interaction Between Breast Cancer and Chronic Myeloid Leukemia. Cells. 2020 Feb 14;9(2):444. doi: 10.3390/cells9020444. PMID: 32075106

Frietsch JJ, Hunstig F, Wittke C, Junghanss C, Franiel T, Scholl S, Hochhaus A, Hilgendorf I: Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity. Bone Marrow Transplant (2020). https://doi.org/10.1038/s41409-020-0984-4

Pfirrmann M, Clark RE, Prejzner W, Lauseker M, Baccarani M, Saussele S, Guilhot F, Heibl S, Hehlmann R, Faber E, Turkina A, Ossenkoppele G, Höglund M, Zaritskey A, Griskevicius L, Olsson-Strömberg U, Everaus H, Koskenvesa P, Labar B, Sacha T, Zackova D, Cervantes F, Colita A, Zupan I, Bogdanovic A, Castagnetti F, Guilhot J, Hasford J, Hochhaus A, Hoffmann VS:The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia (2020). https://doi.org/10.1038/s41375-020-0931-9

Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, Brümmendorf TH, Smith BD, Ernst T, Giraldo-Castellano P, Olsson-Strömberg U, Saussele S, Bardy-Bouxin N, Viqueira A, Leip E, Russell-Smith TA, Leone J, Rosti G, Watts J, Giles FJ, on behalf of the BYOND Study Investigators: Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia (2020). https://doi.org/10.1038/s41375-020-0915-9

La Rosée, F., Bremer, H.C., Gehrke, I. et al. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia (2020). https://doi.org/10.1038/s41375-020-0891-0

Ortmann, J. Torode, W. Schmiegel, C. Thomssen, M. Hakama, P. Basu, U. Ringborg, U. Helbig, For the participants of the ERTM: Knowledge transfer as a tool towards improvement of cancer care in low‑ and middle‑income countries. 6th European Roundtable Meeting (ERTM), June 14th, 2019, Berlin, Germany. Journal of Cancer Research and Clinical Oncology (2020) 146:1813–1818 https://doi.org/10.1007/s00432-020-03209-7 REVIEW – CLINICAL ONCOLOGY. Received: 31 March 2020 / Accepted: 2 April 2020 / Published online: 8 April 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020 PMID: 32270287

Joseph Tintelnot, Eray Goekkurt, Mascha Binder, Peter Thuss-Patience, Sylvie Lorenzen, Jorge Riera Knorrenschild, Albrecht Kretzschmar, Thomas Ettrich, Udo Lindig, Lutz Jacobasch, Daniel Pink, Salah-Eddin Al-Batran, Axel Hinke, Susanna Hegewisch-Becker, Sven Nilsson, Carsten Bokemeyer, Alexander Stein: Ipilimumab or FOLFOX With Nivolumab and Trastuzumab in Previously Untreated HER2-positive Locally Advanced or Metastatic EsophagoGastric Adenocarcinoma - The Randomized Phase 2 INTEGA Trial (AIO STO 0217). BMC Cancer . 2020 Jun 1;20(1):503. doi: 10.1186/s12885-020-06958-3. PMID: 32487035

Christoph Röllig, Michael Kramer, Christoph Schliemann, Jan-Henrik Mikesch, Björn Steffen, Alwin Krämer, Richard Noppeney, Kerstin Schäfer-Eckart, Stefan Krause, Mathias Hänel, Regina Herbst, Volker Kunzmann, Hermann Einsele, Edgar Jost, Tim H. Brümmendorf, Sebastian Scholl, Andreas Hochhaus, Andreas Neubauer, Kristina Sohlbach, Lars Fransecky, Martin Kaufmann, Dirk Niemann, Markus Schaich, Norbert Frickhofen, Alexander Kiani, Frank Heits, Ulrich Krümpelmann, Ulrich Kaiser, Johannes Kullmer, Maxi Wass, Friedrich Stölzel, Malte von Bonin, Moritz Middeke, Christian Thiede, Johannes Schetelig, Wolfgang E Berdel, Gerhard Ehninger, Claudia D Baldus, Carsten Müller-Tidow, Uwe Platzbecker2, Hubert Serve, Martin Bornhäuser: Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? Blood (2020) 136 (7): 823–830.https://doi.org/10.1182/blood.2019004583

Silvio Dutz, Norbert Buske, Joachim Landers , Christine Gräfe , Heiko Wende , Joachim H Clement: Biocompatible Magnetic Fluids of Co-Doped Iron Oxide Nanoparticles With Tunable Magnetic Properties. Nanomaterials (Basel), 2020 May 27;10(6):E1019. doi: 10.3390/nano10061019, PMID: 32471031

Sebastian Stasik , Jan M Middeke , Michael Kramer , Christoph Röllig , Alwin Krämer , Sebastian Scholl, Andreas Hochhaus, Martina Crysandt, Tim H Brümmendorf, Ralph Naumann, Björn Steffen, Volker Kunzmann, Hermann Einsele, Markus Schaich, Andreas Burchert, Andreas Neubauer, Kerstin Schäfer-Eckart, Christoph Schliemann, Stefan Krause, Regina Herbst, Mathias Hänel, Norbert Frickhofen, Richard Noppeney, Ulrich Kaiser, Claudia D Baldus, Martin Kaufmann, Zdenek Rácil, Uwe Platzbecker , Wolfgang E Berdel , Jiri Mayer , Hubert Serve , Carsten Müller-Tidow , Gerhard Ehninger , Martin Bornhäuser , Johannes Schetelig , Christian Thiede , Study Alliance Leukemia (SAL): Haematologica. 2020 May;105(5):e228-e231. doi: 10.3324/haematol.2019.222323. Epub 2019 Aug 14. EZH2 Mutations and Impact on Clinical Outcome: An Analysis in 1,604 Patients With Newly Diagnosed Acute Myeloid Leukemia, PMID: 31413097

Katerina Machova Polakova , Hana Zizkova , Jan Zuna , Eliska Motlova , Lenka Hovorkova , Andrea Gottschalk, Ingmar Glauche , Jitka Koblihova, Pavla Pecherkova , Hana Klamova , Marketa Stastna Markova , Dana Srbova , Adela Benesova , Vaclava Polivkova , Tomas Jurcek , Daniela Zackova , Jiri Mayer , Thomas Ernst , Francois X Mahon , Susanne Saussele , Ingo Roeder , Nicholas C P Cross , Andreas Hochhaus: Analysis of Chronic Myeloid Leukaemia During Deep Molecular Response by Genomic PCR: A Traffic Light Stratification Model With Impact on Treatment-Free Remission. Leukemia. . 2020 May 29. doi: 10.1038/s41375-020-0882-1. Online ahead of print. PMID: 32472084

Midic D, Rinke J, Perner F, Müller V, Hinze A, Pester F, Landschulze J, Ernst J, Gruhn B, Matziolis G, Heidel F , Hochhaus A, Ernst T: Prevalence and Dynamics of Clonal Hematopoiesis Caused by Leukemia-Associated Mutations in Elderly Individuals Without Hematologic Disorders. Leukemia. 2020;34(8):2198-2205. doi:10.1038/s41375-020-0869-y. PMID: 32457355

Roth I, Dubois C, Schmidt T, Jutta Hübner J: Attitude of Cancer Patients From Online Self-Help Groups Towards Physical Activity. J Cancer Res Clin Oncol . 2020 Jun;146(6):1583-1590. doi: 10.1007/s00432-020-03190-1. Epub 2020 Mar 26. PMID: 32219516

Peter G. Miller, Abhishek Niroula, John J. Ceremsak, Christopher J. Gibson, Martin S. Taylor, Sebastian Birndt, Florian Perner, Jon Arnason, Adam S. Sperling, Mridul Agrawal, Alison M. Schram, Sarah Nikiforow, German Pihan, Robert P. Hasserjian, Jon C. Aster, Paul La Rosée,Elizabeth A. Morgan, Nancy Berliner, and Benjamin L. Ebert: Identification of germline variants in adults with hemophagocytic lymphohistiocytosis. Blood Adv . 2020 Mar 10;4(5):925-929. doi: 10.1182/bloodadvances.2019001272. PMID: 32150605

Rassaf T, Totzeck M, Backs J, Bokemeyer C, Hallek M, Hilfiker-Kleiner D, Hochhaus A, Lüftner D, Müller OJ, Neudorf U, Pfister R, von Haehling S, Lehmann LH, Bauersachs J; Committee for Clinical Cardiovascular Medicine of the German Cardiac Society: Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Clin Res Cardiol. 2020 May 13. doi: 10.1007/s00392-020-01636-7. [Epub ahead of print] PMID: 32405737

Rassaf T, Totzeck M, Backs J, Bokemeyer C, Hallek M, Hilfiker-Kleiner D, Hochhaus A, Lüftner D, Müller OJ, Neudorf U, Pfister R, von Haehling S, Lehmann LH, Bauersachs J; für die Kommission für Klinische KardiovaskuläreMedizin der DGK: Onkologische Kardiologie Konsensuspapier der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung, der Deutschen Gesellschaft für Pädiatrische Kardiologie und Angeborene Herzfehler und der Deutschen Gesellschaft für Hämatologie und Medizinische Onkologie. Kardiologe https://doi.org/10.1007/s12181-020-00395-z

von Lilienfeld-Toal M: Community-Acquired Respiratory Viruses in Oncology: Lessons to Be Learnt from the SARS-CoV-2 Pandemic. Oncol Res Treat. 2020 May 14:1-2. doi: 10.1159/000508452. [Epub ahead of print] PMID: 32408304

Capdevila J, Wirth LJ, Ernst T, Ponce Aix S, Lin CC, Ramlau R, Butler MO, Delord JP, Gelderblom H, Ascierto PA, Fasolo A, Führer D, Hütter-Krönke ML, Forde PM, Wrona A, Santoro A, Sadow PM, Szpakowski S, Wu H, Bostel G, Faris J, Cameron S, Varga A, Taylor M: PD-1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol. 2020 May 4:JCO1902727. doi: 10.1200/JCO.19.02727. [Epub ahead of print] PMID: 32364844

Hehlmann R, Voskanyan A, Lauseker M, Markus Pfirrmann M, Kalmanti L, Rinaldetti S, Kohlbrenner K, Haferlach C, Schlegelberger B, Fabarius A, Seifarth W, Spieß B, Wuchter P, Krause S, Kolb H, Neubauer A, Hossfeld D, Nerl C, Gratwohl A, Baerlocher G, Burchert A, Brümmendorf T, Hasford J, Hochhaus A, Saußele S, Baccarani M for the SAKK and the German CML Study Group: High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia, https://doi.org/10.1038/s41375-020-0826-9. Received: 27 February 2020 / Revised: 2 March 2020 / Accepted: 30 March 2020, © The Author(s) 2020. This article is published with open access

Hochhaus A, Breccia M, Saglio G, García-Gutiérrez V, Réa D, Janssen J, Apperley J: Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia, https://doi.org/10.1038/s41375-020-0842-9, Received: 9 April 2020 / Revised: 16 April 2020 / Accepted: 16 April 2020

von Lilienfeld-Toal M, Vehreschild JJ, Cornely O, Pagano L, Compagno F; EHA Infectious Disease Scientific Working Group, Hirsch HH: Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases. Leukemia. 2020 May 1. doi: 10.1038/s41375-020-0832-y. [Epub ahead of print] PMID: 32358568

Hans-Jürgen Laws, Ulrich Baumann, Christian Bogdan, Gerd Burchard, Maximilian Christopeit, Jane Hecht, Ulrich Heininger, Inken Hilgendorf, Winfried Kern, Kerstin Kling, Guido Kobbe, Wiebe Külper,·Thomas Lehrnbecher, Roland Meisel, Arne Simon, Andrew Ullmann: Maike de Wit16, 17 · Fred Zepp4, 18Impfen bei Immundefizienz. Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie. Bundesgesundheitsbl 2020 · 63:588–644; https:// doi.org/ 10.1007/ s00103- 020- 03123-w; © Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2020

Schwaab J, Naumann N, Luebke J, Jawhar M, Somervaille TCP, Williams MS, Frewin R, Jost PJ, Lichtenegger FS, La Rosée P, Storch N, Haferlach T, Horny HP, Fabarius A, Haferlach C, Burchert A, Hofmann WK, Cross NCP, Hochhaus A, Reiter A, Metzgeroth G: Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes. Am J Hematol. 2020 Apr 12. doi: 10.1002/ajh.25825. [Epub ahead of print] PMID: 32279331

Chase A, Score J, Lin F, Bryant C, Waghorn K, Yapp S, Carreno-Tarragona G, Aranaz P, Villasante A, Ernst T, Cross NCP3: Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Leukemia. 2020 Apr 22. doi: 10.1038/s41375-020-0816-y. [Epub ahead of print] PMID: 32322039

von Lilienfeld-Toal M, Rüthrich MM, Mathies V, Wingen-Heimann S, Vehreschild JJ, Wörmann B: SARS-CoV-2: Vorgehen in der Krebstherapie. Dtsch Arztebl 2020; 117(16): A-820 / B-694

Cortes JE, Jiang Q, Wang J, Weng J, Zhu H, Liu X, Hochhaus A, Kim DW, Radich J, Savona M, Martin-Regueira P, Sy O, Gurnani R, Saglio G: Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. Leukemia. 2020 Apr 7. doi: 10.1038/s41375-020-0805-1. [Epub ahead of print] PMID: 32265500

Gale, R.P., Hehlmann, R. & Hochhaus, A. Clara Bloomfield MD: Queen of AML. Dare to cross her at your risk (May 15, 1942 to March 1, 2020). Bone Marrow Transplant (2020). https://doi.org/10.1038/s41409-020-0881-x This article is co-published in the journals Bone Marrow Transplantation and Leukemia. [https://doi.org/10.1038/s41375-020-0807-z. of LEU].

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saußele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R: European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Mar 3. doi: 10.1038/s41375-020-0776-2. [Epub ahead of print] PMID: 32127639

Birndt S, Schenk T, Heinevetter B, Brunkhorst F, Maschmeyer G, Rothmann F, Thomas Weber T, Müller M, Panse J, Penack O, Schroers R, Braess J, Frickhofen N, Ehl S, Janka G, Lehmberg K, Pletz M, Hochhaus A, Ernst T,and Paul La Rosée P: Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry. J Cancer Res Clin Oncol. 2020 Apr;146(4):1065-1077. doi: 10.1007/s00432-020-03139-4. Epub 2020 Feb 20. PMID: 32076823

Kaiser A, Schmidt M, Huber O, Frietsch J, Scholl S, Heidel F, Hochhaus A, Müller J, Ernst T: 3ARTICLEStem cell biologySIRT7: an influence factor in healthy aging and the developmentof age-dependent myeloid stem-cell disorders. Leukemia, https://doi.org/10.1038/s41375-020-0803-3

Ernst P, Engmann B, Frietsch JJ, Schnetzke U, Scholl S, Theis B, Kreipe HH, Ernst T, Glaser A, Haferlach T, Koch T, Hochhaus A, Hilgendorf I: A 19-year-old patient with atypical chronic myeloid leukemia. Ann Hematol. 2020 Mar 19. doi: 10.1007/s00277-020-03992-w. [Epub ahead of print] PMID: 32193626

Eisfeld H, Bauer F, Dubois C, Schmidt T, Kastrati K, Hochhaus A, Hübner J: Importance of and Satisfaction with Information about Their Disease in Cancer Patients. J Cancer Educ. 2020 Apr;35(2):403-411. doi: 10.1007/s13187-019-1480-7. PMID: 30684231

Miller PG, Niroula A, Ceremsak JJ, Gibson CJ, Taylor MS, Birndt S, Perner F, Arnason J, Sperling AS, Agrawal M, Schram AM, Nikiforow S, Pihan G, Hasserjian RP, Aster JC, La Rosée P, Morgan EA, Berliner N, Ebert BL: Identification of germline variants in adults with hemophagocytic lymphohistiocytosis. Blood Adv. 2020 Mar 10;4(5):925-929. doi: 10.1182/bloodadvances.2019001272. PMID: 32150605

Hoffmann K, Cazemier K, Baldow C, Schuster S, Kheifetz Y, Schirm S, Horn M, Ernst T, Volgmann C, Thiede C, Hochhaus A, Bornhäuser M, Suttorp M, Scholz M, Glauche I, Loeffler M, Roeder I: Integration of mathematical model predictions into routine workflows to support clinical decision making in haematology. BMC Med Inform Decis Mak. 2020 Feb 10;20(1):28. doi: 10.1186/s12911-020-1039-x. PMID: 32041606

Metzgeroth G, Schwaab J, Naumann N, Jawhar M, Haferlach T, Fabarius A, Hochhaus A, Hofmann WK, Cross NCP, Reiter A: Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation. Blood Adv. 2020 Feb 11;4(3):440-443. doi: 10.1182/bloodadvances.2019001111. PMID: 31995156

Salchow J, Mann J, Koch B, von Grundherr J, Jensen W, Elmers S, Straub LA, Vettorazzi E, Escherich G, Rutkowski S, Dwinger S, Bergelt C, Sokalska-Duhme M, Bielack S, Calaminus G, Baust K, Classen CF, Rössig C, Faber J, Faller H, Hilgendorf I, Gebauer J, Langer T, Metzler M, Schuster S, Niemeyer C, Puzik A, Reinhardt D, Dirksen U, Sander A, Köhler M, Habermann JK, Bokemeyer C, Stein A: Comprehensive assessments and related interventions to enhance the long-term outcomes of child, adolescent and young adult cancer survivors - presentation of the CARE for CAYA-Program study protocol and associated literature review. BMC Cancer. 2020 Jan 6;20(1):16. doi: 10.1186/s12885-019-6492-5. PMID: 31906955

Beelen DW, Trenschel R, Stelljes M, Groth C , Masszi T, Reményi P , Wagner-Drouet E , Hauptrock B, Dreger P, Luft T, Bethge W, Vogel W, Ciceri F, Jacopo Peccatori J , Stölzel F, Schetelig J, Junghanß C , Grosse-Thie C, Michallet M, Labussiere-Wallet H, Schaefer-Eckart K, Dressler S, Grigoleit GU, Mielke S, Scheid C, Holtick U, Patriarca F, Medeot M, Rambaldi A, Micò MC, Niederwieser D, Franke G, Hilgendorf I, Winkelmann N, Russo D, Socié G, de Latour RP, Holler E, Wolff D, Glass B, Casper J, Wulf G, Menzel H, Basara N, Bieniaszewska M, Stuhler G, Verbeek M, Grass S, Iori AP , Finke J, Benedetti F, Pichlmeier U, Hemmelmann C, Tribanek M, Klein A, Mylius HA, Baumgart J, Dzierzak-Mietla M, Markiewicz M: Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol. 2020;7(1):e28-e39. doi:10.1016/S2352-3026(19)30157-7. PMID: 31606445

2019

Andreas B. Herrmann, Martha-Lena Müller, Martin F. Orth, Jörg P. Müller, Alma Zernecke, Andreas Hochhaus, Thomas Ernst, Elke Butt, Jochen J. Frietsch: Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance. Received: 21 November 2019. Accepted: 30 November 2019, DOI: 10.1111/jcmm.14910

Hartung S, Rauh C, Böttcher S, Hoang MTN, Jahreis S, Rummler S, Hochhaus A, von Lilienfeld-Toal M: Measuring Phagocytosis of Aspergillus fumigatus Conidia by Human Leukocytes using Flow Cytometry. J Vis Exp. 2019 Dec 7;(154). doi: 10.3791/60397. PMID: 31868176

Radivoyevitch T, Weaver D, Hobbs B, Maciejewski JP, Hehlmann R, Jiang Q, Hochhaus A, Gale RP: Do persons with chronic myeloid leukaemia have normal or near normal survival? Leukemia. 2019 Dec 20. doi: 10.1038/s41375-019-0699-y. [Epub ahead of print] PMID: 31862960

Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y1, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW: Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328. PMID: 31826340

Brioli A, Manz K, Pfirrmann M, Hänel M, Schwarzer AC, Prange-Krex G, Fabisch C, Knop S, Illmer T, Krammer-Steiner B, Hochhaus A, von Lilienfeld-Toal M, Mügge LO: Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN). J Cancer Res Clin Oncol. 2019 Dec 2. doi: 10.1007/s00432-019-03101-z. [Epub ahead of print] PMID:31788741

Büntzel, J., Hübner, J. & Büntzel, J. Komplementärmedizinische Behandlungsansätze bei Inappetenz und Ösophagitis. Onkologe (2019) 25: 1110. https://doi.org/10.1007/s00761-019-00667-8

Austin RJ, Straube J, Bruedigam C, Pali G, Jacquelin S, Vu T, Green J, Gräsel J, Lansink L, Cooper L, Lee SJ, Chen NT, Lee CW, Haque A, Heidel FH, D'Andrea R, Hill GR, Mullally A, Milsom MD, Bywater M, Lane SW: Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations. Leukemia. 2019 Nov 15. doi: 10.1038/s41375-019-0638-y. [Epub ahead of print] PMID: 31732720

Mihajlović J, Diehl LAM, Hochhaus A, Clement JH: Inhibition of bone morphogenetic protein signaling reduces viability, growth and migratory potential of non-small cell lung carcinoma cells. J Cancer Res Clin Oncol. 2019 Nov;145(11):2675-2687. doi: 10.1007/s00432-019-03026-7. Epub 2019 Sep 17. PMID: 31531741

Franke GN, Maier J, Wildenberger K, Cross M, Giles FJ, Müller MC, Hochhaus A, Niederwieser D, Lange T: Comparison of Real-Time quantitative PCR and digital droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia. J Mol Diagn. 2019 Oct 24. pii: S1525-1578(19)30403-9. doi: 10.1016/j.jmoldx.2019.08.007. [Epub ahead of print] PMID: 31669230

Hochhaus A, · Höffken K: Fortschritte in der Diagnostik und Therapie chronischer Leukämien und Myelodysplasien. Onkologe 2019 · 25:946–947. https://doi.org/10.1007/s00761-019-00650-3

Heidel F, · Döhner K: Risikoadaptierte Therapie chronischer BCR-ABL1-negativer myeloproliferativer Neoplasien. Onkologe 2019 · 25:985–993. https://doi.org/10.1007/s00761-019-0576-3. Online publiziert: 2. Mai 2019

Hochhaus A, · Fabisch C, · Ernst T: Therapie der chronischen myeloischen Leukämie. Onkologe 2019 ・ 25:971–984. https://doi.org/10.1007/s00761-019-0638-6. Online publiziert: 13. August 2019

Keinki C., · Freuding M, · Micke O, · Büntzel J, · Hübner J: Immunstimulanzien aus der Naturheilkunde. Onkologe 2019 · 25:1014–1019 https://doi.org/10.1007/s00761-019-0625-y Online publiziert: 19. Juli 2019

Kahl M, Brioli A, Bens M4, Perner F, Kresinsky A, Schnetzke U, Hinze A, Sbirkov Y, Stengel S, Simonetti G, Martinelli G, Petrie K, Zelent A, Böhmer FD, Groth M, Ernst T, Heidel FH, Scholl S, Hochhaus A, Schenk T: The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML. Leukemia. 2019 Oct 1. doi: 10.1038/s41375-019-0581-y. [Epub ahead of print] PMID: 31576004

Mihajlović J, Diehl LAM, Hochhaus A, Clement JH: Inhibition of bone morphogenetic protein signaling reduces viability, growth and migratory potential of non-small cell lung carcinoma cells. J Cancer Res Clin Oncol. 2019 Sep 17. doi: 10.1007/s00432-019-03026-7. [Epub ahead of print] PMID: 31531741

Lauseker M, Bachl K, Turkina A, Faber E, Prejzner W, Olsson-Strömberg U, Baccarani M, Lomaia 7, Zackova D, Ossenkoppele G, Griskevicius L, Schubert-Fritschle G, Sacha T, Heibl S, Koskenvesa P, Bogdanovic A, Clark RE, Guilhot J, Hoffmann VS, Hasford J, Hochhaus A, Pfirrmann M: Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. Am J Hematol. 2019 Aug 27. doi: 10.1002/ajh.25628. [Epub ahead of print] PMID: 31456269

Hochhaus A, Ernst T: Neue Entwicklungen der Systemtherapie maligner Erkrankungen. Onkologe 2019 · 25 (Suppl 1):S68–S76, https://doi.org/10.1007/s00761-019-00648-x, Online publiziert: 13. August 2019, © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Alcala N, Leblay N, Gabriel AAG, Mangiante L, Hervas D, Giffon T, Sertier AS, Ferrari A, Derks J, Ghantous A, Delhomme TM, Chabrier A, Cuenin C, Abedi-Ardekani B, Boland A, Olaso R, Meyer V, Altmuller J, Le Calvez-Kelm F, Durand G, Voegele C, Boyault S, Moonen L, Lemaitre N, Lorimier P, Toffart AC, Soltermann A, Clement JH, Saenger J, Field JK, Brevet M, Blanc-Fournier C, Galateau-Salle F, Le Stang N, Russell PA, Wright G, Sozzi G, Pastorino U, Lacomme S, Vignaud JM, Hofman V, Hofman P, Brustugun OT, Lund-Iversen M, Thomas de Montpreville V, Muscarella LA, Graziano P, Popper H, Stojsic J, Deleuze JF, Herceg Z, Viari A, Nuernberg P, Pelosi G, Dingemans AMC, Milione M, Roz L, Brcic L, Volante M, Papotti MG, Caux C, Sandoval J, Hernandez-Vargas H, Brambilla E, Speel EJM, Girard N, Lantuejoul S, McKay JD, Foll M, Fernandez-Cuesta L: Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. Nat Commun. 2019 Aug 20;10(1):3407. doi: 10.1038/s41467-019-11276-9. PMID: 31431620

Perner F, Perner C, Ernst T, Heidel FH: Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation. Cells. 2019 Aug 8;8(8). pii: E854. doi: 10.3390/cells8080854. PMID: 31398915

Hochhaus A, Ernst T: Neue Entwicklungen der Systemtherapie maligner Erkrankungen. Onkologe (2019). https://doi.org/10.1007/s00761-019-00648-x

Hochhaus A, Fabisch C, Ernst T: Therapie der chronischen myeloischen Leukämie. Onkologe (2019). https://doi.org/10.1007/s00761-019-0638-6

Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, Krause SW, Kolb HJ, Hossfeld DK, Nerl C, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Balleisen L, Goebeler ME, Hänel M, Ho A, Dengler J, Falge C, Möhle R, Kremers S, Kneba M, Stegelmann F, Köhne CH, Lindemann HW, Waller CF, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Schenk M, Brossart P, Wündisch T, Geer T, Bildat S, Schäfer E, Hasford J, Hehlmann R4, Pfirrmann M: Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica. 2019 May;104(5):955-962. doi: 10.3324/haematol.2018.206797. Epub 2018 Dec 4. PMID: 30514803

Gebauer J, Hilgendorf I, Koch B, Langer T: Neue Strukturen in der Betreuung und Nachsorge junger Krebspatienten. Oncol Res Treat 2019;42(suppl 3):21–26, DOI: 10.1159/000500818

Hochhaus A, Burchert A, Saußele S: Absetzen der CML-Therapie – „therapiefreie Remission“. JOURNAL ONKOLOGIE, 7/8 2019

Fabisch C, Clauß C, Kolb M: Studien der Deutschen CML-Studiengruppe. JOURNAL ONKOLOGIE, 7/8 2019

Kolb M, Hochhaus A, Tesch H, Geißler J: Deutsche CML-Allianz. JOURNAL ONKOLOGIE, 7/8 2019

Linke P: Erstdiagnose chronische myeloische Leukämie. JOURNAL ONKOLOGIE, 7/8 2019

Fischer M, Hochhaus A, Ernst T: Zytogenetische und molekulare Verlaufskontrolle der CML. JOURNAL ONKOLOGIE, 7/8 2019

Hochhaus A, Ernst T: Management der CML 2019. JOURNAL ONKOLOGIE, 7/8 2019

Bartholomäus M, Zomorodbakhsch B, Micke O, Prott FJ, Rudolph I, Seilacher E, Hochhaus A, Huebner J: Cancer patients' needs for virtues and physicians' characteristics in physician-patient communication: a survey among patient representatives. Support Care Cancer. 2019 Aug;27(8):2783-2788. doi: 10.1007/s00520-018-4585-3. Epub 2018 Dec 6. PMID: 30523413

Dubois C, Eisfeld H, Bauer F, Schmidt T, Kastrati K, Hochhaus A, Hübner J: Not all cancer patients with an interest in CAM are the same. Differences between patients with a CAM interest prior to the cancer diagnosis and those with first-time interest since diagnosis. Complement Ther Med. 2019 Aug;45:167-171. doi: 10.1016/j.ctim.2019.06.009. Epub 2019 Jun 14. PMID: 31331555

Battipaglia G, Labopin M, Kröger N, Vitek A, Afanasyev B, Hilgendorf I, Schetelig J, Ganser A, Blaise D, Itälä-Remes M, Passweg JR, Bonifazi F, Finke J, Ruggeri A, Nagler A, Mohty M: Post-Transplant Cyclophosphamide versus Antithymocyte Globulin in HLA-Mismatched unrelated Donors transplantation. Blood. 2019 Jul 3. pii: blood.2019000487. doi: 10.1182/blood.2019000487. [Epub ahead of print] PMID: 31270102

Lamby P, Wolff D, Mielke S, Grigoleit GU, Ljungman P, Hilgendorf I, Holler E, Holler B, Weber D, Herr W, Schiltz D, Klein S, Graf S, Bjornhagen-Safwenberg V, Dolderer J, Prantl L: Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation-a retrospective analysis on seven patients. Ann Hematol. 2019 Aug;98(8):1867-1875. doi: 10.1007/s00277-019-03687-x. Epub 2019 Apr 16. PMID: 30993415

Wolff D, Hilgendorf I, Wagner-Drouet E, Jedlickova Z, Ayuk F, Zeiser R, Schäfer-Eckart K, Gerbitz A, Stadler M, Klein S, Middeke JM, Lawitschka A, Winkler J, Halter J, Holler E, Kobbe G, Stelljes M, Ditschkowski M, Greinix H: Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland. Biol Blood Marrow Transplant. 2019 Jul;25(7):1450-1455. doi: 10.1016/j.bbmt.2019.03.003. Epub 2019 Mar 13. PMID: 30876928

Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, Radich JP, Hochhaus A, Hughes TP; International CML Foundation Genomics Alliance: Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. 2019 Jun 17. doi: 10.1038/s41375-019-0512-y. [Epub ahead of print] PMID: 31209280

Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators: Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019 Apr 10. pii: S0140-6736(18)32557-1. doi: 10.1016/S0140-6736(18)32557-1. [Epub ahead of print] PMID: 30982686

La Rosée P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, Birndt S, Gil-Herrera J, Girschikofsky M, Jordan MB, Kumar A, van Laar JA, Lachmann G, Nichols KE, Ramanan AV, Wang Y, Wang Z, Janka G, Henter JI: Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019 Apr 16. pii: blood.2018894618. doi: 10.1182/blood.2018894618. [Epub ahead of print] PMID: 30992265

Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Crescenzo R, Mamolo C, Reisman A, Hochhaus A, Brümmendorf TH; BFORE Study Investigators: Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. J Cancer Res Clin Oncol. 2019 Apr 15. doi: 10.1007/s00432-019-02894-3. [Epub ahead of print] PMID: 30989330

Ortmann O, Torode J, Harrison C, Bruns J, Helbig U; Participants of the ERTM: Research driving innovation: what are key factors for successful integration of translational science into oncology care concepts? 5th European Roundtable Meeting (ERTM) May 4th, 2018, Berlin, Germany. J Cancer Res Clin Oncol. 2019 Apr 16. doi: 10.1007/s00432-019-02916-0. [Epub ahead of print] PMID: 30993404

Möbius S, Schenk T, Himsel D, Maier J, Franke GN, Saussele S, Pott C, Andrikovics H, Meggyesi N, Machova-Polakova K, Zizkova H, Jurcek T, Mesanovic S, Zadro R, Gottardi E, Haenig J, Schuld P, Cross NCP, Hochhaus A, Ernst T: Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry). J Cancer Res Clin Oncol. 2019 Apr 2. doi: 10.1007/s00432-019-02910-6. [Epub ahead of print] PMID: 30941573

Hochhaus A, Eigendorff E, Ernst T: Chronische Myeloische Leukämie. TumorDiagn u Ther 2019; 40: 43-49

Frietsch JJ, Michel D, Stamminger T, Hunstig F, Birndt S, Schnetzke U, Scholl S, Hochhaus A, Hilgendorf I: In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation. Mediterr J Hematol Infect Dis. 2019 Jan 1;11(1):e2019001. doi: 10.4084/MJHID.2019.001. eCollection 2019. PMID: 30671207

Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R, Weckesser M, Kroschinsky F, Kotzerke J, Ganser A, Bengel FM, La Rosée P, Freesmeyer M, Höffkes HG, Hertel A, Behringer D, Prange-Krex G, Griesshammer M, Holzinger J, Wilop S, Krohn T, Raghavachar A, Maschmeyer G, Brink I, Schroers R, Gaska T, Bernhard H, Giagounidis A, Schütte J, Dienst A, Hautzel H, Naumann R, Klein A, Hahn D, Pöpperl G, Grube M, Marienhagen J, Schwarzer A, Kurch L, Höhler T, Steiniger H, Nückel H, Südhoff T, Römer W, Brinkmann M, Ose C, Alashkar F, Schmitz C, Dürig J, Hoelzer D, Jöckel KH, Klapper W, Dührsen U: Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial. Ann Hematol. 2019 Jan 4. doi: 10.1007/s00277-018-3578-0. [Epub ahead of print] PMID: 30610279

Frietsch JJ, Winkelmann N, Hunstig F, Schnetzke U, Hammersen FJ, Dönicke T, Lenz M, Gras F, Scholl S, Hochhaus A, Hilgendorf I: A Mosquito Bite with Devastating Complications in an Immunocompromised Patient. Case Rep Oncol. 2019 Jan 4;12(1):22-28. doi: 10.1159/000495878. eCollection 2019 Jan-Apr. PMID: 30792641

Brioli A, Klaus M, Sayer H, Scholl S, Ernst T, Hilgendorf I, Scherag A, Yomade O, Schilling K, Hochhaus A, Mügge LO, von Lilienfeld-Toal M: The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. Ann Hematol. 2019 Jan 24. doi: 10.1007/s00277-019-03621-1. [Epub ahead of print] PMID: 30680505

Eisfeld H, Bauer F, Dubois C, Schmidt T, Kastrati K, Hochhaus A, Hübner J: Importance of and Satisfaction with Information about Their Disease in Cancer Patients. J Cancer Educ. 2019 Jan 25. doi: 10.1007/s13187-019-1480-7. [Epub ahead of print] PMID:30684231

Hübner J: Integrative Onkologie – auch eine ethische Aufgabe. Onkologe 2019 · 25:157–158 https://doi.org/10.1007/s00761-018-0509-6

P Lamby , D Wolff , S Mielke, G U Grigoleit, P Ljungman, I Hilgendorf, E Holler , B Holler, D Weber, W Herr, D Schiltz, S Klein, S Graf, V Bjornhagen-Safwenberg , J Dolderer , L Prantl: Allogeneic Donor Split Skin Grafts for Treatment of Refractory Ulcers in Cutaneous Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation-A Retrospective Analysis on Seven Patients. Case Reports Ann Hematol. 2019 Aug;98(8):1867-1875. doi: 10.1007/s00277-019-03687-x. Epub 2019 Apr 16. PMID: 30993415

Wagner-Drouet E, Teschner D, Wolschke C, Janson D, Schäfer-Eckart K, Gärtner J, Mielke S, Schreder M, Kobbe G, Kondakci M, Hilgendorf I, von Lilienfeld-Toal M, Klein S, Heidenreich D, Kreil S, Verbeek M, Graß S, Ditschkowski M, Gromke T, Koch M, Lindemann M, Hünig T, Schmidt T, Anne Rascle A, HGuldan H, Barabas S, Deml L, Wagner R, Wolff D: Standardized Monitoring of Cytomegalovirus-Specific Immunity Can Improve Risk Stratification of Recurrent Cytomegalovirus Reactivation After Hematopoietic Stem Cell Transplantation. Haematologica. 2019 Dec 26;haematol.2019.229252. doi: 10.3324/haematol.2019.229252. Online ahead of print. PMID: 31879324

Koehler M, Mann J, Richter D, · I. Hilgendorf K: Krebs bei Jugendlichen und jungen Erwachsenen Status quo der interdisziplinären Versorgung in Deutschland. Forum https://doi.org/10.1007/s12312-019-00724-8, published online 3 December 2019

Gräfe C, von der Lühe M, Weidner A, Globig P, Clement JH, Dutz S, Schacher FH: Protein corona formation and its constitutional changes on magnetic nanoparticles in serum featuring a polydehydroalanine coating: effects of charge and incubation conditions. Nanotechnology. 2019;30(26):265707. doi:10.1088/1361-6528/ab0ed0, PMID: 30861506

2018

Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, Berdel WE, Franzius C, Kroschinsky F, Weckesser M, Kofahl-Krause D, Bengel FM, Dürig J, Matschke J, Schmitz C, Pöppel T, Ose C, Brinkmann M, La Rosée P, Freesmeyer M, Hertel A, Höffkes HG, Behringer D, Prange-Krex G, Wilop S, Krohn T, Holzinger J, Griesshammer M, Giagounidis A, Raghavachar A, Maschmeyer G, Brink I, Bernhard H, Haberkorn U, Gaska T, Kurch L, van Assema DME, Klapper W, Hoelzer D, Geworski L, Jöckel KH, Scherag A, Bockisch A, Rekowski J, Hüttmann A; PETAL Trial Investigators: Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. J Clin Oncol. 2018 Jul 10;36(20):2024-2034. doi: 10.1200/JCO.2017.76.8093. Epub 2018 May 11. PMID: 29750632

Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, Montesinos P, Pollyea DA, DesJardins P, Ottmann O, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Heuser M: Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2018 Dec 16. doi: 10.1038/s41375-018-0312-9. [Epub ahead of print] PMID: 30555165

Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, Krause SW, Kolb HJ, Hossfeld DK, Nerl C, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Balleisen L, Goebeler ME, Hänel M, Ho A, Dengler J, Falge C, Möhle R, Kremers S, Kneba M, Stegelmann F, Köhne CH, Lindemann HW, Waller CF, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Schenk M, Brossart P, Wündisch T, Geer T, Bildat S, Schäfer E, Hasford J, Hehlmann R, Pfirrmann M: Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica. 2018 Dec 4. pii: haematol.2018.206797. doi: 10.3324/haematol.2018.206797. [Epub ahead of print] PMID: 30514803

Hartung S, Rauh C, Hoang TNM, Jahreis S, Wagner K, Macheleidt J, Brakhage AA, Rummler S, Hochhaus A, von Lilienfeld-Toal M: Fast and Quantitative Evaluation of Human Leukocyte Interaction with Aspergillus fumigatus Conidia by Flow Cytometry. Cytometry A. 2018 Nov 19. doi: 10.1002/cyto.a.23653. [Epub ahead of print] PMID: 30450827

Hübner J.: Leserbrief zu Steger et al.„Methadon gegen Krebs“. Onkologe 2018 · 24:922923 https://doi.org/10.1007/s00761-018-0466-0 Online publiziert: 11. September 2018 © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Lei Wang, Ming Ni, Angela Hückelhoven-Krauss, Leopold Sellner, Jean-Marc Hoffmann, Brigitte Neuber, Thomas Luft, Ute Hegenbart, Stefan Schönland, Christian Kleist, Martin Sill, Bao-an Chen, Patrick Wuchter, Volker Eckstein, William Krüger, Inken Hilgendorf, Ronit Yerushalmi, Arnon Nagler, Carsten Müller-Tidow, Anthony D. Ho, Peter Dreger, Michael Schmitt and Anita Schmitt: Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects. Front. Immunol., 08 October 2018 | https://doi.org/10.3389/fimmu.2018.02207

Bauer F, Schmidt T, Eisfeld H, Dubois C, Kastrati K, Hochhaus A, Huebner J: Information needs and usage of complementary and alternative medicine in members of a German self-help group for gastrointestinal stroma tumours, sarcoma, and renal cancer. Complementary Therapies in Medicine Volume 41, December 2018, Pages 105-110https://doi.org/10.1016/j.ctim.2018.09.008

Hochhaus A, Eigendorff E, Ernst T: Chronische Myeloische Leukämie. Dtsch Med Wochenschr 2018; 1304-1310; DOI https://doi.org/10.1055/s-0043-121023

A. Moeser, C. Lange, M. von Lilienfeld-Toal, T. Welte, M. Pletz: Pneumonien bei immunsupprimierten Patienten. Pneumologe https://doi.org/10.1007/s10405-018-0174-x

Hughes TP, Laneuville P, Rousselot P, Snyder DS, Rea D, Shah NP, Paar D, Abruzzese E, Hochhaus A, Lipton JH, Cortes JE: Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica. 2018 Aug 9. pii: haematol.2018.188987. doi: 10.3324/haematol.2018.188987. [Epub ahead of print] PMID: 30093398

Jahreis S, Böttcher S, Hartung S, Rachow T, Rummler S, Dietl AM, Haas H, Walther G, Hochhaus A, von Lilienfeld-Toal M: Human MAIT cells are rapidly activated by Aspergillus ssp. in an antigen presenting cell-dependent manner. Eur J Immunol. 2018 Jul 30. doi: 10.1002/eji.201747312. [Epub ahead of print] PMID: 30059139

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM: Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 Jul 26;132(4):393-404. doi: 10.1182/blood-2016-09-739086. Epub 2018 Mar 22. PMID: 29567798

Heidel FH, Al-Ali HK, Hirt C, Kämpfe D, Jentsch-Ullrich K, Junghanss C, Nowak R, Schwarzer A, Spohn C, Vucinic V, Hochhaus A, Lange T; Working Party Myeloproliferative Neoplasms of the East German Study Group Hematology/Oncology (OSHO): Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions. Leukemia. 2018 Jul 24. doi: 10.1038/s41375-018-0214-x. [Epub ahead of print]. PMID: 30042412

Bouillon AS, Ventura Ferreira MS, Awad SA, Richter J, Hochhaus A, Kunzmann V, Dengler J, Janssen J, Ossenkoppele G, Westerweel PE, Te Boekhorst PAW, Mahon FX, Hjorth-Hansen H, Isfort S, Fioretos T, Hummel S, Schemionek M, Wilop S, Koschmieder S, Saußele S, Mustjoki S, Beier F, Brümmendorf TH: Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia. Blood Adv. 2018 Jul 10;2(13):1572-1579. doi: 10.1182/bloodadvances.2018017772. PMID:29980572

Kühl R, Meier S, Baeurle M, Wolff D, Greinix H, Lawitschka A, Halter J, Bertz H, Hilgendorf I: Sport- und physiotherapeutische Maßnahmen zur Behandlung der chronischen Graft-versus-Host-Krankheit. Sport Therapy and Physiotherapy for Treatment of cGvHD© Georg Thieme Verlag KG Stuttgart · New York. Phys Med Rehab Kuror, DOI: 10.1055/a-0626-7317

Thomas Ernst, Melinda Busch, Jenny Rinke, Jana Ernst, Claudia Haferlach, James F. Beck, Andreas Hochhaus, Bernd Gruhn: : Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia. Leukemia (2018), Brief Communication, Published: 13 June 2018, https://doi.org/10.1038/s41375-018-0157-2

von Lilienfeld-Toal M, Maschmeyer G.: Challenges in Infectious Diseases for Haematologists. Oncol Res Treat. 2018 May 7;41(6). doi: 10.1159/000487439. [Epub ahead of print] DOI: 10.1159/000487439. PMID: 29734194

Ross DM, Masszi T, Gómez Casares MT, Hellmann A, Stentoft J, Conneally E, Garcia-Gutierrez V, Gattermann N, le Coutre PD, Martino B, Saussele S, Giles FJ, Radich JP, Saglio G, Deng W, Krunic N, Bédoucha V, Gopalakrishna P, Hochhaus A.: Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J Cancer Res Clin Oncol. 2018 May;144(5):945-954. doi: 10.1007/s00432-018-2604-x. Epub 2018 Feb 22. PMID: 29468438

Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX2; EURO-SKI investigators: Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018 May 4. pii: S1470-2045(18)30192-X. doi: 10.1016/S1470-2045(18)30192-X. [Epub ahead of print] PMID:29735299

Bhatia S, Diedrich D, Frieg B, Ahlert H, Stein S, Bopp B, Lang F, Zang T, Kröger T, Ernst T, Kögler G, Krieg A, Lüdeke S, Kunkel H, Rodrigues Moita AJ, Kassack MU, Marquardt V, Opitz FV, Oldenburg M, Remke M, Babor F, Grez M, Hochhaus A, Borkhardt A, Groth G, Nagel-Steger L, Jose J, Kurz T, Gohlke H, Hansen FK, Hauer J: Targeting HSP90 dimerization via the C-terminus is effective in imatinib resistant CML and lacks heat shock response. Blood. 2018 May 3. pii: blood-2017-10-810986. doi: 10.1182/blood-2017-10-810986. [Epub ahead of print] PMID: 29724897

Tekbas A, Huebner J, Settmacher U, Dahmen U.: Plants and Surgery: The Protective Effects of Thymoquinone on Hepatic Injury-A Systematic Review of In Vivo Studies. Int J Mol Sci. 2018 Apr 5;19(4). pii: E1085. doi: 10.3390/ijms19041085. PMID: 29621129

Ernst, T., Obstfelder, E. & Hochhaus, A. Chronische myeloische Leukämie. Onkologe 24, 427–442 (2018). https://doi.org/10.1007/s00761-018-0380-5

Ortmann O, Helbig U, Torode J, Schreck S, Karjalainen S, Bettio M, Ringborg U, Klinkhammer-Schalke M, Bray F; participants of the ERTM: Quality control and improvement of cancer care: what is needed? 4th European Roundtable Meeting (ERTM) May 5th, 2017, Berlin, Germany. J Cancer Res Clin Oncol. 2018 Apr 9. doi: 10.1007/s00432-018-2638-0. [Epub ahead of print] PMID:29633019

Heidel FH, Gale RP, Hochhaus A: Managing myeloproliferative neoplasms evidence based on the ELN treatment recommendations 2018. Leukemia. 2018 Feb 27. doi: 10.1038/s41375-018-0079-z. [Epub ahead of print] PMID: 29515237

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM: Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 Mar 22. pii: blood-2016-09-739086. doi: 10.1182/blood-2016-09-739086. [Epub ahead of print] PMID: 29567798

Müller, E.K., Gräfe, C., Wiekhorst, F., Bergemann, C., Weidner, A., Dutz, S. und Clement, J.H. 2018. Magnetic nanoparticles interact and pass an in vitro co-culture blood-placenta model. Nanomaterials 8: 108; doi:10.3390/nano8020108; PMID: 29443880

George J, Walter V, Peifer M, Alexandrov LB, Seidel D, Leenders F, Maas L, Müller C, Dahmen I, Delhomme TM, Ardin M, Leblay N, Byrnes G, Sun R, De Reynies A, McLeer-Florin A, Bosco G, Malchers F, Menon R, Altmüller J, Becker C, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soloway MG, Wilkerson MD, Cun Y, McKay JD, Moro-Sibilot D, Brambilla CG, Lantuejoul S, Lemaitre N, Soltermann A, Weder W, Tischler V, Brustugun OT, Lund-Iversen M, Helland Å, Solberg S, Ansén S, Wright G, Solomon B, Roz L, Pastorino U, Petersen I, Clement JH, Sänger J, Wolf J, Vingron M, Zander T, Perner S, Travis WD, Haas SA, Olivier M, Foll M, Büttner R, Hayes DN, Brambilla E, Fernandez-Cuesta L und Thomas RK. 2018. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat Commun. 9: 1048. doi: 10.1038/s41467-018-03099-x. PMID: 29535388

Xiao G, Chan LN, Klemm L, Braas D, Chen Z, Geng H4, Zhang QC, Aghajanirefah A, Cosgun KN, Sadras T, Lee J, Mirzapoiazova T, Salgia R, Ernst T, Hochhaus A, Jumaa H, Jiang X, Weinstock DM, Graeber TG, Müschen M: B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. Cell. 2018 Mar 6. pii: S0092-8674(18)30225-3. doi: 10.1016/j.cell.2018.02.048. [Epub ahead of print] PMID: 29551267

Gale RP, Hochhaus A: Therapy-free remission in chronic myeloid leukemia: possible mechanism. Expert Rev Hematol. 2018 Mar 9:1-4. doi: 10.1080/17474086.2018.1442213. [Epub ahead of print] PMID: 29448857

Schmidt V, Niederwieser D, Schenk T, Behre G, Klink A, Pfrepper C, Hinke A, Beelen DW, Junghanss C, Uharek L, Krüger WH, Hochhaus A, Sayer HG; East German Study Group for Hematology and Oncology (OSHO): Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2018 Mar 15. doi: 10.1038/s41409-018-0135-3. [Epub ahead of print]. PMID: 29545592

Brodt S, Eigendorff E, Matziolis G: Cementless Total Hip Arthroplasty in Primary Myelofibrosis - a Case Report. Acta Chir Orthop Traumatol Cech. 2017;84(3):208-210. PMID:28809641

Drube J, Ernst T, Pfirrmann M, Albert BV, Drube S, Reich D, Kresinsky A, Halfter K, Sorio C, Fabisch C, Hochhaus A, Böhmer FD: PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells. Oncotarget. 2018 Jan 15;9(10):9442-9455. doi: 10.18632/oncotarget.24253. eCollection 2018 Feb 6. PMID:29507701

Saussele S, Hehlmann R, Fabarius A, Jeromin S, Proetel U, Rinaldetti S, Kohlbrenner K, Einsele H, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Oppliger Leibundgut E, Heim D, Krause SW, Hofmann WK, Hasford J, Pfirrmann M, Müller MC, Hochhaus A, Lauseker M: Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. Leukemia. 2018 Feb 26. doi: 10.1038/s41375-018-0055-7. [Epub ahead of print] PMID:29479070

Firkins R, Eisfeld H, Keinki C, Buentzel J, Hochhaus A, Schmidt T, Huebner J: The use of complementary and alternative medicine by patients in routine care and the risk of interactions. J Cancer Res Clin Oncol. 2018 Jan 22. doi: 10.1007/s00432-018-2587-7. [Epub ahead of print] PMID: 29356888

Schumacher H, Stüwe S, Kropp P, Diedrich D, Freitag S, Greger N, Junghanss C, Freund M, Hilgendorf I: A prospective, randomized evaluation of the feasibility of exergaming on patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2018 Jan 15. doi: 10.1038/s41409-017-0070-8. [Epub ahead of print] PMID: 29335629

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells [published correction appears in Nat Med. 2018 Apr 10;24(4):526]. Nat Med. 2018;24(3):282-291. doi:10.1038/nm.4484 PMID: 29431743

Böhme C, von Osthoff MB, Frey K, Hübner J. Qualitative evaluation of mobile cancer apps with particular attention to the target group, content, and advertising. J Cancer Res Clin Oncol. 2018;144(1):173-181. doi:10.1007/s00432-017-2533-0. PMID: 29052039

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. PMID: 29431743

Ortmann O, Helbig U, Torode J, Schreck S, Karjalainen S, Bettio M, Ringborg U, Klinkhammer-Schalke M, Bray F; participants of the ERTM: Quality control and improvement of cancer care: what is needed? 4th European Roundtable Meeting (ERTM) May 5th, 2017, Berlin, Germany. J Cancer Res Clin Oncol. 2018 Jun;144(6):1097-1102. doi: 10.1007/s00432-018-2638-0. Epub 2018 Apr 9. PMID: 29633019

Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX; EURO-SKI investigators: Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018 Jun;19(6):747-757. doi: 10.1016/S1470-2045(18)30192-X. Epub 2018 May 4. PMID: 29735299

Inselmann S , Wang Y, Saussele S, Fritz L, Schütz C, Huber M, Liebler S , Ernst T , Cai D , Botschek S, Brendel C , Calogero RA , Pavlinic D , Benes V, Liu ET, Neubauer A, Hochhaus A , Burchert A: Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia. Cancer Res. 2018 Nov 1;78(21):6223-6234. doi: 10.1158/0008-5472.CAN-18-1477. Epub 2018 Aug 30. PMID: 30166420

Frietsch JJ, Michel D , Stamminger T, Hunstig F , Birndt S, Ulf Schnetzke U , Scholl S , Andreas Hochhaus A , Hilgendorf I: In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient With Acute Myeloid Leukemia After Hematopoietic Cell Transplantation PMID: 30671207 PMCID: PMC6328044 DOI: 10.4084/MJHID.2019.001

2017

Quidde J, Koch B, Jensen W, von Grundherr J, Escherich G, Rutkowski S, Schulz-Kindermann F, Bergelt C, Bokemeyer C, Sokalska-Duhme M, Bielak S, Calaminus G, Classen C, Rössig C, Faber J, Faller H, Hilgendorf I, Langer T, Metzler M, Schuster S, Niemeyer C, Pierce A, Reinhardt D, Dirksen U, Sander A, Köhler M, Stein A: Versorgung von Patienten nach Krebserkrankung im Kindes-, Jugend- oder jungen Erwachsenenalter. Journal Onkologie. 2017;(10/2017):862-866

Quidde J, Koch B, Salchow J, Jensen W, von Grundherr J, Escherich G, Rutkowski S, Schulz-Kindermann F, Bergelt C, Bokemeyer C, Sokalska-Duhme M, Bielak S, Calaminus G, Classen C, Rössig C, Faber J, Faller H, Hilgendorf I, Langer T, Metzler M, Schuster S, Niemeyer C, Pierce A, Reinhardt D, Dirksen U, Sander A, Köhler M, Stein A: Das CARE-for-CAYA-Programm. Präventionskonzept für junge Menschen nach Krebserkrankung. Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2017;(06/2017)

Stellamanns J, Ruetters D, Dahal K, Schillmoeller Z, Huebner J: Visualizing risks in cancer communication: A systematic review of computer-supported visual aids. Patient Educ Couns. 2017 Aug;100(8):1421-1431. doi: 10.1016/j.pec.2017.02.003. Epub 2017 Feb 6. PMID: 28215828

Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, Schmalenberg H, Luley KB, Prasnikar N, Egger M, Probst S, Messmann H, Moehler M, Fischbach W, Hartmann JT, Mayer F, Höffkes HG, Koenigsmann M, Arnold D, Kraus TW, Grimm K, Berkhoff S, Post S, Jäger E, Bechstein W, Ronellenfitsch U, Mönig S, Hofheinz RD: Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. JAMA Oncol. 2017 Sep 1;3(9):1237-1244. PMID:28448662

van Gorkom G, van Gelder M, Eikema DJ, Blok HJ, van Lint MT, Koc Y, Ciceri F, Beelen D, Chevallier P, Selleslag D, Blaise D, Foá R, Corradini P, Castagna L, Moreno C, Solano C, Müller LP, Tischer J, Hilgendorf I, Hallek M, Bittenbring J, Theobald M, Schetelig J, Kröger N; CLL subcommittee; Chronic Malignancies Working Party of the EBMT: Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. Bone Marrow Transplant. 2017 Dec 18. doi: 10.1038/s41409-017-0023-2. [Epub ahead of print] PMID:29255169

Schmalenberg H, Al-Batran SE, Pauligk C, Zander T, Reichart A, Lindig U, Kleiß M, Müller L, Bolling C, Seufferlein T, Reichardt P, Kullmann F, Eschenburg H, Schmittel A, Egger M, Block A, Goetze TO: CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach. J Cancer Res Clin Oncol. 2017 Dec 28. doi: 10.1007/s00432-017-2565-5. [Epub ahead of print] PMID: 29285668

Huebner J, Prott FJ, Muecke R, Buentzel J, Muenstedt K Dennert, G Micke O: Economic evaluation of complementary and alternative medicine in oncology – is there a difference to conventional medicine? Med Princ Pract. 2017;26(1):41-49. doi: 10.1159/000450645. Epub 2016 Sep 7. PMID: 27607437

Loquai C, Dechent D, Garzarolli M, Kaatz M, Kähler K, Kurschat P, Meiss F, Micke O, Muecke R, Muenstedt K, Nashan D, Stein A, Stoll C, Schmidtmann I, Huebner J: Risk of interactions between complementary and alternative medicine and medication for comorbidities in patients with melanoma; Med Oncol. 2016 May;33(5):52. doi: 10.1007/s12032-016-0764-6. Epub 2016 Apr 18. PMID: 27090799

Loquai C, Dechent D, Garzarolli M, Kaatz M, Kaehler K, Kurschat P, Meiss F, Micke O, Muecke R, Muenstedt K, Stein A, Nashan D, Stoll C, Schmidtmann I, Huebner J. Use of complementary and alternative medicine: a multicenter cross-sectional study in 1089 melanoma patients. Eur J Cancer. 2017 Jan;71:70-79. doi: 10.1016/j.ejca.2016.10.029. Epub 2016 Dec 14. PMID: 27984769

Erickson N, Boscheri A, Linke B, Huebner J. Systematic review: isocaloric ketogenic dietary regimes for cancer patients; Med Oncol. 2017 May;34(5):72. doi: 10.1007/s12032-017-0930-5. Epub 2017 Mar 28. PMID: 28353094

Ebel MD, Stellamanns J, Keinki C, Rudolph I, Huebner J: Cancer patients and the internet: a survey among German cancer patients; J Cancer Educ. 2017 Sep;32(3):503-508. doi: 10.1007/s13187-015-0945-6. PMID: 26553327

Boehme C, Baron von Osthoff MB, Frey K, Huebner J: Development of a Rating Tool for Mobile Cancer Apps: Information Analysis and Formal and Content-Related Evaluation of Selected Cancer Apps; Canc Educ; J Cancer Educ. 2017 Aug 17. doi: 10.1007/s13187-017-1273-9. [Epub ahead of print] PMID:28819928

Ruetters D, Marten D, Linke B, Keinki C, Muenstedt K, Buentzel J, Micke O, Zell J, Beer AM, Huebner J: Phytotherapy as part of complementary and alternative therapies in cancer care - a protocol for a systematic review; Trace Elements Electrolytes 2017; 34(3):118-123

Erickson N, Buchholz D, Hübner J für die Arbeitsgemeinschaft Prävention und Integrative Onkologie (PRIO) der Deutschen Krebsgesellschaft (DKG). Stellungnahme zu ketogenen und kohlenhydratarmen Diäten bei Menschen mit Krebs. Ernährungs Umschau 2017;64(9): M541–M516. DOI: 10.4455/eu.2017.036

Buentzel J, Kusterer I, Rudolph I, Kubin T, Micke O, Huebner J: Cancer Patients’ Knowledge and Acceptance of Physical Activities for Rehabilitation; In Vivo. 2017 Nov-Dec;31(6):1187-1192. DOI:10.21873/invivo.11188. PMID:29102944

Anlauf M, Aust N, Bertelsen HW, Boscheinen J, Ernst E, Friedrich DR, Grams N, Hoyningen-Huene P, Hübner J, Hucklenbroich P, Raspe H, Reichardt JO, Schmacke N, Schöne-Seifert B, Scholz OR, Taupitz J, Weymayr C.: Münsteraner Memorandum Heilpraktiker. Die Thesen des „Münsteraner Kreises“ zu einer Neuregelung des Heilpraktikerwesens; Ethik Med 2017; doi.org/10.1007/s00481-017-0461-9

Hoeh JC, Schmidt T, Huebner J: Physical activity among cancer survivors - What is their perception and experience? Supp Care Cancer<brhttps://doi.org/10.1007/s00520-017-3977-0

Huebner J, Prott FJ, Muecke R, Stoll C, Buentzel J, Muenstedt K, Micke O: Prevention and Integrative Oncology of the German Cancer Society Working Group. Economic Evaluation of Complementary and Alternative Medicine in Oncology: Is There a Difference Compared to Conventional Medicine? Med Princ Pract. 2017;26(1):41-49. doi: 10.1159/000450645. PMID: 27607437

Steube A, Schenk T, Tretyakov A, Saluz HP: High-intensity UV laser ChIP-seq for the study of protein-DNA interactions in living cells. Nat Commun. 2017 Nov 3;8(1):1303. doi: 10.1038/s41467-017-01251-7. PMID: 29101361

Fleischmann T, Hilgendorf I, Franiel T.: Das Myelosarkom der Hypophyse – eine Rarität eines isolierten Rezidivs einer akuten myeloischen Leukämie. Rofo. 2017 Nov 20. doi: 10.1055/s-0043-122080. [Epub ahead of print]. PMID: 29156477

Holch JW, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Kullmann F, Scheithauer W, Scholz M, Müller S, Link H, Rost A, Höffkes HG, Moehler M, Lindig RU, Miller-Phillips L, Kirchner T, Jung A, von Einem JC, Modest DP, Heinemann V: Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial. Int J Cancer. 2017 Oct 19. doi: 10.1002/ijc.31114. [Epub ahead of print]PMID: 29047142

Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N1, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Brümmendorf TH: Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol. 2017 Nov 1:JCO2017747162. doi: 10.1200/JCO.2017.74.7162. [Epub ahead of print] PMID:29091516
Erickson, D. Buchholz, J.Hübner: Aktualisierte Stellungnahme ketogene und kohlenhydratarme Diäten veröffentlicht. FORUM 5 2017 32:429–430. https://doi.org/10.1007/s12312-017-0332-9

Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG): Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017 Nov;4(11):e510-e523. doi: 10.1016/S2352-3026(17)30174-6. Epub 2017 Oct 17. PMID: 29054815

Tian Q, Gromov P, Clement JH, Wang Y1, Riemann M, Weih F, Sun XX, Dai MS, Fedorov LM: RHEB1 insufficiency in aged male mice is associated with stress-induced seizures. Geroscience. 2017 Sep 10. doi: 10.1007/s11357-017-9997-3. [Epub ahead of print] PMID: 28891034

Walther G, Stasch S, Kaerger K, Hamprecht A, Roth M, Cornely OA, Geerling G, Mackenzie CR, Kurzai O, von Lilienfeld-Toal M: Fusarium Keratitis in Germany. J Clin Microbiol. 2017 Oct;55(10):2983-2995. doi: 10.1128/JCM.00649-17. Epub 2017 Jul 26. PMID: 28747368

Beck J, Schwarzer A, Gläser D, Mügge LO, Uhlig J, Heyn S, Kragl B, Mohren M, Hoffmann FA, Lange T, Schliwa T, Zehrfeld T, Becker C, Kreibich U, Winkelmann C, Edelmann T, Andrea M, Bill M, Jentzsch M, Schwind S, Niederwieser D, Pönisch W: Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077). J Cancer Res Clin Oncol. 2017 Dec;143(12):2545-2553. doi: 10.1007/s00432-017-2504-5. Epub 2017 Aug 21. PMID: 28828689

Metzelder SK, Schroeder T, Lübbert M, Ditschkowski M, Götze K, Scholl S, Meyer RG, Dreger P, Basara N, Fey MF, Salih HR, Finck A3, Pabst T, Giagounidis A, Kobbe G, Wollmer E, Finke J, Neubauer A1, Burchert A: Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. Eur J Cancer. 2017 Nov;86:233-239. doi: 10.1016/j.ejca.2017.09.016. Epub 2017 Oct 18. PMID: 29055209

Winkelmann N, Schäfer V, Rinke J, Kaiser A, Ernst P, Scholl S, Hochhaus A, Ernst T: Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies. J Cancer Res Clin Oncol. 2017 Sep 14. doi: 10.1007/s00432-017-2518-z. [Epub ahead of print] PMID:28551768

Ranjan S, Goihl A, Kohli S, Gadi I, Pierau M, Shahzad K, Gupta D, Bock F, Wang H, Shaikh H, Kähne T, Reinhold D, Bank U, Zenclussen AC, Niemz J, Schnöder TM, Brunner-Weinzierl M, Fischer T, Kalinski T, Schraven B2, Luft T, Huehn J, Naumann M, Heidel FH, Isermann B: Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells. Nat Commun. 2017 Aug 21;8(1):311. doi: 10.1038/s41467-017-00169-4. PMID: 28827518

Inhestern J, Schmalenberg H, Dietz A, Rotter N, Maschmeyer G, Jungehülsing M, Grosse-Thie C, Kuhnt T, Görner M, Sudhoff H, Wittekindt C, Guntinas-Lichius O: A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1). Ann Oncol. 2017 Aug 1;28(8):1917-1922. doi: 10.1093/annonc/mdx202. PMID: 28498880

Giles FJ, Rea D, Rosti G, Cross NCP, Steegmann JL, Griskevicius L, le Coutre P, Coriu D, Petrov L, Ossenkoppele GJ, Mahon FX, Saussele S, Hellmann A, Koskenvesa P, Brümmendorf TH, Gastl G, Castagnetti F, Vincenzi B, Haenig J, Hochhaus A: Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. J Cancer Res Clin Oncol. 2017 Aug;143(8):1585-1596. doi: 10.1007/s00432-017-2402-x. Epub 2017 Mar 31. PMID: 28364360

Halwas N, Griebel L, Huebner J: eHealth literacy, Internet and eHealth service usage: a survey among cancer patients and their relatives. J Cancer Res Clin Oncol. 2017 Jul 11. doi: 10.1007/s00432-017-2475-6. [Epub ahead of print] PMID: 28699035

Hübner J: Was uns die Methadon-Saga lehrt. FOCUS 37/2017

Allenstein U, Wisotzki EI, Gräfe C, Clement JH, Liu Y, Schroers J, Mayr SG: Binary Fe-Pd submicron structures fabricated through glancing angle deposition (GLAD) for bioapplications. Materials and Design 131 (2017) 366–374. https://doi.org/10.1016/j.matdes.2017.06.032

Knop S, Langer C, Engelhardt M, Mügge LO, Reichle A, Rösler W, Bassermann F, Hertenstein B, Kunitz A, Röllig C, Ostermann H, Schäfer-Eckart K, Ringhoffer M, Günther A, Junghanss C, Biersack H, Schreder M, Liebert A, Held S, Einsele H, Bargou RC: Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma. Leukemia. 2017 Aug;31(8):1816-1819. doi: 10.1038/leu.2017.124. Epub 2017 Apr 25. PMID:28439106

Mothes H, Bauschke A, Schuele S, Eigendorff E, Altendorf-Hofmann A, Settmacher: Surgery for colorectal cancer in elderly patients: how can we improve outcome? J Cancer Res Clin Oncol (2017) 143:1879–1889. DOI 10.1007/s00432-017-2438-y. PMID: 28534171

Hübner J, Hartmann M, Wedding U, Gießler W, Schuler U, Hochhaus A: „Strohhalmfunktion“ ohne Evidenz. Deutsches Ärzteblatt | Jg. 114, Heft 33–3, 21. August 2017

R Hehlmann, M Lauseker, S Sau_ele, M Pfirrmann, S Krause, H J Kolb, A Neubauer, D K Hossfeld, C Nerl, A Gratwohl, G M Baerlocher, D Heim, T H Brümmendorf, A Fabarius, C Haferlach, B Schlegelberger, M C Müller, S Jeromin, U Proetel, K Kohlbrenner, A Voskanyan, S Rinaldetti, W Seifarth, B Spieß, L Balleisen, M C Goebeler, M Hänel, A Ho, J Dengler, C Falge, L Kanz, S Kremers, A Burchert, M Kneba, F Stegelmann, C A Köhne, H W Lindemann, C F Waller,MPfreundschuh, K Spiekermann,WE Berdel, LMüller, M Edinger, J Mayer, D W Beelen, M Bentz, H Link, B Hertenstein, R Fuchs, M Wernli, F Schlegel, R Schlag, M de Wit, L Trümper, H Hebart, M Hahn, J Thomalla, C Scheid, P Schafhausen, W Verbeek, M J Eckart, W Gassmann, A Pezzutto, M Schenk, P Brossart, T Geer, S Bildat, E Schäfer, A Hochhaus, J Hasford, for the SAKK and the German CML Study Group, Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants, Leukemia accepted article preview 14 August 2017; doi: 10.1038/leu.2017.253 PMID: 28804124

von Lilienfeld-Toal M: Antiinfektiöse Therapieprinzipien bei akuten Leukämien. Onkologe 2017 · 23:537–542; DOI 10.1007/s00761-017-0223-9; Online publiziert: 12. April 2017 © Springer Medizin Verlag GmbH 2017

Hochhaus A, Höffken K: Citius – altius – fortius. Fortschritte bei neuen Substanzen und Wirkprinzipien in der Onkologie. Onkologe 2017 · 23:586–587. DOI 10.1007/s00761-017-0254-2; © Springer Medizin Verlag GmbH 2017

Sopper S, Mustjoki S, Gjertsen BT, Giles F, Hochhaus A, Janssen JJWM, Porkka K, Wolf D: NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib. Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.235. [Epub ahead of print]PMID:28744011

Pulewka K, Wolff D, Herzberg PY, Greinix H, Heussner P, Mumm FHA, von Harsdorf S, Rieger K, Hemmati P, Hochhaus A, Hilgendorf I: Physical and psychosocial aspects of adolescent and young adults after allogeneic hematopoietic stem-cell transplantation: results from a prospective multicenter trial. J Cancer Res Clin Oncol. 2017 Aug;143(8):1613-1619. doi: 10.1007/s00432-017-2424-4. Epub 2017 Apr 19.PMID:28424902

Jawhar M, Naumann N, Schwaab J, Baurmann H, Casper J, Dang TA, Dietze L, Döhner K, Hänel A, Lathan B, Link H, Lotfi S, Maywald O, Mielke S, Müller L, Platzbecker U, Prümmer O, Thomssen H, Töpelt K, Panse J, Vieler T, Hofmann WK, Haferlach T, Haferlach C, Fabarius A, Hochhaus A, Cross NCP, Reiter A, Metzgeroth G: Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. Ann Hematol.2017 Sep;96(9):1463-1470. doi: 10.1007/s00277-017-3067-x. Epub 2017 Jul 19.PMID:28725989

Steegmann JL, Colomer D, Gómez-Casares MT, García-Gutiérrez V, Ortí G, Ramírez-Payer A, Olavarria E, Vall-Llovera F, Giraldo P, Conde E, Vallansot R, López-Lorenzo JL, Palomera L, Álvarez-Larrán A, Conesa V, Bautista G, Casas L, Giles F, Hochhaus A, Casado-Montero LF: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol (2017) 143:2059–2066 DOI 10.1007/s00432-017-2445-z PMID: 28551768

Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, J. Richter & C. Buske, on behalf of the ESMO Guidelines Committee: Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 28 (Supplement 4): iv41–iv51, 2017, doi:10.1093/annonc/mdx219

Erickson N, Boscheri A, Linke B, Huebner J. Systematic review: isocaloric ketogenic dietary regimes for cancer patients; Med Oncol 2017; 34:72.PMID:28353094

Goepfert M, Liebl P, Herth N, Ciarlo G, Buentzel J, Huebner J. Aroma oil therapy in palliative care: a pilot study with physiological parameters in conscious as well as unconscious patients; J Cancer Res Clin Oncol; 2017 DOI 10.1007/s00432-017-2460-0, PMID:28634728

Hochhaus A, Mahon FX, le Coutre P, Petrov L, Janssen JJWM, Cross NCP, et al.: Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCRABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis. Journal of Cancer Research and Clinical Oncology ISSN 0171-5216 Volume 143 Number 7 J Cancer Res Clin Oncol (2017) 143:1225-1233 DOI 10.1007/s00432-017-2359-9, PMID 28224300

Rinke J, Müller JP, Blaess MF, Chase A, Meggendorfer M, Schäfer V, Winkelmann N, Haferlach C, Cross NCP, Hochhaus A, Ernst T: Molecular characterization of EZH2-mutant patients with myelodysplastic/myeloproliferative neoplasms. Leukemia. 2017 Jun 19. doi: 10.1038/leu.2017.190. [Epub ahead of print] PMID:28626218

Rachow T, Schlüter V, Bremer-Streck S, Lindig U, Scholl S, Schlattmann P, Kiehntopf M, Hochhaus A3, von Lilienfeld-Toal M.: Measurement of piperacillin plasma concentrations in cancer patients with suspected infection. Infection. 2017 May 17. doi: 10.1007/s15010-017-1026-z. [Epub ahead of print]PMID:28516432

Stein-Erik Gullaksen, Jørn Skavland, Sonia Gavasso, Vinko Tosevski, Krzysztof Warzocha, Claudia Dumrese, Augustin Ferrant, Tobias Gedde-Dahl, Andrzej Hellmann, JeroenJanssen, Boris Labar, Alois Lang, Waleed Majeed, Georgi Mihaylov, Jesper Stentoft, Leif Stenke, Josef Thaler, Noortje Thielen, Gregor Verhoef, Jaroslava Voglova, GertOssenkoppele, Andreas Hochhaus, Henrik Hjorth-Hansen, Satu Mustjoki, Sieghart Sopper, Francis Giles, Kimmo Porkka, Dominik Wolf, Bjørn Tore Gjertsen: Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukaemia treated with nilotinib. Haematologica. 2017 May 18. pii: haematol.2017.167080. doi: 10.3324/haematol.2017.167080. [Epub ahead of print] PMID: 28522574

Bahlis NJ, Corso A, Mugge LO, Shen ZX, Desjardins P, Stoppa AM, Decaux O, de Revel T, Granell M, Marit G, Nahi H, Demuynck H, Huang SY, Basu S, Guthrie TH, Ervin-Haynes A, Marek J, Chen G, Facon T: Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. Leukemia. 2017 Apr 28. doi: 10.1038/leu.2017.111. [Epub ahead of print]PMID:28373701

Schnöder TM, Eberhardt J, Koehler M, Bierhoff HB, Weinert S, Pandey AD, Nimmagadda SC, Wolleschak D, Jöhrens K, Fischer T, Heidel FH: Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN. Cancer Res Clin Oncol. 2017 May;143(5):807-820. doi: 10.1007/s00432-017-2354-1. Epub 2017 Feb 23. PMID: 28233092

Gieseler-Halbach S, Meltendorf S, Pierau M, Weinert S, Heidel FH, Fischer T, Handschuh J, Braun-Dullaeus RC, Schrappe M, Lindquist JA, Mertens PR, Thomas U, Brunner-Weinzierl MC: RSK-mediated nuclear accumulation of the cold-shock Y-box protein-1 controls proliferation of T cells and T-ALL blasts. Cell Death Differ. 2017 Feb;24(2):371-383. doi: 10.1038/cdd.2016.141. Epub 2016 Dec 23. Cell Death Differ. 2017 Feb;24(2):371-383. doi: 10.1038/cdd.2016.141. Epub 2016 Dec 23. PMID: 28009354

Reichenbach F, Wiedenmann C, Schalk E, Becker D, Funk K, Scholz-Kreisel P, Todt F, Wolleschak D, Dohner K, Marquardt JU, Heidel F, Edlich F: Mitochondrial BAX determines the predisposition to apoptosis in human AML.Clin Cancer Res. 2017 Apr 18. pii: clincanres.1941.2016. doi: 10.1158/1078-0432.CCR-16-1941. [Epub ahead of print] PMID: 28420723

Axel R. Göhring, Stefanie Reuter, Joachim H. Clement, Xinlai Cheng, Jannick Theobald, Stefan Wölfl, Ralf Mrowka: Human microRNA-299-3p decreases invasive behavior of cancer cells by downregulation of Oct4 expression and causes apoptosis. PLoS One. 2017 Apr 20;12(4):e0174912. doi: 10.1371/journal.pone.0174912. eCollection 2017. PMID: 28426762

Pulewka K, Wolff D, Herzberg PY, Greinix H, Heussner P, Mumm FHA, von Harsdorf S, Rieger K, Hemmati P, Hochhaus A, Hilgendorf I: Physical and psychosocial aspects of adolescent and young adults after allogeneic hematopoietic stem-cell transplantation: results from a prospective multicenter trial. J Cancer Res Clin Oncol. 2017 Apr 19. doi: 10.1007/s00432-017-2424-4. [Epub ahead of print] PMID:28424902

Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ, Kantarjian HM, Cortes JE: Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 2017 Apr 7. doi: 10.1002/cncr.30558. [Epub ahead of print]. PMID: 28387926

Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gómez Casares MT, Hellmann A, Stentoft J, Conneally E, García-Gutiérrez V, Gattermann N, Wiktor-Jedrzejczak W, le Coutre PD, Martino B, Saussele S, Menssen HD, Deng W, Krunic N, Bedoucha V, Saglio G: Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017 Mar 17. doi: 10.1038/leu.2017.63. [Epub ahead of print] PMID:28218239

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ: Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.PMID:28273028

Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Ernst T, Hochhaus A, Kornblau SM, Konopleva M, Pufall MA, Cazzaniga G, Liu GJ9, Milne TA, Koeffler HP,12, Ross TS, Sánchez-García I, Borkhardt A, Yamamoto KR, Dickins RA, Graeber TG, Müschen M: Metabolic gatekeeper function of B-lymphoid transcription factors. Nature. 2017 Feb 23;542(7642):479-483. doi: 10.1038/nature21076. Epub 2017 Feb 13. PMID:28192788

Andreas Hochhaus, Franҫois‑Xavier Mahon, Philipp le Coutre, Ljubomir Petrov, Jeroen J. W. M. Janssen, Nicholas C. P. Cross, Delphine Rea, Fausto Castagnetti, Andrzej Hellmann, Gianantonio Rosti, Norbert Gattermann, Maria Liz Paciello Coronel, Maria Asuncion Echeveste Gutierrez, Valentin Garcia‑Gutierrez, Beatrice Vincenzi, Luca Dezzani, Francis J. Giles: Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis. J Cancer Res Clin Oncol DOI 10.1007/s00432-017-2359-9. Received: 25 January 2017 / Accepted: 27 January 2017 © The Author(s) 2017. This article is published with open access at Springerlink.com

Billing M, Gräfe C, Saal A, Biehl, Clement JH, Dutz S, Weidner S, Schacher FH: Zwitterionic Iron Oxide (γ-Fe2 O3 ) Nanoparticles Based on P(2VP-grad-AA) Copolymers. Macromol Rapid Commun. 2017 Feb;38(4). doi: 10.1002/marc.201600637. Epub 2016 Dec 22. PMID:28004458

Göllner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, Rohde C, Pabst C, Sauer T, Lerdrup M, Tavor S, Stölzel F, Herold S, Ehninger G, Köhler G, Pan KT, Urlaub H, Serve H, Dugas M, Spiekermann K, Vick B, Jeremias I, Berdel WE, Hansen K, Zelent A, Wickenhauser C, Müller LP, Thiede C, Müller-Tidow C: Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. Nat Med. 2017 Jan;23(1):69-78. doi: 10.1038/nm.4247. Epub 2016 Dec 12. PMID:27941792

Gupta N, Edelmann B, Schnoeder TM, Saalfeld FC, Wolleschak D, Kliche S, Schraven B, Heidel FH* and Fischer T* JAK2-V617F activates β1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1 (VCAM1)-coated surface. Leukemia 2017, in press. *equal contribution, shared corresponding authors. Leukemia. 2017 Jan 18. doi: 10.1038/leu.2017.26. [Epub ahead of print]. PMID:28096537

Nishanth G, Wolleschak D, FahldieckC, Fischer T, Mullally A, Perner F, Schnöder TM, Heidel FH*, Schlüter D*. *equal contribution, shared corresponding authors. Gain of function in Jak2V617F positive T-cells. Leukemia. 2017 Jan 11. doi: 10.1038/leu.2017.6. [Epub ahead of print]PMID:28074070

Maximilian Fleischmann, Ulf Schnetzke, Karin G. Schrenk, Volker Schmidt, Herbert G. Sayer, Inken Hilgendorf, Andreas Hochhaus, Sebastian Scholl: Outcome of FLT3‑ITD‑positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. J Cancer Res Clin Oncol. 2017 Feb;143(2):337-345. doi: 10.1007/s00432-016-2290-5. Epub 2016 Oct 24. PMID:27778197

Annamaria Brioli &, Lars-Olof Mügge, Andreas Hochhaus & Marie von Lilienfeld-Toal: Safety issues and managment of toxicities associated with new treatments for multiple myeloma. Expert Review of Hematology. Received 31 Oct 2016, Accepted 17 Jan 2017, Accepted author version posted online: 24 Jan 2017. http://dx.doi.org/10.1080/17474086.2017.1284584

Hilgendorf I, Greinix H, Halter J, Lawitschka A, Wolff D: Vaccination of allogeneic hematopoietic stem cell transplant recipients-what should be considered? Ann Hematol. 2017 Jan 17. doi: 10.1007/s00277-017-2922-0. [Epub ahead of print] PMID: 28097373

Pfirrmann M, Evtimova D, Saussele S, Castagnetti F, Cervantes F, Janssen J, Hoffmann VS, Gugliotta G, Hehlmann R, Hochhaus A, Hasford J, Baccarani M: No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib. J Cancer Res Clin Oncol. 2017 Jan 12. doi: 10.1007/s00432-016-2321-2. [Epub ahead of print] PMID:28083711

Schütz C, Inselmann S, Sausslele S, Dietz CT, Müller MC, Eigendorff E, Brendel CA, Metzelder SK, Brümmendorf TH, Waller C, Dengler J, Goebeler ME, Herbst R, Freunek G, Hanzel S, Illmer T, Wang Y, Lange T, Finkernagel F, Hehlmann R, Huber M, Neubauer A, Hochhaus A, Guilhot J, Mahon FX, Pfirrmann M, Burchert A: Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia (2017) 31, 829–836; doi:10.1038/leu.2017.9; published online 27 January 2017 PMID: 28074067

Sieghart Sopper, Satu Mustjoki, Deborah White, Timothy Hughes, Peter Valent, Andreas Burchert, Bjørn T. Gjertsen, G¨unther Gastl, Matthias Baldauf, Zlatko Trajanoski, Frank Giles, Andreas Hochhaus, Thomas Ernst, Thomas Schenk, Jeroen J.W.M. Janssen, Gert J. Ossenkoppele, Kimmo Porkka, and Dominik Wolf: Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. J Clin Oncol 35:175-184. 2017 Jan 10;35(2):175-184. Epub 2016 Nov 7. PMID: 28056193

A. Hochhaus: Chronische myeloproliferative Neoplasien. Onko Update 2017 – Handbuch ONKOLOGIE 2017

Hübner J: Was uns die Methadon-Saga lehrt. FOCUS 37/2017

Hochhaus A: Chronische myeloproliferative Neoplasien, Onko Update 2017 – Handbuch ONKOLOGIE 2017

Brioli A, Mügge LO, Hochhaus A, von Lilienfeld-Toal M: Safety issues and managment of toxicities associated with new treatments for multiple myeloma. Journal Expert Review of Hematology Volume 10, 2017 - Issue 3, Pages 193-205 | Received 31 Oct 2016, Accepted 17 Jan 2017, Accepted author version posted online: 24 Jan 2017, Published online: 27 Jan 2017 http://dx.doi.org/10.1080/17474086.2017.1284584

Hochhaus A: Ein Wirkstoff für mehrere Krebserkrankungen. Perspektiven der Onkologie 1/2017 | Deutsches Ärzteblatt

Fischer M, Müller JP, Spies-Weisshart B, Gräfe C, Kurzai O, Hünniger K, Hochhaus A , Sebastian Scholl S, Schnetzke U: Isoform Localization of Dectin-1 Regulates the Signaling Quality of Anti-Fungal Immunity. Eur J Immunol . 2017 May;47(5):848-859. doi: 10.1002/eji.201646849. Epub 2017 Apr 13. PMID: 28303575

2016

Gieseler-Halbach S, Meltendorf S, Pierau M, Weinert S, Heidel F, Fischer T, Handschuh J, Braun-Dullaeus R, Schrappe M, Lindquist J, Mertens P, Thomas U, Brunner-Weinzierl MC. RSK-mediated nuclear accumulation of the cold shock Y-box protein-1 controls proliferation of T-cells and T-ALL blasts. Cell Death Differ. 2016 Dec 23. doi: 10.1038/cdd.2016.141. [Epub ahead of print]. PMID:28009354

Perner F, Schnöder TM, Fischer T, Heidel FH. Kinomics Screening Identifies Aberrant Phosphorylation of CDC25C in FLT3-ITD-positive AML. Anticancer Res. 2016 Dec;36(12):6249-6258.PMID:27919943

Fischer M, Schnetzke U, Spies-Weisshart B, Walther M, Fleischmann M, Hilgendorf I, Hochhaus A, Scholl S: Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia. Haematologica. 2016 Dec 29. pii: haematol.2016.157180. doi: 10.3324/haematol.2016.157180. [Epub ahead of print] PMID: 28034991

Winkelmann N, Desole M1, Hilgendorf I, Ernst T, Sayer HG1, Kunert C, Mügge LO, Hochhaus A, Scholl S: Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients. J Cancer Res Clin Oncol. 2016 Dec;142(12):2603-2610. Epub 2016 Sep 17. PMID: 27640002 DOI:10.1007/s00432-016-2270-9

Karrasch M, Schmidt V, Hammer A, Hochhaus A, Rosée P, Petersen I, Sauerbrei A, Baier M, Sayer HG, Hermann B: Chronic persistent parvovirus B19 bone marrow infection resulting in transfusion-dependent pure red cell aplasia in multiple myeloma after allogeneic haematopoietic stem cell transplantation and severe graft versus host disease. Hematology.2016 Jun 16:1-6.[Epub ahead of print].
PMID:27311084 DOI:10.1080/10245332.2016.1183288

Proschmann R, Baldow C, Rothe T, Suttorp M, Thiede C, Tauer JT, Müller MC, Hochhaus A, Roeder I, Glauche I: Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy. Haematologica. 2016 Nov 17. pii: haematol.2016.154138. [Epub ahead of print]. PMID: 27856510 DOI:10.3324/haematol.2016.154138

Ben Batalla I, Erdmann R, Jørgensen H, Mitchell R, Ernst T, von Amsberg G, Schafhausen P, Velthaus JL, Rankin S, Clark RE, Koschmieder S, Schultze A, Mitra S, Vandenberghe P, Brümmendorf TH, Carmeliet P, Hochhaus A, Pantel K, Bokemeyer C, Helgason GV, Holyoake TL, Loges S: Axl blockade by bgb324 inhibits bcr-abl tyrosine kinase inhibitor-sensitive and -resistant chronic myeloid leukemia. Clin Cancer Res. 2016 Nov 17. pii: clincanres.1930.2016. [Epub ahead of print]
PMID: 27856601, DOI: 10.1158/1078-0432.CCR-16-1930

A. Hochhaus, E. Eigendorff, C. Fabisch, T. Ernst: Chronische myeloische Leukämie – State of the Art. 6 2016 best practice onkologie

Hermann B, Lehners N, Brodhun M, Boden K, Hochhaus A, Kochanek M, Meckel K, Mayer K, Rachow T, Rieger C, Schalk E, Weber T, Schmeier-Jürchott A, Schlattmann P, Teschner D, von Lilienfeld-Toal M: Influenza virus infections in patients with malignancies -- characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO). Eur J Clin Microbiol Infect Dis. 2016 Nov 12. [Epub ahead of print] doi:10.1007/s10096-016-2833-3. PMID: 27838792

Sieghart Sopper, Satu Mustjoki, Deborah White, Timothy Hughes, Peter Valent, Andreas Burchert, Bjørn T. Gjertsen, Gunther Gastl, Matthias Baldauf, Zlatko Trajanoski, Frank Giles, Andreas Hochhaus, Thomas Ernst, Thomas Schenk, Jeroen J.W.M. Janssen, Gert J. Ossenkoppele, Kimmo Porkka, and Dominik Wolf: Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. DOI: 10.1200/JCO.2016.67.0893 Journal of Clinical Oncology - published online before print November 7, 2016

Fleischmann M, Schnetzke U, Schrenk KG, Schmidt V, Sayer HG, Hilgendorf I, Hochhaus A, Scholl S: Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. J Cancer Res Clin Oncol. 2016 Oct 24. [Epub ahead of print] PMID: 27778197

Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Königsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A: Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016 Oct 21. pii: S1470-2045(16)30531-9. doi: 10.1016/S1470-2045(16)30531-9. [Epub ahead of print]. PMID: 27776843

Schlenk RF, Stegelmann F, Reiter A, Jost E, Gattermann N, Hebart H, Waller C, Hochhaus A, Platzbecker U, Schafhausen P, Blau IW, Verbeek W, Heidel FH, Werner M, Kreipe H, Teleanu V, Benner A, Döhner H, Grießhammer M, Döhner K: Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis. Leukemia. 2016 Oct 24. doi: 10.1038/leu.2016.299. [Epub ahead of print] PMID:27774990

I. Freitag, C. Beleites, S. Dochow, J. H. Clement, C. Krafft and J. Popp: Recognition of tumor cells by immuno-SERSmarkers in a microfluidic chip at continuous flow. Analyst, DOI: 10.1039/c6an01739h

Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF, Turkina A, Zackova D, Ossenkoppele G, Zaritskey A, Höglund M, Simonsson B, Indrak K, Sninska Z, Sacha T, Clark R, Bogdanovic A, Hellmann A, Griskevicius L, Schubert-Fritschle G, Sertic D, Guilhot J, Lejniece S, Zupan I, Burgstaller S, Koskenvesa P, Everaus H, Costeas P, Lindoerfer D, Rosti G, Saussele S, Hochhaus A, Hehlmann R: Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. Leukemia. 2016 Sep 23. doi: 10.1038/leu.2016.246. [Epub ahead of print] PMID:27568522

Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, Baccarani M, Eigendorff E, Guilhot J1, Guilhot F, Hehlmann R, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Saussele S, Schiffer CA, Silver RT, Simonsson B, Conti RM: Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. J Natl Cancer Inst. 2016 Mar 4;108(7). pii: djw003. doi: 10.1093/jnci/djw003. Print 2016 Jul. PMID: 26944912

Nils Winkelmann, Max Desole, Inken Hilgendorf, Thomas Ernst, Herbert G. Sayer, Christa Kunert,· Lars‑Olof Mügge, Andreas Hochhaus, Sebastian Scholl: Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients. J Cancer Res Clin Oncol. DOI 10.1007/s00432-016-2270-9. PMID:27640002

Kripp M, Merx K, Wirtz RM, Gaiser T, Eidt S, Schwaab J, Post S, Wenz F, Hochhaus A, Hofheinz RD, Erben P: Prognostic Impact of mRNA Expression Levels of HER1-4 (ERBB1-4) in Patients with Locally Advanced Rectal Cancer. Gastroenterol Res Pract. 2016;2016:3481578. doi: 10.1155/2016/3481578. Epub 2016 Aug 16. PMID: 27610130

Cross NC, White HE, Ernst T, Welden L, Dietz C, Saglio G, Mahon FX, Wong CC, Zheng D, Wong S, Wang SS, Akiki S, Albano F, Andrikovics H, Anwar J, Balatzenko G, Bendit I, Beveridge J, Boeckx N, Cerveira N, Cheng SM, Colomer D, Czurda S, Daraio F, Dulucq S, Eggen L, El Housni H, Gerrard G, Gniot M, Izzo B, Jacquin D, Janssen JJ, Jeromin S, Jurcek T, Kim DW, Machova-Polakova K, Martinez-Lopez J, McBean M, Mesanovic S, Mitterbauer-Hohendanner G, Mobtaker H, Mozziconacci MJ, Pajič T, Pallisgaard N, Panagiotidis P, Press RD, Qin YZ, Radich J, Sacha T, Touloumenidou T, Waits P, Wilkinson E, Zadro R, Müller MC, Hochhaus A, Branford S: Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. Leukemia. 2016 Sep;30(9):1844-52. DOI:10.1038/leu.2016.90. Epub 2016 Apr 25. PMID:27109508

Varghese J, Holz C, Neuhaus P, Bernardi M, Boehm A, Ganser A, Gore S, Heaney M, Hochhaus A, Hofmann WK, Krug U, Müller-Tidow C, Smith A, Weltermann A, de Witte T, Hehlmann R, Dugas M.: Key Data Elements in Myeloid Leukemia. Stud Health Technol Inform. 2016;228:282-6. PMID:27577388

RP Gale, A Hochhaus and M-J Zhang: What is the (p-) value of the P-value? Leukemia advance online publication, 26 August 2016; doi:10.1038/leu.2016.193

Melanie Kripp, Kirsten Merx, Ralph Markus Wirtz, Timo Gaiser, Sebastian Eidt, Juliana Schwaab, Stefan Post, Frederik Wenz, Andreas Hochhaus, Ralf-Dieter Hofheinz, and Philipp Erben: Prognostic Impact of mRNA Expression Levels of HER1–4 (ERBB1–4) in Patients with Locally Advanced Rectal Cancer. Gastroenterology Research and Practice, Volume 2016, Article ID 3481578, 9 pages, http://dx.doi.org/10.1155/2016/3481578

Enrico Schalk, Florian H. Heidel: Leukemic mastopathy. Int J Hematol DOI 10.1007/s12185-016-1948-8

Huang K, Yang M, Pan Z, Heidel FH, Scherr M, Eder M, Fischer T, Büsche G, Welte K, von Neuhoff N, Ganser A, Li Z: Leukemogenic potency of the novel FLT3-N676K mutant. Ann Hematol. 2016 Apr;95(5):783-91. doi: 10.1007/s00277-016-2616-z. Epub 2016 Feb 19. PMID: 26891877

Uras IZ, Walter GJ, Scheicher R, Bellutti F, Prchal-Murphy M, Tigan AS, Valent P, Heidel FH, Kubicek S, Scholl C, Fröhling S, Sexl V: Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood. 2016 Jun 9;127(23):2890-902. doi: 10.1182/blood-2015-11-683581. Epub 2016 Apr 20. PMID: 27099147

Caroline Ebert, Florian Perner, Denise Wolleschak, Tina M. Schnöder, Thomas Fischer, and Florian H. Heidel: Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo. Haematologica March 2016 101: e81-e85; doi:10.3324/haematol.2015.136754

Jentsch-Ullrich K, Eberhardt J, Zeremski V, Koehler M, Wolleschak D, Heidel FH: Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany. J Cancer Res Clin Oncol. 2016 Sep;142(9):2041-9. doi: 10.1007/s00432-016-2209-1. Epub 2016 Jul 18. PMID: 27431664

Thomas Schenk, Paul La Rosée: Hämophagozytische Lymphohistiozytose des Erwachsenen. Dtsch Med Wochenschr 2016; 141: 1141–1143

Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, Haluska FG: Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016 Jul 22;48:84-91. doi: 10.1016/j.leukres.2016.07.007. PMID: 27505637

S Saußele, J Richter, A Hochhaus and F-X Mahon: The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 2016 Aug;30(8):1638-47. doi: 10.1038/leu.2016.115. Epub 2016 May 2. PMID:27133824

JL Steegmann, M Baccarani, M Breccia, LF Casado, V García-Gutiérrez, A Hochhaus, D-W Kim, TD Kim, HJ Khoury, P Le Coutre, J Mayer1, D Milojkovic, K Porkka, D Rea, G Rosti, S Saussele, R Hehlmann and RE Clark: European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016 Aug;30(8):1648-71. doi: 10.1038/leu.2016.104. Epub 2016 Apr 28. PMID:27121688

Denise Wolleschak and Florian H. Heidel: Chronic myelogenous leukemia evolving after treatment of multiple myeloma. Blood, 7 2016 128: 146. DOI 10.1182/blood-2016-03-706945

Jorge E. Cortes, Giuseppe Saglio, Hagop M. Kantarjian, Michele Baccarani, Jirı Mayer, Concepci´on Boqu´e, Neil P. Shah, Charles Chuah, Luis Casanova, Brigid Bradley-Garelik, George Manos, and Andreas Hochhaus: Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016 May 23. pii: JCO648899. [Epub ahead of print]. PMID:27217448

Neil P. Shah, MD, PhD;Philippe Rousselot, MD, PhD; Charles Schiffer, MD; Delphine Rea, MD, PhD; Jorge E. Cortes, MD; Jorge Milone, MD; Hesham Mohamed, MD; Diane Healey, MS;Hagop Kantarjian, MD; Andreas Hochhaus, MD and Giuseppe Saglio, MD: Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016 May 19. doi: 10.1002/ajh.24423. [Epub ahead of print] PMID:27192969 [PubMed - as supplied by publisher]

Tobias Rachow, Sebastian Dornaus, Herbert G. Sayer, Beate Hermann, Andreas Hochhaus & Marie von Lilienfeld-Toal. Case report: false positive elevated serum-galactomannan levels after autologous hematopoietic stem cell transplantation caused by oral nutritional supplements. Clinical Case Reports 2016; 4(5): 505–508 doi: 10.1002/ccr3.516

Vivien Schäfer, Jana Ernst, Jenny Rinke, Nils Winkelmann, James F. Beck, Andreas Hochhaus, Bernd Gruhn, Thomas Ernst: EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia. J Cancer Res Clin Oncol. 2016 May 11. [Epub ahead of print] PMID:27169594 [PubMed - as supplied by publisher]

NCP Cross and A Hochhaus: Deep molecular response in chronic myeloid leukemia. Leukemia advance online publication, 13 May 2016; doi:10.1038/ leu.2016.78 PMID:27174492 [PubMed - as supplied by publisher]

C Gräfe, I Slabu, F Wiekhorst, C Bergemann, F von Eggeling, A Hochhaus, L Trahms and J H Clement: Magnetic particle spectroscopy allows precise quantification of nanoparticles after passage through human brain microvascular endothelial cells. Phys. Med. Biol. 61 (2016) 3986–4000 doi:10.1088/0031-9155/61/11/3986

Richter ME, Neugebauer S, Engelmann F, Hagel S, Ludewig K, La Rosée P, Sayer HG, Hochhaus A, von Lilienfeld-Toal M, Bretschneider T, Pausch C, Engel C, Brunkhorst FM, Kiehntopf M: Biomarker candidates for the detection of an infectious etiology of febrile neutropenia. Infection. 2016 Apr;44(2):175-86. doi: 10.1007/s15010-015-0830-6. Epub 2015 Aug 15. PMID:26275448 [PubMed - in process]

N C P Cross, H E White, T Ernst, L Welden, C Dietz, Guseppe Saglio, F-X Mahon, C C Wong, D Zheng, S Wong, S-S Wang, S Akiki, F Albano, H Andrikovics, J Anwar, G Balatzenko, I Bendit, J Beveridge, N Boeckx, N Cerveira, S-M Cheng, D Colomer, S Czurda, F Daraio, S Dulucq, L Eggen, H El Housni, G Gerrard, M Gniot, B Izzo, D Jacquin, J J W M Janssen, S Jeromin, T Jurcek, D-W Kim, K Machova-Polakova, J Martinez-Lopez, M McBean, S Mesanovic, G Mitterbauer-Hohendanner, H Mobtaker, M-J Mozziconacci, T Pajicˇ, N Pallisgaard, P Panagiotidis, R D Press, Y-Z Qin, J Radich, T Sacha, T Touloumenidou, P Waits, E Wilkinson, R Zadro, M C Müller, A Hochhaus, S Branford, Development and evaluation of a secondary reference panel for BCRABL1 quantitation on the International Scale, Leukemia accepted article preview 25 April 2016; doi: 10.1038/leu.2016.90. PMID: 27109508 [PubMed - as supplied by publisher]

Jeffrey H Lipton, Charles Chuah, Agnès Guerci-Bresler, Gianantonio Rosti, David Simpson, Sarit Assouline, Gabriel Etienne, Franck E Nicolini,Philipp le Coutre, Richard E Clark, Leif Stenke, David Andorsky, Vivian Oehler, Stephanie Lustgarten, Victor M Rivera, Timothy Clackson, Frank G Haluska, Michele Baccarani, Jorge E Cortes, François Guilhot, Andreas Hochhaus, Timothy Hughes, Hagop M Kantarjian, Neil P Shah, Moshe Talpaz, Michael W Deininger, for the EPIC investigators*: Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016 Apr 12. pii: S1470-2045(16)00080-2. doi: 10.1016/S1470-2045(16)00080-2. [Epub ahead of print] Copyright © 2016 Elsevier Ltd. All rights reserved. PMID: 27083332 [PubMed - as supplied by publisher]

Andrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, Maurilio Ponzoni, Martina Deckert, Letterio S Politi, Valter Torri, Christopher P Fox, Paul La Rosée, Elisabeth Schorb, Achille Ambrosetti, Alexander Roth, Claire Hemmaway, Angela Ferrari, Kim M Linton, Roberta Rudà, Mascha Binder, Tobias Pukrop, Monica Balzarotti, Alberto Fabbri, Peter Johnson, Jette Sønderskov Gørløv, Georg Hess, Jens Panse, Francesco Pisani, Alessandra Tucci, Stephan Stilgenbauer, Bernd Hertenstein, Ulrich Keller, Stefan W Krause, Alessandro Levis, Hans J Schmoll, Franco Cavalli, Jürgen Finke, Michele Reni, Emanuele Zucca, Gerald Illerhaus, for the International Extranodal Lymphoma Study Group (IELSG): Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the fi rst randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 2016 Published Online April 6, 2016 http://dx.doi.org/10.1016/ S2352-3026(16)00036-3

Schmidt V, Prell T, Treschl A, Klink A, Hochhaus A, Sayer HG.: Clinical Management of Posterior Reversible Encephalopathy Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series and Review of the Literature. Acta Haematol. 2016;135(1):1-10. doi: 10.1159/000430489. Epub 2015 Jul 4. PMID: 26159650

Martin E. Richter, Sophie Neugebauer, Falco Engelmann,· Stefan Hagel,·Katrin Ludewig· Paul La Rosée, Herbert G. Sayer, Andreas Hochhaus, Marie von Lilienfeld‑Toal, Tom Bretschneider, Christine Pausch, Christoph Engel, Frank M. Brunkhorst, Michael Kiehntopf: Biomarker candidates for the detection of an infectious etiology of febrile neutropenia. Infection. 2016 Apr;44(2):175-86. doi: 10.1007/s15010-015-0830-6. Epub 2015 Aug 15. PMID: 26275448 [PubMed - in process]

Noortje Thielen, Johan Richter, Matthias Baldauf, Gisela Barbany, Thoas Fioretos,Francis Giles, Bjørn-Tore Gjertsen, Andreas Hochhaus, Gerrit Jan Schuurhuis, Sieghart Sopper, Leif Stenke, Sarah Thunberg, Dominik Wolf, Gert Ossenkoppele, Kimmo Porkka, Jeroen Janssen, and Satu Mustjoki: Leukemic stem cell quantification in newly diagnosed chronic myeloid leukemia patients predicts response to nilotinib therapy. Clin Cancer Res. 2016 Mar 22. pii: clincanres.2791.2015. [Epub ahead of print] PMID: 27006491

Jana Ernst, Vivien Schäfer, Jenny Rinke, Susan Wittig, James F. Beck, Thomas Ernst, Bernd Gruhn: Continuous molecular remission and regression of side effects after discontinuation of salvage therapy with sorafenib and donor lymphocyte infusions in a young patient with relapsed AML. Ann Hematol DOI 10.1007/s00277-016-2637-7. PMID: 26979170

Charles A. Schiffer, MD; Jorge E. Cortes, MD; Andreas Hochhaus, MD; Giuseppe Saglio, MD; Philipp le Coutre, MD; Kimmo Porkka, MD, PhD; Satu Mustjoki, MD, PhD; Hesham Mohamed, MD; and Neil P. Shah, MD, PhD: Lymphocytosis After Treatment With Dasatinib in Chronic Myeloid Leukemia: Effects on Response and Toxicity. DOI: 10.1002/cncr.29933, Received: September 29, 2015; Revised: January 11, 2016; Accepted: January 20, 2016, Published online Month 00, 2016 in Wiley. Online Library (wileyonlinelibrary.com). PMID: 26998677

F. Hunstig, S. Schulz, I. Nieten, U. Froster, C. Boltze, S. Schliemann,·A. Hochhaus, P. La Rosée: A case of Brooke–Spiegler syndrome with a novel mutation in the CYLD gene in a patient with aggressive on‑Hodgkin’s lymphoma. J Cancer Res Clin Oncol (2016) 142:845–848 DOI 10.1007/s00432-015-2079-y. PMID: 26660106 [PubMed - in process]

Ute Kossak-Roth, Susanne Saußele,· Carlo Aul, Thomas Büchner,·Hartmut Döhner,·Martin Dugas, Gerhard Ehninger, Arnold Ganser,·Aristoteles Giagounidis, Nicola Gökbuget, Martin Griesshammer,·Jörg Hasford,·Michael Heuser,·Wolfgang Hiddemann,· Andreas Hochhaus,·Dieter Hoelzer,· Dietger Niederwieser, AndreasReiter, Christoph Röllig, Rüdiger Hehlmann: Entstehung, Entwicklung und Erfolge des Kompetenznetzes Akute und Chronische Leukämien (KNL). Bundesgesundheitsbl DOI 10.1007/s00103-016-2315-x © Springer-Verlag Berlin Heidelberg 2016

Seyedmehdi Shojaee, Lai N Chan, Maike Buchner, Valeria Cazzaniga, Kadriye Nehir Cosgun, Huimin Geng, Yi Hua Qiu, Marcus Dühren von Minden, Thomas Ernst, Andreas Hochhaus, Giovanni Cazzaniga, Ari Melnick, Steven M Kornblau, Thomas G Graeber, Hong Wu, Hassan Jumaa & Markus Müschen: PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nat Med. 2016 Mar 14. doi: 10.1038/nm.4062. [Epub ahead of print] PMID: 26974310 [PubMed - as supplied by publisher]

Fischer M, Spies-Weisshart B, Schrenk K, Gruhn B, Wittig S, Glaser A, et al. (2016) Polymorphisms of Dectin-1 and TLR2 Predispose to Invasive Fungal Disease in Patients with Acute Myeloid Leukemia. PLoS ONE 11(3): e0150632. doi:10.1371/journal.pone.0150632. PMID: 26963509 [PubMed - in process]

MB Miranda, M Lauseke, M-P Kraus, U Proetel, B Hanfstein, A Fabarius, GM Baerlocher, D Heim, DK Hossfeld, H-J Kolb, SW Krause, C Nerl, TH Brümmendorf, W Verbeek, AA Fauser, O Prümmer, K Neben, U Hess, R Mahlberg, C Plöger, M Flasshove, B Rendenbach, W-K Hofmann, MC Müller, M Pfirrmann, A Hochhaus, J Hasford, R Hehlmann and S Saußele: Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study I. Leukemia (2016), 1–8 © 2016 Macmillan Publishers Limited All rights reserved 0887-6924/16. PMID:26859076

A Hochhaus, T Ernst, S Saußele: Absetzen der Therapie zurzeit nur experimentell. Die Prognose von CML-Patienten hat sich nach Einführung der Tyrosinkinase-Inhibitoren dramatisch verbessert. Bei Erreichen einer tiefen molekularen Remission stellt sich nun die Frage, ob und wann man von einer Heilung sprechen kann. Perspektiven der Onkologie 1/2016 Deutsches Ärzteblatt; DOI: 10.3238/PersOnko/2016.02.12.11. Zum Artikel

A Hochhaus:Therapiekonzepte der chronischen myeloischen Leukämie. TumorDiagn u Ther 2016; 37. Zum Artikel

The European Hematology Association Roadmap for European Hematology Research: a consensus document by Andreas Engert, Carlo Balduini, Anneke Brand, Bertrand Coiffier, Catherine Cordonnier, Hartmut Döhner, Thom Duyvené de Wit, Sabine Eichinger, Willem Fibbe, Tony Green, Fleur de Haas, Achille Iolascon, Thierry Jaffredo, Francesco Rodeghiero, Gilles Salles, Jan Jacob Schuringa, and the other authors of the EHA Roadmap for European Hematology Research. Haematologica. 2016 Feb;101(2):115-208. doi: 10.3324/haematol.2015.136739. Epub 2016 Jan 27. PMID: 26819058 [PubMed - in process

Pfrepper C, Klink A, Behre G, Schenk T, Franke GN, Jentzsch M, Schwind S, Al-Ali HK, Hochhaus A, Niederwieser D, Sayer HG: Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation. J Cancer Res Clin Oncol. 2016 Jan;142(1):317-24. doi: 10.1007/s00432-015-2050-y. Epub 2015 Sep 30. PMID: 26424692 [PubMed - in process]

Kahl C, Krahl R, Becker C, Al-Ali HK, Sayer HG, Schulze A, Herold M, Hänel M, Scholl S, Hochhaus A, Uharek L, Maschmeyer G, Haehling D, Junghanß C, Peter N, Kämpfe D, Kettner E, Heinicke T, Fischer T, Kreibich U, Wolf HH, Niederwieser D: Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO). J Cancer Res Clin Oncol. 2016 Jan;142(1):305-15. doi: 10.1007/s00432-015-2045-8. Epub 2015 Sep 25. PMID: 26407768 [PubMed - in process]

Usemann J, Ernst T, Schäfer V, Lehmberg K, Seeger K. 2016. EZH2 mutation in an adolescent with Weaver syndrome developing acute myeloid leukemia and secondary hemophagocytic lymphohistiocytosis. Am J Med Genet A. 2016 May;170A(5):1274-7. doi: 10.1002/ajmg.a.37562. Epub 2016 Jan 14. PMID:26762561

A Hochhaus, G Rosti, NCP Cross, JL Steegmann, P le Coutre, G Ossenkoppele, L Petrov, T Masszi, A Hellmann, L Griskevicius, W Wiktor-Jedrzejczak, D Rea, D Coriu, TH Brümmendorf, K Porkka, G Saglio, G Gastl, MC Müller, P Schuld, P Di Matteo, A Pellegrino, L Dezzani, F-X Mahon, M Baccarani and FJ Giles: Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia. 2016 Jan;30(1):57-64. doi: 10.1038/leu.2015.270. Epub 2015 Oct 6. PMID:26437782 [PubMed - in process]

Ebert C, Perner F, Wolleschak D, Schnöder TM, Fischer T , Heidel FH: Expression and Function of ABC-transporter Protein ABCB1 Correlates With Inhibitory Capacity of Ruxolitinib in Vitro and in Vivo. Haematologica. 2016 Mar;101(3):e81-5. doi: 10.3324/haematol.2015.136754. Epub 2015 Nov 20. PMID: 26589910

Richter ME, Neugebauer S, Engelmann F, Hagel S, Ludewig K, La Rosée P, Sayer HG, Hochhaus A, von Lilienfeld-Toal M, Bretschneider T, Pausch C, Engel C, Brunkhorst FM, Kiehntopf M¸ Biomarker candidates for the detection of an infectious etiology of febrile neutropenia. Infection. 2016 Apr;44(2):175-86. doi: 10.1007/s15010-015-0830-6. Epub 2015 Aug 15. PMID: 26275448

2015

Karrasch M, Pfister W, Edel B, Stallmach A, Hagel S, Hochhaus A, Rödel J: Campylobacter jejuni ssp. jejuni bacteraemia in a patient with BCR-ABL-positive chronic myelogenous leukaemia in remission on dasatinib therapy Open Access. JMM Case Reports Volume 2, Issue 6, First Published: 13 December 2015 https://doi.org/10.1099/jmmcr.0.005001

Kalmanti L, Saussele S, Lauseker M, Müller MC, Dietz CT, Heinrich L, Hanfstein B, Proetel U, Fabarius U, Krause SW, Rinaldetti S , Dengler J , Falge C , Oppliger-Leibundgut E, Burchert A, Neubauer A, Kanz L , Stegelmann F , Pfreundschuh M , Spiekermann K , Scheid C , Pfirrmann M , Hochhaus A , Hasford J, Hehlmann R : Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015;29(5):1123-1132. doi:10.1038/leu.2015.36 PMID: 25676422

Kiani A, Kuhlencordt P, Hochhaus A, Tesch H, Saussele S, Le Coutre P: Prävention und Management kardiovaskulärer Erkrankungen mit Nilotinib. Onkologe 21, 724–731 (2015). https://doi.org/10.1007/s00761-015-2990-5

Hilgendorf I, Hochhaus A: Spätfolgen der allogenen Blutstammzelltransplantation. Onkologe 2015 · 21:433–442, DOI 10.1007/s00761-015-2923-3, © Springer-Verlag Berlin Heidelberg 2015

Cross NC, Müller MC, Hochhaus A. Response to Ho-Wan Ip and Chi-Chiu. Leukemia. 2015;29(7):1619. doi:10.1038/leu.2015.97. PMID: 25999150

Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, Lange T, Lion T, Machova Polakova K, Dulucq S, Martinelli G, Oppliger Leibundgut E, Pallisgaard N, Barbany G, Sacha T, Talmaci R, Izzo B, Saglio G, Pane F, Müller MC, Hochhaus A: Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia, Leukemia accepted article preview 5 February 2015; doi: 10.1038/leu.2015.29. PMID: 25652737

Guntinas-Lichius O, Wendt TG, Buentzel J, Esser D, Böger D, Mueller AH, Piesold JU, Schultze-Mosgau S, Schlattmann P, Schmalenberg H: Incidence, treatment, and outcome of parotid carcinoma, 1996-2011: a population-based study in Thuringia, Germany. J Cancer Res Clin Oncol. 2015;141(9):1679-1688. doi:10.1007/s00432-015-1961-y. PMID: 25800621

Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C, Göhring G, Schlegelberger B, Jotterand M, Hanfstein B, Seifarth W, Hänel M, Köhne CH, Lindemann HW, Berdel WE, Staib P , Müller MC, Proetel U, Balleisen L, Goebeler ME, Dengler J, Falge C, Kanz L, Burchert A, Kneba M 18 , Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Brümmendorf TH, Edinger M, Hofmann W, Pfirrmann M, Hasford J, Krause S, Hochhaus A, Saußele S, Hehlmann R, SAKK and the German CML Study Group: Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Ann Hematol. 2015;94(12):2015-2024. doi:10.1007/s00277-015-2494-9. PMID: 26385387

Schrenk KG, Schnetzke U, Stegemann K, von Lilienfeld-Toal M, Hochhaus A, Scholl S. Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia. J Cancer Res Clin Oncol. 2015;141(9):1661-1668. doi:10.1007/s00432-015-1962-x. PMID: 25800622

Eigendorff E, Hochhaus A: Akute Leukämien des Erwachsenen. Pathologe 2015 · 36:503–519, DOI 10.1007/s00292-015-0087-y. Online publiziert: 28. August 2015

Maschmeyer G, Mügge LO, Kämpfe D, Kreibich U, Wilhelm S, Aßmann M, Schwarz M, Kahl C, Köhler S, Grobe N, Niederwieser D: A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding primary lung cancer) in 10 oncological institutions of the East German Study Group of Hematology and Oncology (OSHO), 2010-2012. J Cancer Res Clin Oncol. 2015;141(9):1639-1644. doi:10.1007/s00432-015-1954-x PMID: 25773126

Qi Tia, James L. Smart, Joachim H. Clement, Yingming Wang, Alex Derkatch, Harald Schubert, Michael V. Danilchik, Daniel L. Marks, Lev M. Fedorov: RHEB1 expression in embryonic and postnatal mouse. Histochem Cell Biol, DOI 10.1007/s00418-015-1394-3. PMID: 26708151 [PubMed - as supplied by publisher]

La Rosée P: First prospective clinical trial in adult HLH. Blood. 2015 Nov 5;126(19):2169-71. doi: 10.1182/blood-2015-09-666503. PMID:26542249 [PubMed - in process]

Max Desole, Karin G. Schrenk, Ulf Schnetzke, Andreas Hochhaus, Sebastian Scholl: Detection of Enterococcus spp. in bronchoalveolar lavage fluid of patients with high‑risk neutropenia: May it be ignored? J Cancer Res Clin Oncol DOI 10.1007/s00432-015-2084-1. PMID:26621154

Michael W Deininger, J Graeme Hodgson, Neil P Shah, Jorge E Cortes, Dong-Wook Kim, Franck E Nicolini, Moshe Talpaz, Michele Baccarani, Martin C Müller, Jin Li, Wendy T. Parker, Stephanie Lustgarten, Tim Clackson, Frank G Haluska, Francois Guilhot, Hagop M Kantarjian, Simona Soverini, Andreas Hochhaus, Timothy P Hughes, Victor M Rivera, and Susan Branford: Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood First Edition Paper, prepublished online November 24, 2015; DOI 10.1182/blood-2015-08-660977. PMID: 26603839

Gräfe, C., Weidner, A., von der Lühe, M., Bergemann, C., Schacher, F.H., Clement, J.H. und Dutz, S: Intentional formation of a protein corona on nanoparticles: Serumconcentration affects protein corona mass, surface charge, and nano-particle–cell interaction. J Biochem Cell Biol (2015), http://dx.doi.org/10.1016/j.biocel.2015.11.005

A Gratwohl, M Pfirrmann, A Zander, N Kröger, D Beelen, J Novotny, C Nerl, C Scheid, K Spiekermann, J Mayer, HG Sayer, C Falge, D Bunjes, H Döhner, A Ganser, I Schmidt-Wolf, R Schwerdtfeger, H Baurmann, R Kuse, N Schmitz, A Wehmeier, J Th Fischer, AD Ho, M Wilhelm, M-E Goebeler, HW Lindemann, M Bormann, B Hertenstein, G Schlimok, GM Baerlocher, C Aul, M Pfreundschuh, M Fabian, P Staib, M Edinger, M Schatz, A Fauser, R Arnold, T Kindler, G Wulf, A Rosselet, A Hellmann, E Schäfer, O Prümmer, M Schenk, J Hasford, H Heimpel, DK Hossfeld, H-J Kolb, G Büsche, C Haferlach, S Schnittger, MC Müller, A Reiter, U Berger, S Saußele, A Hochhaus, and R Hehlmann: Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia advance online publication, 20 November 2015; doi:10.1038/leu.2015.281. PMID: 26464170

Karin G. Schrenk, Janina Frosinski, Sebastian Scholl, Sylvia Otto, Paul La Rosée, Andreas Hochhaus, Mathias W. Pletz: Successful treatment of neutropenic MRSA bacteremia with septic superior vena cava thrombus and cerebral embolism using high-dose daptomycin. Ann Hematol DOI 10.1007/s00277-015-2526-5, PMID: 26490881

Christian Pfrepper, Anne Klink, Gerhard Behre, Thomas Schenk,·Georg‑Nikolaus Franke, Madlen Jentzsch, Sebastian Schwind, Haifa‑Kathrin Al‑Ali, Andreas Hochhaus, Dietger Niederwieser, Herbert Gottfried Sayer: Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced‑intensity conditioning and allogeneic stem cell transplantation. J Cancer Res Clin Oncol DOI 10.1007/s00432-015-2050-y, PMID: 26424692

C. Kahl, R. Krahl, C. Becker, H. K. Al‑Ali, H. G. Sayer, A. Schulze, M. Herold, M. Hänel, S. Scholl, A. Hochhaus, L. Uharek, G. Maschmeyer, D. Haehling, C. Junghanß, N. Peter, D. Kämpfe, E. Kettner, T. Heinicke, T. Fischer, U. Kreibich, H.‑H. Wolf, D. Niederwieser: Long‑term follow‑up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO). J Cancer Res Clin Oncol, DOI 10.1007/s00432-015-2045-8, PMID: 26407768

Matthias Karrasch, Wolfgang Pfister, Birgit Edel,Andreas Stallmach, Stefan Hagel, Andreas Hochhaus and Jürgen Rödel: Campylobacter jejuni ssp. jejuni bacteraemia in a patient with BCR-ABL-positive chronic myelogenous leukaemia in remission on dasatinib therapy. JMM Case Reports (2015) DOI 10.1099/jmmcr.0.000083

K Wenn, L Tomala, S Wilop, L Vankann, C Hasenbank, O Frank, A Hochhaus, F J Giles, T Lange, M C Müller, S Koschmieder, F Beier, P Ziegler, T H Brümmendorf, Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib, Leukemia accepted article preview 15 September 2015; doi: 10.1038/leu.2015.245.PMID:26369986

Andreas Hochhaus, Michele Baccarani, Francis J. Giles, Philipp D. le Coutre, Martin C. Müller, Andreas Reiter, Helene Santanastasio, Mimi Leung, Steven Novick, Hagop M.Kantarjian: Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. J Cancer Res Clin Oncol (2015) 141:2047–2060 DOI 10.1007/s00432-015-1988-0 PMID: 26002753 [PubMed - in process]

E. Eigendorff, A. Hochhaus: Akute Leukämien des Erwachsenen. Pathologe. 2015 Aug 28. [Epub ahead of print] PMID: 26314268

Karin G. Schrenk, Kathrin Katenkamp, Jörg Felber, Lars-Olof Mügge, Andreas Hochhaus, Sebastian Scholl: Lower gastrointestinal bleeding in a patient with Crohn’s disease and plasma cell leukemia in remission. Ann Hematol. 2015 Aug 21. [Epub ahead of print], PMID: 26289474

Richter ME, Neugebauer S, Engelmann F, Hagel S, Ludewig K, La Rosée P, Sayer HG, Hochhaus A, von Lilienfeld-Toal M, Bretschneider T, Pausch C, Engel C, Brunkhorst FM, Kiehntopf M.: Biomarker candidates for the detection of an infectious etiology of febrile neutropenia. Infection. 2015 Aug 15. [Epub ahead of print], PMID: 26275448

Kai Lehmberg, Kim E. Nichols, Jan-Inge Henter, Michael Girschikofsky, Tatiana Greenwood, Michael Jordan, Ashish Kumar, Milen Minkov, Paul La Rosée, and Sheila Weitzmann, for the Study Group on Hemophagocytic Lymphohistiocytosis Subtypes of the Histiocyte Society: Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies. doi:10.3324/haematol.2015.123562. PMID: 26314082

U. Wehkamp, D. Glaeser, I. Oschlies, I. Hilgendorf, W. Klapper, M. Weichenthal: Successful stem cell transplantation in a patient with primary cutaneous aggressive cytotoxic epidermotropic CD8 + T-Cell lymphoma. British Journal of Dermatology (2015) DOI: 10.1111/bjd.13792. PMID: 25816848

A Weidner, C Gräfe, M von der Lühe, H Remmer, J H Clement, D Eberbeck, F Ludwig, R Müller, F H Schacher and S Dutz: Preparation of Core-Shell Hybrid Materials by Producing a Protein Corona Around Magnetic Nanoparticles. Nanoscale Research Letters (2015) 10:282 DOI 10.1186/s11671-015-0992-2. PMID: 26153125

T P Hughes, G Saglio, A Quinta´s-Cardama,MJ Mauro, D-W Kim, J H Lipton, M B Bradley-Garelik, J Ukropec, A Hochhaus: BCR-ABL1mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase, Leukemia; doi: 10.1038/leu.2015.168. PMID: 26118315

Fernandez-Cuesta L, Sun R, Menon R, George J, Lorenz S, Meza-Zepeda LA, Peifer M, Plenker D, Heuckmann JM, Leenders F, Zander T, Dahmen I, Koker M, Schöttle J, Ullrich RT, Altmüller J, Becker C, Nürnberg P, Seidel H, Böhm D, Göke F, Ansén S, Russell PA, Wright GM, Wainer Z, Solomon B, Petersen I, Clement JH, Sänger J, Brustugun OT, Helland Å, Solberg S, Lund-Iversen M, Buettner R, Wolf J, Brambilla E, Vingron M, Perner S, Haas SA, Thomas RK: Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biol. (2015) Jan 5;16:7. doi: 10.1186/s13059-014-0558-0. PMID: 25650807

von der Lühe M, Günther U, Weidner A, Gräfe C, Clement HJ, Dutz S, Schacher FH: SPION@polydehydroalanine hybrid particles. RSC Adv., 2015, 5, 31920
DOI: 10.1039/C5RA01737H

Steinbach C1, Steinbrücker C, Pollok S, Walther K, Clement JH, Chen Y, Petersen I, Cialla-May D, Weber K, Popp J: KRAS mutation screening by chip-based DNA hybridization - a further step towards personalized oncology. Analyst. 2015 Apr 21;140(8):2747-54. doi: 10.1039/c4an02086c. Epub 2015 Feb 23.
PMID: 25706807

2014

Agrawal M, Hanfstein B, Erben P, Wolf D, Ernst T, Fabarius A, Saussele S, Purkayastha D, Woodman RC, Hofmann W-K,
Hehlmann R, Hochhaus A, Müller MC: MDR1 expression predicts outcome of Phþ chronic phase CML patients on second-line nilotinib therapy after imatinib failure. Leukemia (2014), 1-8. PMID: 24472814

Busch A, Zeh D, Janzen V, Mügge L-O, Wolf D, Fingerhut L, Hahn-Ast C, Maurer O, Brossart P, von Lilienfeld-Toal M: Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients. British Society for Immunology, Clinical and Experimental Immunology (2014), 177, 439–453.
PMID: 24712857

Erben P, Schwaab J, Metzgeroth G, Horny HP, Jawhar M, Sotlar K, Fabarius A, Teichmann M, Schneider S, Ernst T, Müller MC, Giehl M, Marx A, Hartmann K, Hochhaus A, Hofmann WK, Cross NC, Reiter A: The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol. (2014) 93, 81 - 88. doi: 10.1007/s00277-013-1964-1.
PMID: 24281161

Fernandez-Cuesta L, Plenker D, Osada H, Sun R, Menon R, Leenders F, Ortiz-Cuaran S, Peifer M, Bos M, Dabler J, Malchers F, Schottle J, Vogel W, Dahmen I, Koker M, Ullrich RT, Wright GM, Russell PA, Wainer Z, Solomon B, Brambilla E, Nagy-Mignotte H, Moro-Sibilot D, Brambilla CG, Lantuejoul S, Altmuller J, Becker C, Nurnberg P, Heuckmann JM, Stoelben E, Petersen I, Clement JH, Sanger J, Muscarella LA, la Torre A, Fazio VM, Lahortiga I, Perera T, Ogata S, Parade M, Brehmer D, Vingron M, Heukamp LC, Buettner R, Zander T, Wolf J, Perner S, Ansen S, Haas SA, Yatabe Y, Thomas RK: CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discovery (2014). 415-422.
PMID: 24469108

Frietsch JJ, Dornaus S, Neumann T, Scholl S, Schmidt V, Kunert C, Sayer HG, Hochhaus A, La Rosée P: Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: Case series with focus on 5-azacytidine and literature review. European Journal of Histochemistry (2014). doi: 10.1111/ejh.12311. PMID: 24635656

Frietsch JJ, Kastner C, Grunewald TGP, Schweigel H, Nollau P, Ziermann J, Clement JH, La Rosée P, Hochhaus A, Butt E: LASP1 is a novel BCR-ABL substrate and a phosphorylationdependent binding partner of CRKL in chronic myeloid leukemia. Oncotarget (2014). PMID: 24913448

Gale RP, Hochhaus A: OBITUARY Nicole Muller-Bérat Killmann 1932–2014 Leukemia pioneer. Leukemia (2014) 28, 727–728. PMID:24714344

García-Albéniz X, Gallego R, Hofheinz RD, Fernández-Esparrach G, Ayuso-Colella JR, Bombí JA, Conill C, Cuatrecasas M, Delgado S, Ginés A, Miquel R, Pagés M, Pineda E, Pereira V, Sosa A, Reig O, Victoria I, Feliz L, María de Lacy A, Castells A, Burkholder I, Hochhaus A, Maurel J: Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation.
World J Gastroenterol. (2014) 20, 15820-9. doi: 10.3748/wjg.v20.i42.15820.
PMID: 25400468

Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, Fabarius A, Proetel U, Schnittger S, Haferlach C, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann W-K, Hochhaus A, Müller MC: Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica (2014). doi:10.3324/haematol.2013.096537. PMID: 24837466

Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, Erben P, Fabarius A, Proetel U, Schnittger S, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann W-K, Hochhaus A, Müller MC, for the SAKK and the German CML
Study Group: Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia (2014). 1-5. PMID: 24798484

Hehlmann R, Hasford J, Pfirrmann M, Lauseker M, Saußele S, Hochhaus A: Reply to H. Kantarjian and Cortes. Journal of Clinical Oncology Vol 32, 2014. PMID: 25002729

Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Ehninger G, Heim D, Heimpel H, Nerl C, Krause SW, Hossfeld DK, Kolb H-J, Hasford J, Saußele S, Hochhaus A: Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. Journal of Clinical Oncology 32 (5) 2014, 415-23. PMID: 24297946

Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. (2014) 15, 1065-75. doi: 10.1016/S1470-2045(14)70330-4. PMID: 25088940

Hochhaus A: Optimizing tolerability of TKI therapy in CML. Blood, Vol 123, No 9. 1284-85. PMID:24578491

Hughes TP, Hochhaus A, Kantarjian HM, Cervantes F, Guilhot F, Niederwieser D, le Coutre PD, Rosti G, Ossenkoppele G, Lobo C, Shibayama H, Fan X, Menssen HD, Kemp C, Larson RA, Saglio G: Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on frontline imatinib or nilotinib 300 mg twice daily. Haematologica (2014). PMID: 24532039

Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, Nakaseko C, De Souza CA, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A: Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. (2014) 27, 1353-60. doi: 10.1182/blood-2013-06-510396.
PMID: 24335106

Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A: Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. (2014) 23, 494-500. doi: 10.1182/blood-2013-06-511592.
PMID: 24311723

Jabbour EJ, Hughes TP, Cortés JE, Kantarjian HM, Hochhaus A: Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leuk Lymphoma. (2014) 55, 1451-62. doi: 10.3109/10428194.2013.845883.
PMID: 24050507

Jabbour E, Ottmann OG, Deininger M, Hochhaus A: Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica (2014) 99, 1. 7-18. PMID: 24425689

Kalmanti L, Saussele S, Lauseker M, Proetel U, Müller MC, Hanfstein B, Schreiber A, Fabarius A, Pfirrmann M, Schnittger S, Dengler J, Falge C, Kanz L, Neubauer A, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Krause SW, Heim D, Nerl C, Hossfeld DK, Kolb HJ, Hochhaus A, Hasford J, Hehlmann R: Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK). Ann Hematol. (2014) 93, 71-80. doi: 10.1007/s00277-013-1937-4. PMID: 24162333

Klein S, Schmidt C, La Rosée P, Pletz M, Harz S, Dirsch O, Fritzenwanger M, Stallmach A:
Fulminant gastrointestinal bleeding caused by EBV-triggered hemophagocytic lymphohistiocytosis: report of a case. Z Gastroenterol. (2014)52, 354-9. doi: 10.1055/s-0034-1366154. PMID: 24718941

Kripp M, Willer A, Schmidt C, Pilz LR, Gencer D, Buchheidt D, Hochhaus A, Hofmann WK, Hofheinz RD: Patients with malignant hematological disorders treated on a palliative care unit: prognostic impact of clinical factors. Ann Hematol. (2014) 93,317-25. doi: 10.1007/s00277-013-1861-7.
PMID: 23925929

La Rosée P: Therapie der chronischen myeloischen Leukämie nach Versagen der Erstlinientherapie: THIEME REFRESHER ONKOLOGIE (2014) 6, R37 - R52

Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A, Schlegelberger B, Saußele S, Dietz CT, Erben P, Hehlmann R, Hasford J, Hochhaus A, Müller MC: Equivalence of BCR‑ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. J Cancer Res Clin Oncol (2014). DOI 10.1007/s00432-014-1746-8. PMID: 24952896

Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. (2014) 201, 27-65. PMID: 24756784

Mayerhöfer T, Krafft C, Neugebauer U, Dochow S, Matthäus C, Kirsch M, Schackert G, Clement JH, Bauer M, Brehm BR, Popp J: Schnelle und schonende Aufklärung, Potenzial und Grenzen Raman-spektroskopischer Verfahren in der medizinischen Diagnostik. labor&more 3.14, 45-48.

Miranda MB, Hartmann JT, Al‑Batran S-E, Kripp M, Gencer D, Hochhaus A, Hofheinz R-D, Merx K: Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study. J Cancer Res Clin Oncol (2014), 140, 829–837. PMID: 24556803

Mügge C, Liu R, Görls H, Gabbiani C, Michelucci E, Rüdiger N, Clement JH, Messori L, Weigand W: Novel platinum(II) compounds with O,S bidentate ligands: synthesis, characterization, antiproliferative properties and biomolecular interactions. Dalton Trans. (2014) 28, 3072-86. doi: 10.1039/c3dt52284a. PMID: 24169734

Neugebauer U, Kurz C, Bocklitz T, Berger T, Velten T, Clement JH, Krafft C, Popp J: Raman-Spectroscopy Based Cell Identification on a Microhole Array Chip: MICROMACHINES (2014) 5, 2014 - 2015

Penack O, Becker C, Buchheidt D, Christopeit M, Kiehl M, von Lilienfeld-Toal M, Hentrich M, Reinwald M, Salwender H, Schalk E, Schmidt-Hieber M, Weber T, Ostermann H: Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). Ann Hematol (2014) 93, 1083–1095. PMID: 24777705

Pfirrmann M, Saussele S, Hochhaus A, Reiter A, Berger U, Hossfeld DK, Nerl C, Scheid C, Spiekermann K, Mayer J, Hellmann A, Lechner K, Falge C, Sayer HG, Bunjes D, Ganser A, Beelen DW, Baldomero H, Schanz U, Heimpel H, Kolb H-J, Hasford J, Gratwohl A, Hehlmann R, for the Schweizerische Arbeitsgemeinschaft für Klinische Forschung (SAKK) and the German CML Study Group: Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia. J Cancer Res Clin Oncol (2014) 140, 1367–1381. PMID: 24718719

Philipp M, Schwaab J, Dietz CT, Hanfstein B, Kalmanti L, Munjal U, Mossner M, Nowak D, Seifarth W, Hofmann WK, Hochhaus A, Müller MC, Erben P: Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML). J Cancer Res Clin Oncol. (2014) 140, 411-7. doi: 10.1007/s00432-013-1579-x. PMID: 24390277

Proetel U, Pletsch N, Lauseker M, Müller MC, Hanfstein B, Krause SW, Kalmanti L, Schreiber A, Heim D, Baerlocher GM, Hofmann W-K, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Müller L, Hänel M, Link H, Hertenstein B, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R, Saußele S, for the German Chronic Myeloid Leukemia Study Group, and the Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK): Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. Ann Hematol (2014 93, 1167-1176. PMID: 24658964

Schilling K, Hochhaus A: Paraneoplastische Gerinnungsstörungen. Der Onkologe (2014) 20, 497–508.

Schmidt M, Rinke J, Schäfer V, Schnittger S, Kohlmann A, Obstfelder E, Kunert C, Ziermann J, Winkelmann N, Eigendorff E, Haferlach T, Haferlach C, Hochhaus A, Ernst T: Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia. (2014) 28, 2292-9. doi: 10.1038/leu.2014.272. PMID: 25212276

Schnetzke U, Schrenk K, Spies-Weisshart B, Kunert C, Hochhaus A, Scholl S: Different clones of acute leukemia after successful treatment of Hodgkin’s disease. Ann Hematol (2014). DOI 10.1007/s00277-014-2095-z. PMID: 24801016

Schnetzke U, Fischer M, Frietsch JJ, Finkensieper A, Clement JH, Hochhaus A, La Rosée P: Paradoxical MAPK-activation in response to treatment with tyrosine kinase inhibitors in CML: flow cytometry loses track. Cytometry B Clin Cytom. (2014) 86, 229-35. doi: 10.1002/cyto.b.21091. PMID: 23576291

Schnetzke U, Fix P, Spies‑Weisshart B, Schrenk K, Glaser A, Fricke H-J, La Rosée P, Hochhaus A, Scholl S: Efficacy and feasibility of cyclophosphamide combined with intermediate‑ dose or high‑dose cytarabine for relapsed and refractory acute myeloid leukemia (AML). J Cancer Res Clin Oncol (2014) 140, 1391–1397. PMID: 24728467

Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brümmendorf TH, Kantarjian HM, Hochhaus A, Rousselot P, Mohamed H, Healey D, Cunningham M, Saglio G: Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of phase 3 study. Blood (2014), Vol 123, No 15. 2317-24. PMID: 24569263

Stein BL, Swords R, Hochhaus A, Giles F: Novel myelofibrosis treatment strategies: potential partners for combination therapies. Leukemia (2014). doi: 10.1038/leu.2014.176. PMID: 24888274

Schwab KS, Hahn-Ast C, Heinz WJ, Germing U, Egerer G, Glasmacher A, Leyendecker C, Marklein G, Nellessen CM, Brossart P, von Lilienfeld-Toal M: Tigecycline in febrile neutropenic patients with haematological malignancies: a retrospective case documentation in four university hospitals. Infection. (2014) 42, 97-104. doi: 10.1007/s15010-013-0524-x. PMID: 23979853

Vehreschild MJ, Hamprecht A, Peterson L, Schubert S, Häntschel M, Peter S, Schafhausen P, Rohde H, Lilienfeld-Toal MV, Bekeredjian-Ding I, Libam J, Hellmich M, Vehreschild JJ, Cornely OA, Seifert H: A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. J Antimicrob Chemother. (2014) 69, 3387-92. doi: 10.1093/jac/dku305. PMID: 25103492

White H, Deprez L, Corbisier P, Hall V, Lin F, Mazoua S, Trapmann S, Aggerholm A, Andrikovics H, Akiki S, Barbany G, Boeckx N, Bench A, Catherwood M, Cayuela J-M, Chudleigh S, Clench T, Colomer D, Daraio F, Dulucq S, Farrugia J, Fletcher L, Foroni L, Ganderton R, Gerrard G, Gineikienė E, Hayette S, El Housni H, Izzo B, Jansson M, Johnels P, Jurcek T, Kairisto V, Kizilors A, Kim D-W, Lange T, Lion T, Polakova KM, Martinelli G, McCarron S, Merle PA, Milner B, Mitterbauer-Hohendanner G, Nagar M, Nickless G, Nomdedéu J, Nymoen DA, Leibundgut EO, Ozbek U, T Pajič , Pfeifer H, Preudhomme C, Raudsepp K, Romeo G, Sacha T, Talmaci R, Touloumenidou T, Van der Velden VHJ, Waits P, Wang L, Wilkinson E, Wilson G, Wren D, Zadro R, Ziermann J, Zoi K, M C Müller MC, Hochhaus A, Schimmel H, Cross NCP, Emons H: A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real time quantitative PCR. Leukemia (2014). doi: 10.1038/leu.2014.217. PMID: 25036192

Popp J, Mayerhöfer T, Krafft C, Neugebauer U, Dochow S, Matthäus C, Kirsch M, Schackert G, Clement JH, Bauer M, Brehm BR: Potenzial und Grenzen Raman-spektroskopischer Verfahren in der medizinischen Diagnostik. Labor&More 3 / 2014

Theumer A, Gräfe C, Bähring F, Bergemann C, Hochhaus A, Clement JH: Superparamagnetic iron oxide nanoparticles exert different cytotoxic effects on cells grown in monolayer cell culture versus as multicellular as multicellular spheroids. JournalofMagnetismandMagneticMaterials(2014), http://dx.doi.org/10.1016/j. jmmm.2014.10.039i

2013

Winkelmann N, Hidalgo-Curtis C, Waghorn K, Score J, Dickinson H, Jack A, Ali S, C.P. Cross N: Recurrent CEP85L-PDGFRB fusion in a patient with a t(5;6) and an imatinib-responsive myeloproliferative neoplasm with eosinophilia. Leukemia & Lymphoma (2013). PMID: 23186533

Schnetzke U, Fischer M, Kuhn A-K, Spies-Weisshart B, Zirm E, Hochhaus A, Müller JP, Scholl S: The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells. J Cancer Res Clin Oncol (2013). PMID: 23263202

Ottmann OG, Larson RA, Kantarjian HM, le Coutre PD, Baccarani M, Hochhaus A, Kim DW, Fan X, Novick S, Giles FJ: Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia (2013). PMID: 23138184

Oscier DG, Rose-Zerilli MJJ, Winkelmann N, Gonzalez de Castro D, Gomez B, Forster J, Parker H, Parker A, Gardiner A, Collins A, Else M, Cross NCP, Catovsky D, Strefford JC: The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013. PMID: 23086750

Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim D-W, Larson RA, Lipton JH, Mahon F-X, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann J-L, Goldman JM, Hehlmann R: European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013, 122 (6), 827-884. PMID: 23803709

Bähring F, Schlenk F, Wotschadlo J, Buske N, Liebert T, Bergemann C, Heinze T, Hochhaus A, Fischer D, Clement JH: Suitability of Viability Assays for Testing Biological Effects of Coated Superparamagnetic Nanoparticles. IEEE TRANSACTIONS ON MAGNETICS 49 (1), 383-388. DOI: 10.1109/TMAG.2012.2222635

Becker-Putsche M, Bocklitz T, Clement J, Rösch P, Popp J: Towards improving fine needle aspiration cytology by applying Raman microspectroscopy. J Biomed Optics (2013). PMID: 23545854

Boda-Heggemann J, Weiss C, Schneider V, Hofheinz R-D, Haneder S, Michaely H, Wertz H, Ronellenfitsch U, Hochhaus A, Wenz F, Lohr F: Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer. Strahlenther Onkol (2013). PMID: 23558673

Cortes J, Digumarti R, Parikh PM, Wetzler M, Lipton JH, Hochhaus A, Craig AR, Benichou A-C, Nicolini FE, Kantarjian HM, Omacetaxine 203 Study Group: Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. American Journal of Hematology (2013). PMID: 23468307

Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H: A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias. N Engl J Med Vol. 369 No. 19. PMID: 24180494

Cortes JE, Nicolini FE, Wetzler M, Lipton JH, Akard L, Craig A, Nanda N, Benichou A-C, Leonoudakis J, Khoury HJ, Hochhaus A, Baccarani M, Kantarjian HM: Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib. Clinical Lymphoma, Myeloma & Leukemia, Vol. 13, No. 5, 584-91. PMID: 23787123

Dochow S, Beleites C, Henkel T, Mayer G, Albert J, Clement J, Krafft C, Popp J: Quartz microfluidic chip for tumour cell identification by Raman spectroscopy in combination with optical traps. Anal Bioanal Chem (2013). PMID: 23371531

Dochow S, Bergner N, Krafft C, Clement J, Mazilu M, Praveen BB, Ashok PC, Marchington R, Dholakiac K, Popp J: Classification of Raman spectra of single cells with autofluorescence suppression by wavelength modulated excitation. Anal. Methods 2013, 5, 4608. https://doi.org/10.1039/C3AY40193F

Editorial: Die CML-Studiengruppe und die MPN-Intergroup als kooperative Verbünde der akademischen Forschung. Journal Onkologie 2/2013. 69.

Feldmann G, Brossart P, von Lilienfeld-Toal M: Transient and fully reversible leukocytosis in a myelodysplastic syndrome patient upon initiation of azacitidine treatment. Ann Hematol. (2013). PMID: 23584506

Feldmann G, Brossart P, Zipfel M, von Lilienfeld-Toal M: Mixed response to ipilimumab in a melanoma patient with brain metastases: case report and review of the literature. Case Rep Oncol. 2013, 6 (1), 229-35. PMID: 23687494

Fensterer H, Schade-Brittinger C, Müller H-H, Tebbe S, Fass J, Lindig U, Settmacher U, Schmidt WE, Märten A, Ebert MP, Kornmann M, Hofheinz R, Endlicher E, Brendel C, Barth PJ, Bartsch DK, Michl P, Gress TM: Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). Annals of Oncology (2013). PMID: 23897705

Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim D-W, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM: Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013, 27 (1), 107-112. PMID: 22763385

Giles FJ, Mauro MJ, Hong F, Ortmann C-E, McNeill C, Woodman RC, Hochhaus A, le Coutre PD, Saglio G: Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: A retrospective cohort analysis. Leukemia (2013). PMID: 23459450

Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA, Talpaz M, Clark J, Watson P, Xiao A, Zhao B, Bergstrom D, LeCoutre PD, Freedman SJ, Cortes JE: MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. Leukemia 2013, 27 (1), 113-117. PMID: 22772060

Griesshammer M, Ernst T, Schlenk RF, Lengfelder E, Stegelmann F, Reiter A, Döhner K, Koschmieder S: Diagnostik und medikamentöse Therapie der myeloproliferativen Neoplasien (MPN). Journal Onkologie 2/2013, 96-106. PMID: 23404582

Heublein S, Wehner F, Höchsmann B, Hochhaus A, Hartmann M, La Rosée P: Modelling cost effectiveness of horse antithymocyte globulin for treating severe aplastic anaemia in Germany. Ann Hematol (2013).

Hochhaus A: Chronische myeloische Leukämie: aktuelle Therapiekonzepte. Pharma Fokus Onkologie 10. Jahrg. 2013, Nr. 1, 4-10.

Hochhaus A: Chronische Myeloische Leukämie (CML). DLH Info 52 III/ 2013.

Hochhaus A: Dosisanpassung nach Verträglichkeit verbessert die Ergebnisse einer intensiven Imatinibtherapie. Kompetenznetz Akute und chronische Leukämien Rundbrief Dezember 2012, 23.

Hochhaus A: Optimierung der Erstlinientherapie der CML mit Nilotinib plus Interferon alpha. Evaluierung der Chance der funktionellen Heilung. TIGER-Studie. Kompetenznetz Akute und chronische Leukämien Rundbrief Dezember 2012, 10-11.

Hochhaus A, Kantarjian H: The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. J Cancer Res Clin Oncol (2013), 139. 1971-1984. PMID: 23942795

Hochhaus A, La Rosée P: Maßgeschneiderte Therapie der chronischen myeloischen Leukämie. Internist 54, 155–163 (2013). https://doi.org/10.1007/s00108-012-3152-0

Hochhaus A, La Rosée P: Therapie der chronischen myeloischen Leukämie - Offene Fragen und Lösungsansätze. krebsmedizin 22 (2013) Nr. 2, 79-86.

Hochhaus A, La Rosée P, Brümmendorf TH, Burchert A, Saußele S: Chronische myeloische Leukämie - Heilung durch medikamentöse Therapie? Journal Onkologie 2/2013. 77-82.

Hochhaus A, La Rosée P, Mügge L-O, Sayer HG, Scholl S: Zielgerichtete Therapien bei hämatologischen Erkrankungen - Standards und Perspektiven. Der Onkologe (2013).

Hochhaus A, le Coutre PD, Kantarjian HM, Baccarani M, Erben P, Reiter A, McCulloch T, Fan X, Novick S, Giles FJ: Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open‑label, single‑arm A2101 study. J Cancer Res Clin Oncol (2013), 139. 1985-1993. PMID: 24057647

Hochhaus A, Lüftner D, Mackensen A: Gezielte Therapie: alte und neue Hoffnungsträger. Onkologie 2013;36(suppl 5):2–11, https://doi.org/10.1159/000351997

Hochhaus A, Saglio G, Larson RA, Kim D-W, Etienne G, Rosti G, De Souza C, Kurokawa M, Kalaycio ME, Hoenekopp A, Fan X, Shou Y, Kantarjian HM, Hughes TP: Nilotinib is associated with a reduced incidence of BCR-ABL mutations versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2013;121(18):3703-3708. doi:10.1182/blood-2012-04-423418. PMID: 23502220

Hochhaus A, Schlag PM, Cordes N, Höffken K: Paul Ehrlichs „magic bullets“. Onkologe 19, 806–808 (2013). https://doi.org/10.1007/s00761-013-2501-5

Hoehler T, von Wichert G, Schimanski C, Kanzler S, Moehler MH, Hinke A, Seufferlein T, Siebler J, Hochhaus A, Arnold D, Hallek M, Hofheinz R, Hacker UT: Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205. Br J Cancer. 2013 Sep 17;109(6):1408-13. doi: 10.1038/bjc.2013.409. Epub 2013 Aug 20. PubMed PMID: 23963139; PubMed Central PMCID: PMC3776974. PMID: 23963139

Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, Nakaseko C, Antonio De Souza C, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A: Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood (2013). PMID: 24335106

Hunstig F, Hammersen J, Kunert C, Petersen I, Merz H, Glaser A, Teichgräber U, Hochhaus A, La Rosée P: Complete Remission After Treatment With Single-Agent Ofatumumab in a Patient With High-Risk Leukemic Mantle-Cell Lymphoma. Journal of Clinical Oncology (2013). PMID: 23690428

Jabbour EJ, Hughes TP, Cortés JE, Kantarjian HM, Hochhaus A: Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leukemia & Lymphoma (2013), Vol 55, No 7. 1451-1462. PMID: 24050507

Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim D-W, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A: Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood (2013).PMID: 24311723

Kalmanti L, Saussele S, Lauseker M, Proetel U, Müller MC, Hanfstein B, Schreiber A, Fabarius A, Pfirrmann M, Schnittger S, Dengler J, Falge C, Kanz L, Neubauer A, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Krause SW, Heim D, Nerl C, Hossfeld DK, Kolb H-J, Hochhaus A, Hasford J, Hehlmann R, German Chronic Myeloid Leukemia Study Group, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK): Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Ann Hematol (2013). PMID: 24162333

La Rosée P: Die Hämophagozytische Lymphohistiozytose (HLH) und das Makrophagen-Aktivierungs - Syndrom (MAS): Differentialdiagnose bei SIRS, Sepsis und MODS. Intensiv-News (17) 4/ 2013.

La Rosée P, Ernst T, von Bubnoff N, Brümmendorf TH, Hochhaus A: CML: Ursachen und Therapie der Resistenz. Journal Onkologie 2/2013. 89-94.

La Rosée P, Martiat P, Leitner A, Klag T, Müller MC, Erben P, Schenk T, Saussele S, Hochhaus A: Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol (2013) 92. 1345-1350. PMID: 23625298

La Rosée P, Schenk T, Kunert C, Hochhaus A: Die hämophagozytische Lymphohistiozytose (HLH) und das Makrophagenaktivierungssyndrom (MAS): Klinisches Erscheinungsbild und Diagnostik. Laboratoriumsmedizin (2013).

La Rosée P, Stallmach A, Hochhaus A: Jahrestagung der Gesellschaft für Innere Medizin Thüringens e.V. - Pharmakotherapie in der Onkologie: Was der Internist wissen sollte. Ärzteblatt Thüringen 2/ 2013 24. Jahrgang. 98-99.

Lange T, Ernst T, Gruber FX, Maier J, Cross M, Müller MC, Niederwieser D, Hochhaus A, Pfirrmann M: The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. Haematologica. 2013 May;98(5):714-7. doi: 10.3324/haematol.2012.068890. Epub 2012 Oct 12. PubMed PMID: 23065514; PubMed Central PMCID: PMC3640114.PMID: 23065514

Mahmoudi M, Abdelmonem AM, Behzadi S, Clement JH, Dutz S, Ejtehadi MR, Hartmann R, Kantner K, Linne U, Maffre P, Metzler S, Moghadam M, Pfeiffer C, Rezaie M, Ruiz-Lozano P, Serpooshan V, Shokrgozar M, Nienhaus GU, Parak WJ: Temperature - The “Ignored” Factor at the NanoBio Interface. ACS Nano (2013). PMID: 23808533

Merx K, Fabarius A, Erben P, Griesshammer M, Reiter A, Hofmann W-K, Hehlmann R, Hochhaus A, Lengfelder E: Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study. Ann Hematol (2013). PMID: 23525684

Metzgeroth G, Schwaab J, Gosenca D, Fabarius A, Haferlach C, Hochhaus A, Cross NCP, Hofmann W-K, Reiter A: Long-term follow-up of treatment with imatinib in eosinophiliaassociated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase. Leukemia (2013). PMID: 23615556

Mothes H, Settmacher U, Hochhaus A: 10. Thüringer Krebskongreß im März - Partnerschaftliche Onkologie. Ärzteblatt Thüringen 7-8/ 2013 24. Jahrgang. 404-407.

Müller MC, Dietz C, Fabarius A, Ernst T, Hanfstein B, Lange T, Hochhaus A: CML: Optimierte molekulare und zytogenetische Diagnostik. Journal Onkologie 2/2013. 83-88.

Neumann S, Krause SW, Maschmeyer G, Schiel X, von Lilienfeld-Toal M: Infectious Diseases Working Party (AGIHO); German Society of Hematology and Oncology (DGHO). Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2013 92 (4). 433-42.PMID: 23412562

Nicolini FE, Ibrahim AR, Soverini S, Martinelli G, Müller MC, Hochhaus A, Dufva IH, Kim D-W, Cortes J, Mauro MJ, Chuah C, Labussière H, Morisset S, Roche-Lestienne C, Lippert E, Hayette S, Peter S, Zhou W, Maguer-Satta V, Michallet M, Goldman J, Apperley JF, Mahon FX, Marin D, Etienne G: The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica (2013). PMID: 23716543

Nieborowska-Skorska M, Hoser G, Hochhaus A, Stoklosa T, Skorski T: Anti-oxidant vitamin E prevents accumulation of imatinibresistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice. Leukemia (2013). PMID: 23604228

Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, Sinn M, Hinke A, Riess H: Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer The CONKO-001 Randomized Trial. JAMA 2013 310 (14). 1473-1481. PMID: 24104372

Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, Antolini L, Mologni L, Donadoni C, Papaemmanuil E, Schnittger S, Kim D-W, Boultwood J, Rossi F, Gaipa G, De Martini GP, di Celle PF, Jang HG, Fantin V, Bignell GR, Magistroni V, Haferlach T, Pogliani EM, Campbell PJ, Chase AJ, Tapper WJ, Cross NCP, Gambacorti-Passerini C: Recurrent SETBP1 mutations in atypical chronic
myeloid leukemia. Nature Genetics 45 (1). 18-24. PMID: 23222956

Rinke J, Schäfer V, Schmidt M, Ziermann J, Kohlmann A, Hochhaus A, Ernst T: Genotyping of 25 Leukemia-Associated Genes in a Single Work Flow by Next-Generation Sequencing Technology with Low Amounts of Input Template DNA. Clinical Chemistry (2013). PMID: 23592507

Rosendahl J, Brunkhorst FM, Jaenichen D, Strauss B: Physical and mental health in patients and spouses after intensive care of severe sepsis: a dyadic perspective on long-term sequelae testing the Actor-Partner Interdependence Model. Crit Care Med (2013) 41 (1). 69–75.

Schnetzke U, Fischer M, Frietsch JJ, Finkensieper A, Clement JH, Hochhaus A, La Rosée P: Paradoxical MAPK-Activation in Response to Treatment with Tyrosine Kinase Inhibitors in CML: Flow Cytometry Loses Track. Cytometry Part B: Clinical Cytometry (2013). PMID: 23576291

Schnetzke U, Fischer M, Spies-Weisshart B, Zirm E, Hochhaus A, Müller JP, Scholl S: The E3 ubiquitin ligase TRAF2 can contribute to TNF- resistance inFLT3-ITD-positive AML cells. Leukemia Research (2013). PMID: 23998902

Schrenk KG, Krokowski M, Feller AC, Bernhard V, Mügge L-O, Oelzner P, Wolf G, Hochhaus A, Neumann T: Clonal T-LGL population mimicking leukemia in Felty’s syndrome-part of a continuous spectrum of T-LGL proliferations? Ann Hematol (2013). PMID: 23322212

Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, Kohlmann A, Grossmann V, Meggendorfer M, Horny H-P, Valent P, Jawhar M, Teichmann M, Metzgeroth G, Erben P, Ernst T, Hochhaus A, Haferlach T, Hofmann W-K, Cross NCP, Reiter A: Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 22 (14). 2460-2466. PMID: 23958953

Spies-Weisshart B, Schilling K, Böhmer F, Hochhaus A, Sayer HG, Scholl S: Lack of association of platelet-derived growth factor (PDGF) receptor autoantibodies and severity of chronic graft-versus-host disease (GvHD). J Cancer Res Clin Oncol 2013, 139. 1397-1404. PMID: 23728535

Stallmach A, Bauer M, Hochhaus A: Klinische Forschung als wichtiger Bestandteil der Weiterbildung in der Inneren Medizin. Ärzteblatt Thüringen 1/ 2012, 23. Jahrgang. 7-8.

Stallmach A, La Rosée P: Entzündung: Mehr als Bakterien oder Viren - Frühjahrstagung der Gesellschaft für Innere Medizin Thüringens e. V. im Rahmen des Internistenkongresses in Wiesbaden. Ärzteblatt Thüringen 6/2013 24. Jahrgang. 343-345.

Stein AM, Martinelli G, Hughes TP, Müller MC, Beppu L, Gottardi E, Branford S, Soverini S, Woodman RC, Hochhaus A, Kim D-W, Saglio G, Radich JP: Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. BMC Cancer (2013).PMID: 23547655

The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM): A Genomics-Based Classification of Human Lung Tumors. Sci Transl Med (2013) 5, 209. PMID: 24174329

Übersicht über die Eckdaten der Studien der MPN- und CML-Studiengruppen mit Kontaktdaten. Journal Onkologie 2/2013. 116.

Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen T-T, Shah NP: Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. Clinical Pharmacology: Advances and Applications 2013:5. 85-97. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. PMID: 23788844

White HE, Hedges J, Bendit I, Branford S, Colomer D, Hochhaus A, Hughes T, Kamel-Reid S, Kim D-W, Modur V, Müller MC, Pagnano KB, Pane F, Radich J, Cross NCP, Labourier E: Establishment and Validation of Analytical Reference Panels for the Standardization of Quantitative BCR-ABL1 Measurements on the International Scale. Clinical Chemistry (2013). PMID: 23471097

Yomade O, Spies-Weisshart B, Glaser A, Schnetzke U, Hochhaus A, Scholl S: Impact of NOD2 polymorphisms on infectious complications following chemotherapy in patients with acute myeloid leukaemia. Ann Hematol (2013). PMID: 23558906

Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, Kohlmann A, Grossmann V, Meggendorfer M, Horny HP, Valent P, Jawhar M, Teichmann M, Metzgeroth G, Erben P, Ernst T, Hochhaus A, Haferlach T, Hofmann WK, Cross NCP, Reiter A: Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122(14):2460-2466. doi:10.1182/blood-2013-04-496448. PMID: 23958953

Hochhaus A, La Rosée P, Mügge LO, Sayer HG, Scholl S: Zielgerichtete Therapien bei hämatologischen Erkrankungen. Onkologe 19, 835–847 (2013). https://doi.org/10.1007/s00761-013-2497-x

Nieborowska-Skorska M, Hoser G, Hochhaus A, Stoklosa T, Skorski T: Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice. Leukemia. 2013;27(11):2253-2254. doi:10.1038/leu.2013.123. PMID: 23604228

Jabbour E, le Coutre P, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TR, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM:Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia 27, 907–913 (2013). https://doi.org/10.1038/leu.2012.305

Hochhaus A, · Lüftner D, · Mackensen A: Gezielte Therapie: alte und neue Hoffnungsträger, Onkologie 2013;36(suppl 5):2-11, https://doi.org/10.1159/000351997

2012

Grossmann V, Kohlmann A, Zenger M, Schindela S, Eder C, Weissmann S, Schnittger S, Kern W, Müller MC, Hochhaus A, Haferlach T, Haferlach C: A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia. 2011;25(3):557-560. doi:10.1038/leu.2010.298. PMID: 21274004

Saussele S, Hehlmann R, Gratwohl A, Hochhaus A. Outcome of patients with CML after SCT in the era of tyrosine kinase inhibitors. Bone Marrow Transplant. 2012;47(2):304. doi:10.1038/bmt.2011.70. PMID: 21441956

le Coutre, Philipp D.; Giles, Francis J.; Hochhaus, Andreas; Apperley, Jane F.; Ossenkoppele, Gert J.; Blakesley, Rick; Shou, Yaping, Gallagher, Neil J.; Baccarani, Michele; Cortes, Jorge E.; Kantarjian, Hagop M.: Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia PMID: 22076466

Al-Batran S-E, Pauligk C, Wirtz R, Werner D, Steinmetz K, Homann N, Schmalenberg H, Hofheinz R-D, Hartmann JT, Atmaca A, Altmannsbergeg H-M, Jäger E: The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer. Ann Oncol. 23 (7), 1699-1705. PMID: 22112973

Branford S, Kim D-W, Soverini S, Haque A, Shou Y, Woodman RC, Kantarjian HM, Martinelli G, Radich JP, Saglio G, Hochhaus A, Hughes TP, Müller MC: Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in
Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib. J Clin Oncol (2012). PMID: 23109697

Bohne S, Kentouche K, Petersen I, Fritzenwanger M, Pletz MW, Lehmberg K, La Roseé P, Guntinas-Lichius O: Fulminant Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis. The Laryngoscope (2012). PMID: 27496079

Brede-Hekimian K: Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer. The Lancet Oncology Vol. 379 (9833), 2237-2238. PMID: 22704161

Briest F, Berndt A, Clement J, Junker K, von Eggeling F, Grimm S, Friedrich K: Tumor-stroma interactions in tumorigenesis: lessons from stem cell biology. Front Biosci (Elite Ed.) 2012, 1871-1887. PMID: 22202004

Büchner T, Schlenk RF, Schaich M, Döhner K, Krahl R, Krauter J, Heil G, Krug U, Sauerland MC, Heinecke A, Späth D, Kramer M,
Scholl S, Berdel WE, Hiddemann W, Hoelzer D, Hehlmann R, Hasford J, Hoffmann VS, Döhner H, Ehninger G, Ganser A, Niederwieser DW, Pfirrmann M: Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm-Combined Prospective Analysis by the German AML Intergroup. J Clin Oncol 30 (29), 3604-3610. PMID: 22965967

Cross NCP, White H, Müller MC, Saglio G, Hochhaus A: Standardized definitions of molecular response in chronic
myeloid leukemia. Leukemia 2012, 26, 2172-2175. PMID: 22504141

Ernst T, Hochhaus A: Chronic Myeloid Leukemia: Clinical Impact of BCR-ABL1 Mutations and Other Lesions Associated With Disease Progression. Semin Oncol 39 (1), 58-66. PMID: 22289492

Ernst T, Pflug A, Rinke J, Ernst J, Bierbach U, Beck JF, Hochhaus A, Gruhn B: A somatic EZH2 mutation in a child with acute myeloid leukemia. Leukemia (2012).

Fuchs M, Reinhöfer M, Ragoschke-Schumm A, Sayer HG, Böer K, Witte OW, Hochhaus A, Axer H: Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation. BMC Blood Disorders (2012). PMID: 22871019

Giles FJ, Kantarjian HM, le Coutre PD, Baccarani M, Mahon F-X, Blakesley RE, Gallagher NJ, Gillis K, Goldberg SL, Larson RA, Hochhaus A, Ottmann OG: Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 2012, 26 (5), 959-62. PMID: 22157807

Gruber FX, Ernst T, Porkka K, Engh RA, Mikkola I, Maier J, Lange T, Hochhaus A: Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients. Leukemia 2012, 26 (1), 172-177. PMID: 21818112

Godfrey R, Bauer R, Stopp S, Müller JP, Heinrich T, Böhmer S-A, Dagnell M, Schnetzke U, Scholl S, Östman A, Böhmer F-D: Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/PTPRJ. Blood (2012). PMID: 22438257

Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A, Kulikov S, Mayer J, Petzer AL, Rosti G, Rousselot P, Saglio G, Saussele S, Simonsson B, Steegmann J-L, Zaritskey A, Hehlmann R: Definitions, methodological, and statistical issues for phase III clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood (2012). PMID: 22508936

Hanfstein B, Müller MC, Hehlmann R, Erben P, LausekerM, Fabarius A, Schnittger S, Haferlach C, Göhring G, Proetel U, Kolb H-J, Krause SW, Hofmann W-K, Schubert J, Einsele H, Dengler J, Hänel M, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Sauele S, Hochhaus A: Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012, 26 (9), 2096-2102. PMID: 22446502

Hekimian K, Meisezahl S, Trompelt K, Rabenstein C, Pachmann K: Epithelial Cell Dissemination and Readhesion: Analysis of
Factors Contributing to Metastasis Formation in Breast Cancer. ISRN Oncology (Vol. 2012). PMID: 22530147

Hochhaus A, Ernst T, Ziermann J, Eigendorff E, La Rosée P: Chronische myeloische Leukämie Heilung durch medikamentöse Therapie? Der Onkologe 12 (2012), 1105-1114.

Hochhaus A, Müller MC, Lange T, Thiede C, Haferlach T: Befundinterpretation der molekularen Diagnostik in der Verlaufskontrolle der chronischen myeloischen Leukämie: Empfehlungen einer deutschen Expertengruppe. J Lab Med 2012, 36 (6), 405-411.

Hochhaus A, Reiter A, Ernst T, La Rosée P: Imatinib and Beyond - Targeting Activated Tyrosine Kinases in Myeloproliferative Disorders. Onkologie. 2012; 35 (Suppl 1), 34-41. PMID: 22286586

Hoff PM, Hochhaus A, Pestalozzi BC, Tebbutt NC, Li J, Won Kim T, Koynov KD, Kurteva G, Pintér T, Cheng Y, van Eyll B, Pike L,
Fielding A, Robertson JD, Saunders MP: Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II). Journal of Clinical Oncology (2012). PMID: 22965965

Hofheinz R-D, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A: Chemoradiotherapy with capecitabine versus fl uorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. The Lancet Oncology (2012). PMID: 22503032

Horn M, Glauche I, Müller MC, Hehlmann R, Hochhaus A, Loeffler M, Roeder I: Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Blood (2012). PMID: 23175686

Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A,
Hughes TP, Saglio G, Radich JP, Kim D-W, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM: Prediction of outcomes in patients with Phþ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia (2012). PMID: 23174881

Jaenichen D, Brunkhorst FM, Strauss B, Rosendahl J: Physical and mental long-term sequelae following intensive care of severe sepsis in patients and relatives. Psychother Psychosom Med Psychol (2012) ,62 (9–10), 335–43. PMID: 22585583

Klag T, Härtel N, Erben P, Schwaab J, Schnetzke U, Schenk T, Hochhaus A, La Rosée P: Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common b-subunit c of cytokine receptors. Leukemia 2012, 26 (6), 1321-1328. PMID: 22289991

Klag T, Schnetzke U, Benz R, Zanow J, Glaser A, Pörner TC, Scholl S, Reiter A, Hochhaus A, La Rosée P: Leriche’s syndrome and Löffler endocarditis in a 30-year-old patient presenting with hypereosinophilic syndrome. Ann Hematol (2012) 91, 139-141. PMID: 21494797

Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, Wang J, Kassack Ipiña JJ, Kim D-W, Ogura M, Pavlovsky C, Junghanss C, Milone JH, Nicolini FE, Robak T, Van Droogenbroeck J, Vellenga E, Bradley-Garelik MB, Zhu C, Hochhaus A: Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012, 119 (5), 1123-1129. PMID: 22160483

Kumari A, Brendel C, Hochhaus A, Neubauer A, Burchert A: Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood 2012, 119 (2), 530-539. PMID: 22101898

Lange T, Ernst T, Gruber F, Maier J, Cross M, Müller MC, Niederwieser D, Hochhaus A, Pfirrmann M: The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. Haematologica (2012). PMID: 23065514

Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim D-W, Flinn IW, Kurokawa M, Moiraghi B, Yu R, Blakesley RE, Gallagher NJ, Saglio G, Kantarjian HM: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012, 26, 2197-2203. PMID: 22699418

le Coutre PD, Giles FJ, Hochhaus A, Apperley JF, Ossenkoppele GJ, Blakesley R, Shou Y, Gallagher NJ, Baccarani M, Cortes J, Kantarjian HM: Nilotinib in patients with Phþ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 2012, 26 (6), 1189-1194. PMID: 22076466

Metzelder SK, Schroeder T, Finck A, Scholl S, Fey M, Götze K, Linn YC, Kröger M, Reiter A, Salih HR, Heinicke T, Stuhlmann R, Müller L, Giagounidis A, Meyer RG, Brugger W, Vöhringer M, Dreger P, Mori M, Basara N, Schäfer-Eckart K, Schultheis B, Baldus C, Neubauer A, Burchert A: High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia 2012, 26, 2353-2359. PMID: 22504140

Metzgeroth G, Erben P, Martin H, Mousset S, Teichmann M, Walz C, Klippstein T, Hochhaus A, Cross NC, Hofmann WK, Reiter A: Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia 2012, 26 (1), 162-164. PMID: 21818111

Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, Cramer K, Reddy MR, Koptyra M, Penserga T, Glodkowska-Mrowka E, Bolton E, Holyoake TL, Eaves CJ, Cerny-Reiterer S, Valent P, Hochhaus A, Hughes TP, van der Kuip H, Sattler M, Wiktor-Jedrzejczak W, Richardson C, Dorrance A, Stoklosa T, Williams DA, Skorski T: Rac2-mitochondrial respiratory chain complex III-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood (2012). PMID: 22411871

Nikolajski M, Wotschadlo J, Clement JH, Heinze T: Amino-Functionalized Cellulose Nanoparticles: Preparation, Characterization, and Interactions with Living Cellsa . Macromolecular Bioscience 2012, 12, 920-925. PMID: 22535832

Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, Schildhaus H-U, Altmüller J, Baessmann I, Becker C, de Wilde B, Vandesompele J, Böhm D, Ansén S, Gabler F, Wilkening I, Heynck S, Heuckmann JM, Lu X, Carter SL, Cibulskis K, Banerji S, Getz G, Park K-S, Rauh D, Grütter C, Fischer M, Pasqualucci L, Wright G, Wainer Z, Russell P, Petersen I, Chen Y, Stoelben E, Ludwig C, Schnabel P, Hoffmann H, Muley T, Brockmann M, Engel-Riedel W, Muscarella LA, Fazio VM, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman DAM, Snijders PJF, Cappuzzo F, Ligorio C, Damiani S, Field J, Solberg S, Terje Brustugun O, Lund-Iversen M, Sänger J, Clement JH, Soltermann A, Moch H, Weder W, Solomon B, Soria J-C, Validire P, Besse B, Brambilla E, Brambilla C, Lantuejoul S, Lorimier P, Schneider PM, Hallek M, Pao W, Meyerson M, Sage J, Shendure J, Schneider R, Büttner R, Wolf J, Nürnberg P, Perner S, Heukamp LC, Brindle PK, Haas S,Thomas RK: Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics (2012). PMID: 22941188

Rehnitz J, Hochhaus A, Schaffelder R, Erben P, Sütterlin M: Pregnancy and spontaneous delivery in a patient with primary myelofibrosis. Journal of Neonatal-Perinatal Medicine 5 (2012), 393-395.

Saußele S, Hehlmann R, Gratwohl A, Hochhaus A: Outcome of patients with CML after SCT in the era of tyrosine kinase inhibitors. Bone Marrow Transplantation (2012) 47, 304. PMID: 21441956

Schmalenberg H: Zertifizierungsverfahren für Onkologische Zentren in Deutschland. Der Onkologe 2012 (18), 501-510.

Schwaab J, Ernst T, Erben P, Rinke J, Schnittger S, Ströbel P, Metzgeroth G, Mossner M, Haferlach T, Cross NCP, Hochhaus A, Hofmann W-K, Reiter A: Activating CBL mutations are associated with a distinct MDS/MPN phenotype. Ann Hematol (2012). PMID: 23010802

Wotschadlo J, Liebert T, Clement JH, Anspach N, Höppener S, Rudolph T, Müller R, Schacher FH, Schubert US, Heinze T: Biocompatible Multishell Architecture for Iron Oxide Nanoparticles. Macromol Biosci (2012). PMID: 23161745

Yin OQP, Giles FJ, Baccarani M, le Coutre P, Chiparus O, Gallagher N, Saglio G, Hughes TP, Hochhaus A, Kantarjian HM, Larson RA: Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. (2012) PMID: 22623211

Zirm E, Spies-Weisshart B, Heidel F, Schnetzke U, Böhmer F-D, Hochhaus A, Fischer T, Scholl S: Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation. British Journal of Haematology (2012), 1365-2141. PMID: 22409268

2011

Ernst T, La Rosée P, Müller MC, Hochhaus A. BCR-ABL mutations in chronic myeloid leukemia. Hematol Oncol Clin North Am. 2011;25(5):997-vi. doi:10.1016/j.hoc.2011.09.005, PMID: 22054731

Hochhaus A: Chronic myeloid leukemia. Dtsch Med Wochenschr 2011; 136(40): 2007-2010, 136: 2007–2010 · © Georg, Thieme Verlag KG Stuttgart, New York ISSN 0012-0472; DOI: 10.1055/s-0031-1286381,

Bacher, Ulrike; Haferlach, Torsten; Alpermann, Tamara; Zenger, Melanie; Hochhaus, Andreas; Beelen, Dietrich W. et al.: Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations. Br. J. Haematol 152 (6), 713-720. PMID: 21275954

Cortes, Jorge E.; Hochhaus, Andreas; Hughes, Timothy; Kantarjian, Hagop: Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J. Clin. Oncol 29 (5), 524-531. PMID: 21220597

Cortes, Jorge E.; Hochhaus, Andreas; Le Coutre, Philipp D.; Rosti, Gianantonio; Pinilla-Ibarz, Javier; Jabbour, Elias et al.: Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood 117 (21), 5600-5606. PMID: 21467546

Elling, Christian; Erben, Philipp; Walz, Christoph; Frickenhaus, Marie; Schemionek, Mirle; Stehling, Martin et al.: Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 117 (10), 2935-2943. PMID: 21224473

Ernst, Thomas; La Rosée, Paul; Müller, Martin C.; Hochhaus, Andreas: BCR-ABL Mutations in Chronic Myeloid Leukemia. Hematol. Oncol. Clin. North Am. 25 (5), 997-1008

Fabarius, Alice; Leitner, Armin; Hochhaus, Andreas; Müller, Martin C.; Hanfstein, Benjamin; Haferlach, Claudia et al.: Impact of ACA at diagnosis on prognosis of CML: long term observation from 1151 patients of the randomized CML Study IV. Blood PMID: 22039253

Gencer, Deniz; Tauchert, Felix; Keilhauer, Nina; Al-Batran, Salah-Eddin; Stahl, Michael; Oskay-Özcelik, Gülten et al.: Cancer Patients and the Internet: A Survey of the 'Quality of Life' Working Groups of the Arbeitsgemeinschaft für Internistische Onkologie and the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie. Onkologie 34 (8-9), 435-440. PMID: 21934343

Gerth, Jens; Sachse, Anja; Busch, Martin; Illner, Nico; Muegge, Lars-Olof; Gröne, Hermann-Josef; Wolf, Gunter: Screening and Differential Diagnosis of Renal Light Chain-Associated Diseases. Kidney & Blood Pressure Research. PMID: 22056791

Giles, Francis J.; Kantarjian, Hagop M.;le Coutre, Philipd D.; Baccarani, Michele; Mahon, François-Xavier; Blakesley, Rick; Gallagher, Neil J.; Gillis, Karen; Goldberg, Stuart L.; Larson, Richard A.; Hochhaus, Andreas; Ottmann, Oliver G.: Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia. PMID: 22157807

Guglielmelli, Paola; Biamonte, Flavia; Score, Joannah; Hidalgo-Curtis, Claire; Cervantes, Francisco; Maffioli, Margherita et al.: EZH2 mutational status predicts poor survival in myelofibrosis. Blood 118 (19), 5227-5234. PMID: 21921040

Härtel, Nicolai; Klag, Thomas; Hanfstein, Benjamin; Mueller, Martin C.; Schenk, Thomas; Erben, Philipp; Hochhaus, Andreas; La Rosée, Paul: Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity. J. Cancer Res. Clin. Oncol. PMID: 22089930

Hammerman, Peter S.; Sos L. Martin; Ramos, Alex H.; Xu, Chunxiao; Dutt, Amit; Zhou, Wenjun; Brace, Lear E. et al: Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer. Cancer Discovery, June 2011, 78-89. PMID: 22328973

Hanfstein, Benjamin; Müller, Martin C.; Kreil, Sebastian; Ernst, Thomas; Schenk, Thomas; Lorentz, Christian et al.: Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica 96 (3), 360-366. PMID: 21134983

Kantarjian, Hagop M.; Shah, Neil P.; Cortes, Jorge E.; Baccarani, Michele; Agarwal, Mohan B.; Undurraga, María Soledad; Wang, Jianxiang; Kassack Ipiña, Juan Julio; Kim, Dong-Wook; Ogura, Michinori; Pavlovsky, Carolina; Junghanss, Christian; Milone, Jorge H.; Nicolini, Franck E.; Robak, Tadeusz; Van Droogenbroeck, Jan; Vellenga, Edo; Bradley-Garelik, M. Brigid; Zhu, Chao; Hochhaus, Andreas: Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood, 2011. PMID: 22160483

Hehlmann, Rüdiger; Grimwade, David; Simonsson, Bengt; Apperley, Jane; Baccarani, Michele; Barbui, Tiziano et al.: The European LeukemiaNet: achievements and perspectives. Haematologica 96 (1), 156-162. PMID: 21048032

Hehlmann, Rüdiger; Lauseker, Michael; Jung-Munkwitz, Susanne; Leitner, Armin; Müller, Martin C.; Pletsch, Nadine et al.: Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J. Clin. Oncol 29 (12), 1634-1642. PMID: 21422420

Hochhaus, Andreas: Chronische myeloische Leukämie. Dtsch. Med. Wochenschr 136 (40), 2007-2010.

Hochhaus, Andreas: Educational Session: Managing Chronic Myeloid Leukemia as a Chronic Disease. Hematology Am Soc Hematol Educ Program, 2011, 128-135. PMID: 22160024

Hochhaus, Andreas: Management of newly diagnosed chronic myeloid leukemia patients Hematology Education. The education programme for the annual congress of the EHA, Bd.5, 120-126.

Hochhaus, Andreas; La Rosée, Paul; Müller, Martin C.; Ernst, Thomas; Cross, Nicholas C. P.: Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. Cell Cycle 10 (2), 250-260. PMID: 21220945

Hurtz, Christian; Hatzi, Katerina; Cerchietti, Leandro; Braig, Melanie; Park, Eugene; Kim, Yong-Mi et al.: BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. The Journal of Experimental Medicine 208 (11), 2163-2174. PMID: 21911423

Jabbour, Elias; Deininger, Michael; Hochhaus, Andreas: Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 25 (2), 201-210. PMID: 30587215

Kantarjian, Hagop M.; Giles, Francis J.; Bhalla, Kapil N.; Pinilla-Ibarz, Javier; Larson, Richard A.; Gattermann, Norbert et al.: Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 117 (4), 1141-1145. PMID: 21098399

Kantarjian, Hagop M.; Hochhaus, Andreas; Saglio, Giuseppe; Souza, Carmino de; Flinn, Ian W.; Stenke, Leif et al.: Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 12 (9), 841-851. PMID: 21856226

La Rosée, Paul: Tyrosinkinaseinhibitoren "-nibs". Der Onkologe, Bd.7, S. 641-649.

Larson, Richard A.; Yin, Ophelia Q. P.; Hochhaus, Andreas; Saglio, Giuseppe; Clark, Richard E.; Nakamae, Hirohisa; Gallagher, Neil J.; Demirhan, Eren; Hughes, Timothy P.; Kantarjian, Hagop M.; le Coutre, Philipp D.: Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol PMID: 22207416

Leitner, Armin A.; Hochhaus, Andreas; Müller, Martin C.: Current treatment concepts of CML. Curr Cancer Drug Targets 11 (1), 31-43. PMID: 21062245

Mügge, Lars-Olof; Schüler, Aurelian; Hochhaus, Andreas: Therapy of brain metastases and neoplastic meningitis. Onkologe (17/4), 292 ff.

Nguyen, Xuan Duc; La Rosée, Paul; Nebe, Thomas; Klüter, Harald; Buchheidt, Dieter: Rapid Treatment of Leukostasis in Leukemic Mantle Cell Lymphoma using Therapeutic Leukapheresis. A Case Report. The Scientific World Journal, Bd.11, 1554-1559. PMID: 22224069

Nicolini, Franck Emmanuel; Basak, Grzegorz W.; Soverini, Simona; Martinelli, Giovanni; Mauro, Michael J.; Müller, Martin C. et al.: Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood 118, 5697-5700 PMID: 21926354

Pachmann, Katharina: Tumor Cell Seeding During Surgery. Possible Contribution to Metastasis Formations. Cancers (3), 2540-2553. PMID: 24212822

Pachmann, Katharina; Camara, Oumar; Kroll, Torsten; Gajda, Mieczyslaw; Gellner, A. K.; Wotschadlo, Jana; Runnebaum, Ingo B.: Efficacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": trastuzumab in HER2/neu-positive breast carcinoma. J. Cancer Res. Clin. Oncol 137 (9), 1317-1327. PMID: 21739182

Pachmann, Katharina; Camara, Oumar; Kohlhase, Annika; Rabenstein, Carola; Kroll, Torsten; Runnebaum, Ingo B.; Hoeffken, Klaus: Assessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): the example of SERM therapy monitoring as a unique tool to individualize therapy. J. Cancer Res. Clin. Oncol 137 (5), 821-828. PMID: 20694797

Pachmann, Ulrich A.; Hekimian, Katya; Carl, Stephanie; Rüdiger, Nadine; Rabenstein, Carola; Pachmann, Katharina: Comparing Sequential Steps For Detection Of Circulating Tumor Cells: More Specific Or Just Less Sensitive? WebmedCentral Cancer (2(2)), WMC001490.

Pfirrmann, Markus; Hochhaus, Andreas; Lauseker, Michael; Saussele, Susanne; Hehlmann, Rüdiger; Hasford, Joerg: Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia 25 (9), 1433-1438. PMID: 21597465

Ritter, Ellen; Husain, Ralf A.; Hinderhofer, Katrin; Prell, Tino; Fricke, Hans-Jörg; Scholl, Sebastian et al.: Ornithine transcarbamylase (OTC) deficiency based on a hemizygous p.R277W mutation causing life-threatening hyperammonemic crisis during treatment for Hodgkin's lymphoma. Ann. Hematol. PMID: 21061009

Rommeley, Maraike; Spies-Weisshart, Baerbel; Schilling, Kristina; Hochhaus, Andreas; Sayer, Herbert G.; Scholl, Sebastian: Reconstitution and functional analyses of neutrophils and distinct subsets of monocytes after allogeneic stem cell transplantation. J. Cancer Res. Clin. Oncol 137 (9), 1293-1300. PMID: 21713449

Schmidt, Thomas; Kharabi Masouleh, Behzad; Loges, Sonja; Cauwenberghs, Sandra; Fraisl, Peter; Maes, Christa et al.: Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. Cancer Cell 19 (6), 740-753. PMID: 31935370

Schnetzke, Ulf; Bossert, Theo; Scholl, Sebastian; Freesmeyer, Martin; Hochhaus, Andreas; La Rosée, Paul: Drug-induced lymphadenopathy with eosinophilia and renal failure mimicking lymphoma disease: dramatic onset of DRESS syndrome associated with antibiotic treatment. Ann. Hematol 90 (11), 1353-1355. PMID: 21298267

Scholl, Sebastian; Spies-Weisshart, Baerbel; Klink, Anne; Muegge, Lars-Olof; Fricke, Hans-Joerg; Hochhaus, Andreas: Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations. Ann. Hematol 90 (4), 473-475. PMID: 20652568

Soverini, Simona; Score, Joannah; Iacobucci, Ilaria; Poerio, Angela; Lonetti, Annalisa; Gnani, Alessandra et al.: IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. Leukemia 25 (1), 178-181. PMID: 20962862

Soverini, Simona; Hochhaus, Andreas; Nicolini, Franck E.; Gruber, Franz; Lange, Thoralf; Saglio, Giuseppe et al.: BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118 (5), 1208-1215. PMID: 21562040

Spolverini, Ambra; Jones, Amy V.; Hochhaus, Andreas; Pieri, Lisa; Cross, Nicholas C. P.; Vannucchi, Alessandro M.: The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia. Ann. Hematol 90 (3), 365-366. PMID: 20556390

Stein, Andrew M.; Bottino, Dean; Modur, Vijay; Branford, Susan; Kaeda, Jaspal S.; Goldman, John et al.: BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment. Clinical cancer research : an official journal of the American Association for Cancer Research. PMID: 21903771

Walz, Christoph; Erben, Philipp; Ritter, Michael; Bloor, Adrian; Metzgeroth, Georgia; Telford, Nick et al.: Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. Blood 118 (8), 2239-2242. PMID: 21705501

Winkelmann, Nils; Petersen, Iver; Kiehntopf, Michael; Fricke, Hans Joerg; Hochhaus, Andreas; Wedding, Ulrich: Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma. J. Cancer Res. Clin. Oncol 137 (4), 733-738. PMID: 20602238

2010

Hermann R, Pfeil A, Busch M, Christiane Kettner, Kretzschmar D, Hansch A, La Rosée P, Wolf G: Schwerste thrombotisch-thrombozytopenische Purpura (TTP) nach H1N1-Vakzinierung [Very severe thrombotic thrombocytopenic purpura (TTP) after H1N1 vaccination]. Med Klin (Munich). 2010;105(9):663-668. doi:10.1007/s00063-010-1107-6. PMID: 20878304

Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, Vela-Ojeda J, Silver RT, Khoury HJ, Müller MC, Lambert A, Matloub Y, Hochhaus A: Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010;95(2):232-240. doi:10.3324/haematol.2009.011452. PMID: 20139391

Burchert, Andreas; Müller, Martin C.; Kostrewa, Philipp; Erben, Philipp; Bostel, Tilmann; Liebler, Simone; Hehlmann, Rüdiger; Neubauer, Aandreas; Hochhaus, Andreas: Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. Journal of Clinical Oncology 28 (8), 1429-1435. PMID: 20142590

Erben, Philipp; Ströbel, Philipp; Horisberger, Karoline; Popa, Juliana; Bohn, Beatrice; Hanfstein, Benjamin; Kähler, Georg; Kienle, Peter; Post, Stefan; Wenz, Frederik; Hochhaus, Andreas; Hofheinz, Ralf-Dieter: KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer. Int. J. Rad. Oncol. Biol. Phys. 81 (4) PMID: 20947270

Erben, Philipp; Gosenca, Darko; Müller, Martin C.; Reinhard, Jelena; Score, Joannah; del Valle, Francesco; Walz, Christoph; Mix, Jürgen; Metzgeroth, Georgia; Ernst, Thomas; Haferlach, Claudia; Cross, Nicholas C.P.; Hochhaus, Andreas; Reiter, Andreas: Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. HAEMATOLOGICA - THE HEMATOLOGY JOURNAL 95 (5), 738-744. PMID: 20107158

Ernst, Thomas; Chase, Andrew; Zoi, Katerina; Waghorn, Katherine; Hidalgo-Curtis, Claire; Score, Joannah; Jones, Amy; Grand, Francis; Reiter, Andreas; Hochhaus, Andreas; Cross, Nicholas C.P.: Transcription factor mutations in myelodysplasic/myeloproliferative neoplasms. HAEMATOLOGICA - THE HEMATOLOGY JOURNAL 95 (9), 1473-1480. PMID: 20421268

Ernst, Thomas; Chase, Andrew; Score, Joannah; Hidalgo-Curtis, Claire; Bryant, Catherine; Jones, Amy; Waghorn, Katherine; Zoi, Katerina; Ross, Fiona M.; Reiter, Andreas; Hochhaus, Andreas; Drexler, Hans G.; Duncombe, Andrew; Cervantes, Francisco; Oscier, David; Boultwood, Jacqueline; Grand, Francis H.; Cross, Nicholas C.P.: Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. NATURE GENETICS 42 (8), 722-726. PMID: 20601953

Escher, Niko; Ernst, Günther; Melle, CHristian; Berndt, Alexander; Clement, Joachim H.; Junker, Kerstin; Friedrich, Karlheinz; Guntinas-Lichius, Orlando; von Eggeling, Ferdinand: Comparative proteomic analysis of normal and tumor stromal cells by tissue on chip based mass spectrometry (toc-MS). DIAGNOSTIC PATHOLOGY 5 (10). PMID: 20205871

Giehl, Michelle; Leitner, Armin; Haferlach, Claudia; Duesberg, Peter; Hofmann, Wolf-Karsten; Hofheinz, Ralf; Seifarth, Wolfgang; Hochhaus, Andreas; Fabarius, Alice: Detection of centrosome aberrations in disease-unrelated cells from patients with tumor treated with tyrosine kinase inhibitors. EUROPEAN JOURNAL OF HAEMATOLOGY 85 (2), 139-148. PMID: 20408871

Gottschaldt, Michael; Schubert, Ulrich S.; Rau, Sven; Yano, Shigenobu; Vos, Johannes G.; Kroll, Torsten; Clement, Joachim; Hilger, Ingrid: Suger-selective enrichment of a D-glucose-substituted ruthenium bipyridyl complex inside HepG2 cancer cells. CHEMBIOCHEM 11 (5), 649-652. PMID: 20157911

Greiner, Eva J.; Mügge, Lars-Olof; Romeike, Bernd F.M.; Topalidis, Theodoros; Theis, Bernhard; Ragoschke-Schumm, Andreas; Witte, Otto W.; Günther, Albrecht: A case with coincidental diagnosis of primary central nervous system lymphoma and lymph node sarcoidosis. JOURNAL OF NEURO-ONCOLOGY 99 (1), 129-134. PMID: 20054702

Gruber, Franz X.; Ernst, Thomas; Kiselev, Yuri; Hochhaus, Andreas; Mikkola, Ingvild: Detection of drug-resistant clones in chronic myelogenous leukemia patients during dasatinib and nilotinib treatment. CLINICAL CHEMISTRY 56 (3), 469-473. PMID: 20040619

Gundermann, Christin; La Rosée, Paul; Hartmann, Michael: Krankheitskosten in der Onkologie im internationalen Vergleich. ONKOLOGE 16 (10), 964-971.

Hermann, Regina; Pfeil, Alexander; Busch, Martin; Kettner, Christiane; Kretzmar, Daniel; Hansch, Andreas; La Rosee, Paul; Wolf, Gunther: Schwerste thrombotisch-thrombozytopenische Purpura (TTP) nach H1N1-Vakzinierung. Med Klinik 105 (9), 663-668.

Hochhaus, Andreas; Duyster, Justus; Haferlach, Torsten; Lange, Thoralf; Jakob, Abraham; Overkamp, Friedrich; Hasford, Joerg: Therapy of chronic myeloid leukemia in elderly patients. ONKOLOGE 16 (1), 67-72.

Hochhaus, Andreas; Overkamp, Friedrich; Lange, Thoralf; Mohr, Brigitte; Ottmann, Oliver; le Coutre, Philipp; Haferlach, Torsten: Recommendations on monitoring and second-line therapy for chronic myeloid leukemia. ONKOLOGE 16 (7), 701-708.

Hofheinz, Ralf-Dieter; Al-Batran, Salah-Eddin; Hochhaus, Andreas; Jäger, Elke; Reichardt, Volker L.; Fritsch, Holger; Trommeshauser, Dirk; Munzert, Gerd: An Open-Label, Phase-I Study of the Polo-like Kinase-I Inhibitor, BI 2536, in Patients with Advanced Solid Tumors. CLINICAL CANCER RESEARCH 16 (18), 4666-4674.

Horisberger, Karoline; Erben, Philipp; Ströbel, Philipp; Bohn, Beatrice; Hahn, Melanie; Kähler, Georg; Wenz, Frederik; Hochhaus, Andreas; Post, Stefan; Willeke, Frank; Hofheinz, Ralf-Dieter: Annexin and survivin in locally advanced rectal cancer: Indicators of resistence to preoperative chemoradiotherapy? ONKOLOGIE 33, 439-444. PMID: 20838059

Hughes, Timothy P.; Hochhaus, Andreas; Branford, Susan; Müller, Martin C.; Kaeda, Jaspal S.; Foroni, Letizia; Druker, Brian J.; Giulhot, François; Larson, Richard A.; O'Brien, Stephen G. et al.: Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). BLOOD 116 (19), 3758-3765. PMID: 20679528

Jabbour, Elias; Hochhaus, Andreas; Cortes, Jorge; La Rosee, Paul; Kantarjian, Hagop M.: Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. LEUKEMIA 24 (1), 6-12. PMID: 19798095

Kantarjian, Hagop M.; Shah, Neil P.; Hochhaus, Andreas; Cortes, Jorge; Shah, Sandip; Ayala, Manuel; Moiraghi, Beatriz; Shen, Zhixiang; Mayer, Jiri; Pasquini, Ricardo et al.: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. NEW ENGLAND JOURNAL OF MEDICINE 362 (24), 2260-2270. PMID: 20525995

Kantarjian, Hagop M.; Cortes, Jorge; La Rosee, Paul; Hochhaus, Andreas: Optimizing therpy for patients with chronic myelogenous leukemia in chronic phase. CANCER 116 (6), 1419-1430.

Kruth, Jens; Nissen, Johanna; Ernst, Thomas; Kripp, Melanie; Lukan, Nadine; Merx, K; Hofmann, Wolf-Karsten; Hochhaus, Andreas; Hofheinz, Ralf-Dieter: Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 136 (12), 1845-1851. PMID: 20224968

La Rosee, Paul; Deininger, Michael W.: Resistance to imatinib: mutations and beyond. SEM HEMATOL 47 (4), 335-343. PMID: 20875550

La Rosee, Paul; Hochhaus, Andreas: Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia. CURRENT OPINION IN HEMATOLOGY 17 (2), 91-96. PMID: 20071983

Neugebauer Ute, Bocklitz Thomas, Clement Joachim H., Krafft Christoph, Popp Jürgen: Towards detection and identification of circulating tumor cells using Raman spectroscopy. ANALYST 135, 3178-3182. PMID: 20941448

Neugebauer, Ute; Clement, Joachim H.; Bocklitz, Thomas; Krafft, Christoph; Popp, Jürgen: Identification and differentiation of single cells from peripheral blood by Raman spectroscopic imaging. JOURNAL OF BIOPHOTONICS 3 (8-9), 579-587. PMID: 20449831

Saglio Giuseppe; Kim, Dong-Wook; Issaragrisil, Surapo; le Coutre, Philipp; Etienne, Gabriel; Lobo, Clarisse; Pasquini, Ricardo; Clark, Richard E.; Hochhaus, Andreas; Hughes, Timothy P. et al.: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. NEW ENGLAND JOURNAL OF MEDICINE 362 (24), 2251-2259. PMID: 20525993

Saglio, Giuseppe; Hochhaus, Andreas; Goh, YT; Masszi, T; Pasquini, R; Maloisel, F; Erben, P; Cortes, J; Paquette, R; Bradley-Garelik, MB et al.: Dasatinib in Imatinib-resistant or Imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. CANCER 116 (16), 3852-3861. PMID: 20564086

Saussele, Susanne; Lauseker, Michael; Gratwohl, Alois; Beelen, Dietrich W.; Bunjes, Donald; Schwerdtfeger, ainer; Kolb, Hans-Jochen; Ho, Aanthony D.; Falge, Christiane; Holler, Ernst et al.: Allogeneic hematopoietic stem cell transplantation (alloSCT) for chronic myeloid leukemia in the imatinib era: evaluation impact within a subgroup of the randomized German CML Study IV. BLOOD 115 (10), 1880-1885. PMID: 19965667

Scholl, Sebastian; Spies-Weisshardt, Baerbel; Klink, Anne; Muegge, Lars-Olof; Fricke, Hans-Joerg; Hochhaus, Andreas: Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations. ANNALS OF HEMATOLOGY 90 (4), 473-475. PMID: 20652568

Shah, Neil P.; Kim, Dong-Wook; Kantarjian, Hagop M.; Rousselot, Philippe; Llacer, Pedro Enrique Dorlhiac; Enrico, Alicia; Vela-Ojeda, Jorge; Silver, Richard T.; Khoury, Hannah Jean; Müller, Martin C. et al.: Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic meloid leukemia patients with resistence, suboptimal response or intolerance to imatinib. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 95 (2), 232-240.

Wagner, Kerstin; Seemann, Thomas; Wyrwa, Ralf; Clement, Joachim H.; Müller, Robert; Nietzsche, Sandor; Schnabelrauch, Matthias: Synthesis and investigation of cell interaction of magnetic nanoparticles with catechol-containing shells. AIP Conference Proceedings 1311, 28-33.

Walz, Christoph; Grimwade, David; Saussele, Susanne; Lengfelder, Eva; Haferlach, Claudia; Schnittger, Susanne; Lafage-Pochitaloff, Marina; Hochhaus, Andreas; Cross, Nicholas C.P.; Reiter, Andreas: Atypical mRNA fusions in PML-RARA positive, RARA-PML negative acute promyelocytic leukemia. GENES CHROMOSOME & CANCER 49 (5), 471-479. PMID: 20155840

Weiss, Jonathan; Sos, Martin L.; Seidel, Danila; Peifer, Martin; Zander, Thomas; Heuckmann, Johannes M.; Ullrich, Roland T.; Menon, Roopika; Maier, Sebastian; Soltermann, Alex et al.: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Transl Med 2, 62ra93. PMID: 21160078

Winkelmann, Nils; Petersen, Iver; Kiehntopf, Michael; Fricke; Hans-Joerg, Hochhaus, Andreas; Wedding, Ulrich: Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 137 (4), 733-738. PMID: 20602238

Wotschadlo, Jana; Müller, Bianca; Kühn, Julia; Nikolajski, Melanie; Pachmann, Katharina; Buske, Norbert; Müller, Robert;, Liebert, Tim; Schnabelrauch, Matthias, Heinze, Thomas, Hochhaus, Andreas, Clement, Joachim H.: Short-term application of magnetic core-shell nanoparticles - Effect on immune cells. AIP Conference Proceedings 1311, 431-437.

White, Helen E.; Matejtschuk, Paul; Rigsby, Peter; Gabert, Jean; Lin, Feng; Wang, Y Lynn; Branford, Susan; Müller, Martin C.; Beaufils, Nathalie; Beillard, Emmanuel et al.: Establishment of the first World Health Organization International Genetic Reference Panel for quantification of BCR-ABL mRNA. BLOOD 116 (22), E111-E117. PMID: 20720184

Pressemitteilung
15.12.2016

Jenaer Wissenschaftler gehören zu den meistzitierten weltweit:

UKJ-Hämatologe Prof. Dr. Andreas Hochhaus ist einer von drei Professoren der Universität Jena unter den „Highly Cited Researchers“

Prof. Dr. med. A. Hochhaus

Editor-in-Chief

LEUKEMIA

Section Editor, Associate Editor, Regional Editor
bzw. Mitglied des Editorial Boards

Annals of Hematology
Blood Cancer Journal
Haematologia
Journal of Cancer Research and Clinical Oncology
Der Onkologe
Onkologie

Dr. J. Clement

Managing Editor

Journal of Cancer Research and Clinical Oncology